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Summary 
 
Sequence analysis showed that the essential glnA1 gene of Mycobacterium tuberculosis might 
be closely related to an actinomycetes progenitor sequence and that this sequence may have 
undergone duplication into other non-essential GS encoding genes in some Actinobateria, 
notably the mycobacteria. Also, the M. tuberculosis glnA1 sequence remains conserved 
throughout the evolution of M. tuberculosis. It was also shown that glnA1 is widely expressed in 
M. tuberculosis infected human pulmonary tissue, where M. tuberculosis might be present in 
altered phenotypes. These results imply that glnA1 is under selective pressure against 
evolutionary change. 
 
At transcriptional level it was shown that M. tuberculosis glnA1 might be expressed from two 
alternate promoter sites, but that these promoter sites may not be controlled by environmental 
nitrogen (in the form of ammonium) variation. We also showed that M. tuberculosis GS is 
effectively exported by M. smegmatis to the cell wall, but that GS secretion into the exogenous 
environment does not occur. Also, evidence has been presented which suggested that M. 
tuberculosis GS might be modified at the C-terminus, probably as part of a mechanism that 
retains GS in the cytosol. This hypothesis was further substantiated where it was demonstrated 
that two GS isoforms of different size (short isoform in cytosol, longer isoform in cell wall) are 
present in M. bovis BCG. It is unknown what causes this modification, since it couldn’t be 
observed in M. smegmatis, but it was suggested that it might be through the action of a cis- or 
trans-acting element present in proximity of the M. tuberculosis glnA1 gene. It was also shown 
that a cluster of genes found immediately downstream of the M. tuberculosis glnA1 sequence 
might be regulated in an operonic fashion under conditions of elevated environmental nitrogen 
concentrations. Two of the genes (glnE and glnA2) in this operon arrangement have been 
previously shown to be involved in nitrogen and glutamine metabolism. The function of the other 
gene, Rv2223c, is unknown. It was shown that Rv2223c homologs are mostly found in the 
mycobacteria and that it may encode an exported protease. It was hypothesised that this 
sequence and its adjacently located progenitor sequence, Rv2224c, might be involved in M. 
tuberculosis GS mediated metabolism. It was showed that over-expression of Rv2223c and 
Rv2224c may be toxic to E. coli and mycobacterial hosts, such as M. smegmatis, but that 
inhibition of transcription of these genes may be fatal to M. bovis BCG and M. tuberculosis 
H37Rv. It was also shown that Rv2223c is widely expressed in M. tuberculosis infected human 
tissue, which was comparable to that of glnA1.  
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The results presented in this study shed more light on the distribution and transcriptional 
regulation of GS in mycobacteria and has identified new genes that might be involved in GS 
regulation. These results may present new approaches to tuberculosis control and thereby 
contribute to alleviate the burden of the disease. 
 
Opsomming 
 
Genetiese en proteien volgorde analise het aangedui dat die glnA1 (kodeer vir glutamien 
sintetase (GS), ‘n essentiele protein) geen van Mycobacterium tuberculosis die naaste verwant 
is aan ‘n actinomycetes voorloper volgorde wat duplikasie ondergaan het om die ander nie-
essensiele GS koderende gene in sommige Actinobakterieë te vorm, veral in die mikobakterieë. 
Voords het die glnA1 geen geneties gekonserveerd gebly gedurende die evolusie van M. 
tuberculosis. Dit is ook aangetoon dat volop transkribasie van die glnA1 geen voorkom in die M. 
tuberculosis geïnfekteerde pulmonêre weefsel waar M. tuberculosis moontlik mag voorkom. 
 
Op transkriptionele vlak is dit aangetoon dat die M. tuberculosis glnA1 geen vanaf twee 
onderskeie promotors uitgedruk mag word, maar dat hierdie twee promotors nie deur variasies 
in die konsentrasie van stikstof (in die vorm van ammonium) in die omgewing beïnvloed word 
nie. Daar is ook aangedui dat M. tuberculosis GS effektief deur M. smegmatis oor die 
selmembraan na die selwand vervoer word, maar dat daar nie GS sekresie na die ekstra-
sellulêre omgewing geskied nie. Ook is bewyse gevind dat M. tuberculosis GS modifikasie aan 
die C-terminus mag ondergaan wat waarskynlik dien om GS beweging uit die sitosol te verhoed. 
Hierdie hipotese is versterk deurdat twee isoforms van verskillende grootte (klein in sitosol en 
groter in die selwand) gevind is in M. bovis BCG. Dit modifikasie meganisme is onbekend, maar 
vind moontlik nie plaas in nie-patogeniese mikobakterieë soos M. smegmatis nie en mag 
moontlik deur cis- of trans-werkende elemente gefasiliteer word. Daar is aangedui dat ‘n 
groepering van vier gene lanksaan die glnA1 lokus in ‘n operoniese meganisme gereguleer mag 
word onder variërende konsentrasies van stikstof in die omgewing. Dit is bekend dat twee van 
die gene in die operon (glnE en glnA2) betrokke in stikstof en gultamien metabolisme is. 
Die funksie van die ander twee gene (Rv2223c en Rv2224c) is onbekend. Daar is aangetoon 
dat volgordes soortgelyk aan Rv2223c beperk is tot die mikobakterieë en dat die geen ‘n 
protease, wat moontlik gesekreteer word vanuit die sitosol, kodeer. Daar is aangetoon dat die 
oor-produksie van die Rv2223c en Rv2224c proteine toksies is vir E. coli en mikobakterieë, 
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soos M. smegmatis, maar dat transkripsie inhibisie hierdie gene dodelik is vir M. tuberculosis 
H37Rv en M. bovis BCG. Daar is ook angedui dat die ekspresie van hierdie gene volop 
verspreid is in M. tuberculosis geïnfekteerde menslike weefsel, soortgelyk aan diè van glnA1.  
 
Die resultate vervat in hierdie studie werp meer lig op die verspreiding en transkiptionele 
regulasie van GS in mikobakteriee en nuwe gene is ontdek wat betrokke by GS regulasie mag 
wees. Hierdie resultate mag bydra tot nuwe maniere om tuberkulose te bekamp en daardeur die 
voorkoms van die siekte te beperk. 
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CHAPTER ONE 
 
 
 
INTRODUCTION 
 
 
“The most exciting phrase to hear in science, the one that heralds the most discoveries, is 
not "Eureka!", but "That's funny..." 
 
Isaac Asimov 
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 2
1.1 PREAMBLE 
 
“if the number of victims which a disease claims is the measure of its significance, then all 
diseases, particularly the most dreaded infectious disease, must rank far behind 
tuberculosis. Statistics teach that one seventh of all human beings die of tuberculosis, and 
that if one considers only productive middle-aged groups, tuberculosis carried away one-
third and often more of these…”  
 
These were the words of Robert Koch standing before an audience in Berlin during 1882 
pointing out the devastating effect that tuberculosis has on the world’s population, which still 
holds true more than two centuries later (Figure 1.1). Tuberculosis is still one of the leading 
causes of mortality due to an infectious agent (Ehlers, 1993), despite the availability of anti-
tubercular drugs and the widespread use of a live, attenuated vaccine (NIAID, 2001). The 
disease is easily transmitted through inhalation of contaminated aerosol droplets that carries 
the pathogen Mycobacterium tuberculosis into the lungs of an individual (Nicas, 1995), 
where it encounters cells of the innate immune system (such as alveolar macrophages). The 
success of M. tuberculosis as a pathogen lies in its ability to evade destruction by, and 
continue to survive and replicate within these immune cells (Pethe et al., 2004). It has been 
estimated that over 80% of tuberculosis cases present in the form of chronic pulmonary 
infection, which leads to symptoms such as coughing, fever, we ight loss, tiredness and 
coughing up blood in the latter stages of disease progression (Hopewell, 1994). 
 
Although it is true that only about 5% - 10% of non-immunosupressed infected individuals 
will progress to active disease during their lifetimes, co-infection with the human 
immunodeficiency virus (HIV) significantly increases the risk to develop active disease to 
10% per year (Dye et al., 2002). It has been estimated by the World Health Organisation 
(WHO) that in the 20 years between the turn of the millennium and the year 2020, an 
additional 200 million individuals will develop active tuberculosis, while around 35 million 
infected individuals will have succumbed to the disease (WHO, 2002). But due to the rise in 
HIV co-infections, the number of mortalities may rise significantly, which would have 
profound implications on world economies, besides untold human suffering. Therefore, it is 
as important now as it was in 1882 to understand the agent of tuberculosis in order to 
effectively combat the disease.    
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Figure 1.1. Despite modern medical advances, tuberculosis is still devastating countries with 
low gross national products in Africa, Asia, and Latin America. The WHO estimates that 
annually 3 million individuals die from tuberculosis while another 8 million are infected, with 
95% of cases occurring in developing countries. The map shows the estimated tuberculosis 
cases per annum (available data as of 21 March 2005; source: WHO Stop TB Department) 
1.2 THE MYCOBACTERIA  
 
 1.2.1 Ancestral taxonomy: the Actinobacteria 
 
Currently, over forty different species of mycobacteria are recognised. These mycobacteria 
include pathogens from a variety of hosts other than humans, including fish, birds, rodents 
and animals, most notably agricultural animals such as dairy cows. The mycobacteria are 
classified as members of the gram-positive prokaryote phylum Actinomycetales. This phylum 
represents one of the major groups of the Regnum Bacteria and its members are all 
characterised by 61% to 71% guanine + cytosine (G+C) content of their genomes. The 
Division Actinobacteria include the CMN cluster of mycolic acid containing bacteria 
(Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae), Pseudonocardineae, 
Streptosporangineae, Streptomycineae, Micrococcineae and some out-groups, such as the 
Tropheryma, Symbiobacterium and Bacillus spp. (Figure 1.2), which have a diverse range of 
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morphological appearances, such as coccoid (Micrococcus), fragmenting hyphae (Nocardia) 
and branched mycelia (Streptomyces). The bacterial families of the Actinobacteria are 
commonly found in terrestrial and aquatic ecosystems, where they may play an integral role 
in biodegradation of organic material and humus formation. Some, such as the Nocardia, are 
plant symbionts and function as nitrogen fixators. Some of the Actinobacteria, other than 
some members of the mycobacterial lineage, are also known to cause human infection, such 
as Corynebacterium diphtheria (diphtheria) and Propionibacterium acnes (acne).  
 
 1.2.2 Genus Mycobacterium 
 
The genus Mycobacterium (Myces, Gr. meaning ‘a fungus’; bakterion, Gr. ‘a small rod’; 
Mycobacterium ‘a fungus rodlet’) was first introduced by Lehmann and Neumann (1896) to 
describe the infectious agents of leprosy and tuberculosis, based on their morphological and 
staining characteristics. These infectious agents have previously been known as Bacterium 
leprae and B. tuberculosis after Robert Koch first observed them in 1882. Today, the genus 
Mycobacterium includes a host of species defined as non-motile aerobic rod-shaped 
prokaryotic Actinobacteria that form colonies or bio-films consisting of straight or slightly 
curved rods that may in some cases branch. The Mycobacteria are further considered as 
Gram-positive bacilli with acid-fast cell walls, because of the presence of lipid components 
unique to the mycobacteria, namely the mycolic acids. According to modern taxonomy that 
uses defined protein families for phylogenetic tree constructions, the Streptomyces appears 
to be the out-group from which the mycobacteria and Corynebacteria have evolved (Bern 
and Goldberg, 2005; Gao and Gupta, 2005).  
 
In general, the mycobacteria can be divided into two major groups, i.e. slow and fast growers 
(Figure 1.3). In culture, slow growing mycobacteria usually have replication times of 13 to 20 
hours, while the fast growing mycobacteria have replication times ranging from 2 to 5 hours 
(David, 1973). It is interesting to note that most of the mycobacteria that cause disease in 
humans are of the slow growing species, and this is probably the reason for the chronic 
nature of mycobacterial infection and disease. 
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Figure 1.2. Bacterial phylogeny of the evolutionary relation between the various genera of 
the Division Actinobacteria (modified, Gao and Gupta, 2005).   
 
Mycobacteria usually form tight, compact colonies with most of the organisms coagulating 
instead of forming a plaque on solid media, which may be due to the lipid content and 
hydrophobic nature of their cell wall constituents (Section 1.4). Mycobacteria are prototrophic 
and have minimal nutritional requirements (Barclay and Wheeler, 1989). It can survive on 
minimal media with basic carbon (such as glucose, glycerol or acetate) and nitrogen 
(ammonium or ammonium- containing amino acids such as asparagines) sources. Growth 
could be stimulated by addition of lipids and fatty acids, and a previous study suggested that 
lipids and fatty acids might be essential for mycobacterial survival in the stationary growth 
phase (McKinney et al., 2000). 
 
 
http://scholar.sun.ac.za
 6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
Gordonia aichiensis 
M. gadium 
M. cookii 
M. fallax 
M. chitae M. manitobense 
M. flavescens 
M. duvalii M. tuscia 
M. vaccae 
M. vanbaalenii 
M. aurum 
M. novocastrense 
M. smegmatis 
M. goodii 
M. moriokaense 
M. thermoresistibile 
M. pulveris 
M. elephantis 
M. confluentis 
M. phlei 
M. brumae 
M. holsaticum 
M. triviale 
M. heidelbergense 
M. simiae 
M. genavense 
M. lentiflavum 
M. kubicae 
M. interjectum 
M. intermedium 
M. scrofulaceum 
M. lacus 
M. celatum 
M. terrae 
M. nonchromogenicum 
M. hiberniae 
M. shimoidei 
M. heckeshornense 
M. botniense 
M. xenopi 
M. ulcerans 
M. gordonae 
M. asiaticum 
M. szulgai 
M. malmoense 
M. gastri 
M. kansasii 
M. intracellulare 
M. komossense 
M. fortuitum 
M. sphagni 
M. parafortuitum 
M. gilvum 
M. aichiense 
M. obuense 
M. wolinskyi 
M. peregrinum 
M. chlorophenolicum 
M. chubuense 
M. septicum 
M. alvei 
M. senegalense 
M. farcinogenes 
M. frederiksbergense 
M. diernhoferi 
M. neoaurum 
M. hodleri 
M. chelonae 
M. microti 
M. bovis 
RAPID GROWERS
SLOW GROWERS
M. tuberculosis complex 
M. avium complex 
M. abscessus 
M. doricum 
M. canettii 
M. africanum 
M. tuberculosis 
M. haemophilum 
M. sp. JLS 
M. monacense 
M. sp. KMS 
M. sp. MCS 
M. acapulcensis 
M. austroafricanum 
M. avium 
M. leprae 
M. paratuberculosis 
M. palustre 
M. marinum 
M. shottsii 
http://scholar.sun.ac.za
 7
 
 
 
 
 
 
 
 
 
Figure 1.3. The mycobacterial phylogeny showing the evolutionary relation between the slow 
(usually pathogenic) and fast growing mycobacteria  (Adapted with kind permission N. Gey 
van Pitteus). 
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 Besides the etiological agents of human tuberculosis (M. tuberculosis) and leprosy (M. 
leprae), other usually harmless environmental saprophytic mycobacteria are emerging as 
infectious agents (Table 1.1). A growing body of evidence shows that these MOTTs 
(“mycobacteria other than tubercle bacilli”) may be involved in some opportunistic pulmonary 
and non-pulmonary infections especially in immunocompromised individuals (Horsburgh, Jr., 
1996; Dobos et al., 1999; Buijtels et al., 2005; Lai et al., 2005b; Koh et al., 2006). This may 
in part be due to the lipid rich mycobacterial cell wall (Section 1.4) and certain cell surface 
moieties (Katoch, 2004) affording a protective barrier to the bacteria, but mainly because of 
impaired immune responses of the HIV-infected individual, which would otherwise be able to 
contain the infection (von Reyn et al., 1994). The infection and pathogenesis mechanisms of 
MOTTs are as yet not clear, although MOTTs have been reported to cause either localised 
or disseminated (i.e. not localised to a specific tissue or organ) disease depending on the 
extend of the immune deficit of the individual (Wayne and Sramrek, 1992). 
 
1.3 MYCOBACTERIUM TUBERCULOSIS: A BRIEF HISTORY 
 
Tuberculosis is one of the leading causes of mortality in the world despite the availability of 
anti-tubercular drugs and the widespread use of the live, attenuated M. bovis BCG vaccine. 
Although > 90% of individuals exposed to tuberculosis will not develop active disease, 
tuberculosis still accounts for more than two million deaths and eight million new cases 
globally each year (WHO, 2002). However, tuberculosis, caused by the Mycobacterium 
tuberculosis bacillus, is a disease of antiquity and may have been the cause of human 
suffering from the earliest times. Tuberculosis may have been well-known to the ancient 
Babylonians, judging from cuneiform inscriptions describing symptoms of the disease. These 
inscriptions are of the earliest known human records of tuberculosis. The oldest pathological 
evidence was observed in the skeleton of a 5400-year-old pre-dynastic Egyptian showing 
the typical kyphotic spinal deformity associated with mycobacterial infection (Crubezy et al., 
1998). A DNA fragment was retrievable from the skeleton and DNA sequencing showed that 
it was of mycobacterial origin, however, due to the antiquity of the sample it was not possible 
to distinguish between M. tuberculosis and M. bovis. 
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Table 1.1. Summary of MOTT infections in mostly aged or immunocompromised individuals. 
Mycobacterium  Type of infection Reference 
  M. avium pulmonary  (Kuwabara et al., 2004;Kirschner et al., 1992) 
      subsp. paratuberculosis Crohn's disease (regional ileitis)  (Chacon et al., 2004) 
  M. intracellulare pulmonary 
(Meissner and Falkinham, III, 1986; Kobashi et al., 
2005; Kirschner et al., 1992) 
  M. kansasii pulmonary  (Zhang et al., 2004) 
  M. scrofulaceum pulmonary; disseminated  (Rodriguez et al., 2004; Hsueh et al., 1996) 
  M. simiae pulmonary; disseminated 
 (Samra et al., 2005;Yoshimura et al., 2005; Marrache 
et al., 2004) 
  M. habana disseminated; extra pulmonary  (Chaturvedi and Gupta, 2002; Valdivia, 1973) 
  M. interjectum lymphadenitis  (Springer et al., 1993;De Baere et al., 2001) 
  M. xenopi pulmonary  (Gazzola et al., 2004) 
  M. heckeshornense pulmonary 
 (van Hest et al., 2004;Richter et al., 2001;Roth et al., 
2000) 
  M. szulgai arthritis; pulmonary; skin ulcers 
 (Hamada et al., 2005;Hakawi and Alrajhi, 
2005;Tappe et al., 2004) 
  M. fortuitum cutaneous; pulmonary  (Palwade et al., 2006;Inoue et al., 2004) 
  M. immunogenum ulceritis, hypersensitivity pneumonitis  (Loots et al., 2005;Wallace, Jr. et al., 2002) 
  M. chelonae corneal ulceritis  (Bottone and Cho, 2005) 
  M. marinum skin ulcers; pulmonary  (Contios et al., 2005;Lai et al., 2005) 
  M. genavense disseminated  (Monill et al., 2001;Hillebrand-Haverkort et al., 1999) 
  M. bohemicum cervical lymphadenitis  (Tortoli et al., 2000) 
  M. haemophilum cutaneous  (Tan et al., 2004) 
  M. celatum pulmonary  (Piersimoni et al., 2003;Shahdad et al., 2005) 
  M. conspicuum disseminated  (Springer et al., 1995) 
  M. malmoense pulmonary  (Handrick et al., 2005) 
  M. ulcerans Buruli ulcer disease  (Bretzel et al., 2005;Siegmund et al., 2005) 
  M. smegmatis male genitalia  (Wallace, Jr. et al., 1988) 
  M. wolinskyi post-surgical wound infections  (Brown et al., 1999) 
  M. goodii post-surgical wound infections 
 (Brown et al., 1999;Spencer, Teske, and Bernstein, 
2005) 
  M. thermoresistible cutaneous  (Cummings et al., 2000) 
  M. neoaurum urinary tract; possible meningoencephalitis  (Heckman et al., 2004;Zanetti et al., 2001) 
  M. vaccae cutaneous; pulmonary  (Hachem et al., 1996) 
  M. palustre cervical lymphadenitis  (Torkko et al., 2002) 
  M. elephantis pulmonary  (Potters et al., 2003) 
  M. septicum pulmonary  (Adekambi and Drancourt, 2005) 
  M. nonchromogenicum pulmonary; chronic tenosynovitis  (Sawai et al., 2006) 
  M. lentiflavum disseminated; pulmonary 
(Suffys et al., 2006;Niobe et al., 2001;Tortoli et al.,   
2002) 
  M. abscessus pulmonary  (Chung et al., 2005) 
  M. tilburgii pulmonary  (Kolditz et al., 2005) 
  M. saskatchewanense bronchiectasis  (Turenne et al., 2004) 
 
Other evidence suggests that M. tuberculosis infection might actually have been common in 
lower class as well as upper-class ancient Egyptians, as M. tuberculosis DNA could be 
detected in the remains of Egyptian mummies dating back to as early as 3000 B.C (Zink et 
al., 2001; Zink et al., 2003). These mummies were from different regions of Egypt, 
suggesting that the infection was not only common, but also widespread. Evidence also 
suggest that tuberculosis spread by means of human hosts to other continents, since lesions 
http://scholar.sun.ac.za
 10
were found in Iron-age skeletons from Britain (Mays et al., 2002) and South-Eastern Asia 
(Tayles and Buckley, 2004). 
The first clear reference to tuberculosis disease is attributed to Hippocrates in 460 B.C., 
when he identified "phthisis" (a Greek word meaning consumption) as the most prevalent 
disease of the times. Aristotle, a contemporary of Hippocrates, noted that the Greeks 
generally believed phthisis to be contagious. Hippocrates observed that nearly everyone 
suffering from phthisis was killed by the disease and even went so far as to warn other 
physicians not to visit patients in late stages of the disease due to the danger of contracting 
it themselves. Interestingly, the Hippocratic School believed in the benefits of a change of 
residence, a thought later endorsed by Aretaeus (50 BC), who believed in the efficacy of sea 
voyages and country air. This manner of treatment was later refined by Galen (A.D 131 – 
201) who defined phthisis as an ulceration that could be cured by drying the secretion, a 
process that could be encouraged through living in the high land of Phrygia (Western Part of 
Asia Minor in the region of Turkey).    
Although the symptoms described by Hippocrates in 460 B.C were not elaborated on for 
many centuries, the pathology of phthisis was first described by the Leyden professor of 
medicine, Dr. Sylvius (Franciscus de la Boe) in his 1679 “Opera Medica”. Therein were 
described the tubercles, abscesses and cavities associated with phthisis as a characteristic 
change of the lungs and other parts of the body in patients suffering from phthisis. Doctor 
Sylvius regarded the tubercles as enlarged lymph glands of the lung and believed in the 
contagiousness of the disease. The English physician Richard Morton (1637-1698) brought 
the tubercle as the cause of the disease to the foreground in his landmark book (1689) 
“Phthisiologia, seu exercitationes de Phthisi tribus libris comprehensae “ (Trail, 1970). This 
book was widely known to English physicians of the time, since the Bills of Mortality for 
London in the 1700s showed that of the 19433 annual deaths from causes other than 
suicide, phthisis accounted for 2819 (18.5%) making it a very prominent disease.  Notably, 
Morton believed in a hereditary predisposition to phthisis, an idea that would survive even 
after the causative agent of phthisis was discovered. Most noteworthy is the work by 
Gaspard Laurent Bayle (1774-1816) and Réne Theophile Hyacinthe Laennaec (1781-1826), 
who performed hundreds of post mortems on patients that complained of pain in the chest 
and night time sweats. Bayle and Laennaec defined the present day knowledge of the 
pathology (tubercle formation in the lungs), signs and symptoms of tuberculosis disease. 
Perhaps not surprisingly, Laennaec himself contracted phthisis and died in 1826, after 
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having undergone panacea (bleeding), in that time a common treatment for the disease. But 
his and Bayles’ work showed that nodules in the lungs (termed “tubercles”) were common to 
all patients succumbing to phthisis, hence the term “tuberculosis” coined by Johann Lukas 
Shönlein in 1839.     
   1.3.1 The identification of Mycobacterium tuberculosis 
By the 1870s, the Dutch scientist Antoni van Leewenhoek (1623 – 1723) had already 
described the existence of microbes, which the pioneering work of Louis Pasteur (1822 – 
1895) incorporated into the “germ theory of disease”, which proposed that micro organisms 
were the cause of many diseases. Initially, many still adhered to the philosophy that germs 
were too ubiquitous to be the cause of disease, and that host factors such as heredity were 
the major cause of disease contractibility and progression. The pathways of infection by M. 
tuberculosis were inferred from the many intravenous (leading to miliary tuberculosis) and 
inhalation infection experiments. The search for the specific infectious agent began, notably 
through the experimentation of Edwin Klebs (1834 – 1913). In 1877 Klebs saw transference 
of the germ (via passaging on egg albumin media) and identified Monas tuberculosum, 
which he wrongly assumed to be the etiological agent of tuberculosis. Other researchers 
included Emanuel Aufrecht (in 1881) and Paul Clemens von Baumgarten (10 days after 
Koch, 1882), who independently described bacilli located in the tubercles, but owing to lack 
of culturing and staining methods, failed to identify these bacilli as the etiological agents.  
The breakthrough in identifying Mycobacterium tuberculosis as the etiological agent of 
tuberculosis came in 1882 by Robert Koch (1843 - 1910) after he discovered a special 
staining technique that allowed him to see the (mycobacterial) bacillus (Koch, 1882). Koch’s 
staining technique was later modified by the German doctors Franz Ziehl and Friedrich 
Neelsen, which became known as the acid-fast stain or Ziehl-Neelsen stain, which is still 
used today. Koch also observed the reaction of the skin to inoculation of M. tuberculosis, 
when the host has been previously exposed to the pathogen. This observation led to the 
development of the Mantoux skin test by Charles Mantoux in 1907, which is still in use 
today. 
 
 
 
http://scholar.sun.ac.za
 12
1.4 THE MYCOBACTERIAL CELL WALL 
 
The success of the mycobacteria as a pathogen is probably due to the complex cell 
envelope or cell wall, demonstrated by the ability of dead mycobacteria to persist in 
macrophages for two weeks after phagocytosis (Clemens, 1997). Besides being the cellular 
exoskeleton that offers defence against mechanical and osmotic lysis, the cell envelope is 
also the interphase of physical interaction between the mycobacterial bacillus and its host-
cell environment, protecting the bacillus from the harsh environment created by the human 
immune system. Also, it may serve as a barrier that impedes the diffusion of 
macromolecules, such as anti-mycobacterial drugs, into the bacillus (Raynaud et al., 1999). 
The mycobacterial cell envelope plays host to a wide variety of molecules that serve a 
multitude of functions, most of which are critical to the viability of the bacillus. It is imperative 
to understand the nature and function of this complex envelope structure to enable 
understanding of the function of current anti-tuberculosis drugs and allow rational drug 
design.  
 
The M. tuberculosis cell envelope can be divided into three regions, being the electron 
transparent capsule, the underlying electron dense cell wall core and cell membrane (Figure 
1.4) (Daffe and Draper, 1998). The capsular region and cell wall core are probably also 
involved in M. tuberculosis virulence and may contain cell wall constituents unique to 
human-disease causing mycobacteria (which will be discussed in subsequent sections) 
which may be absent from non-virulent mycobacteria, such as M. smegmatis.  
 
 1.4.1 The capsule 
 
The ability of pathogenic mycobacteria to grow in host cells has long been linked to a 
surrounding electron transparent zone (ETZ), or mycobacterial capsule, since this structure 
may be the site of physical interaction of the pathogen with the host-cell environment 
(Draper and Rees, 1970). The existence of the ETZ was first described in 1959 as an non-
stainable membrane-enclosed space (“capsular space”) surrounding M. lepraemurium bacilli 
residing in mouse spleen cells (Chapman et al., 1959). In that study, the authors speculated 
that the ETZ might be of host-cell origin due to a lack of an organised structure of the 
capsular space and since the enclosing membrane may become more distantly located from 
the mycobacterial bacillus. In 1961 it was concluded that the chemical and physical 
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characteristics of the ETZ was of mycobacterial rather than host origin (Hanks, 1961) and 
results presented in other studies supported that conclusion (Frehel et al., 1986). 
Interestingly, the presence of an ETZ appears to be a characteristic of pathogenic 
mycobacteria, such as M. tuberculosis and M. avium, while it appears to be absent in non-
pathogens such as M. smegmatis and M. aurum (Frehel et al., 1988). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Schematic representation of the mycobacterial cell envelope showing the main 
constituents and predicted thickness of each layer.   
  
In more recent studies it was shown that the capsular region of M. tuberculosis consists of a 
mixture of non-covalently bound polysaccharides, proteins and some lipids of which some 
may be involved in M. tuberculosis pathogenicity (Rastogi and Hellio, 1990; Ortalo-Magne et 
al., 1995; Lemassu et al., 1996). The polysaccharides consist mainly of glucan, 
arabinomannan (AM) and mannan (Daffe and Draper, 1998). The glucan is composed of five 
to six repeating 4-α-D-glycosyl residues with a mono- or di-glucosyl substitution on the sixth 
residue (Ortalo-Magne et al., 1995). It has also been observed that, although similar in 
structure, capsular glucan may be of smaller molecular size than the M. tuberculosis cytosol-
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associated glucan. Arabinomannan (D-arabino-D-mannan) is composed of mannan chains 
linked with short arabinan side chains (Misaki et al., 1977). The arabinan termini of the 
arabinomannan were found to be extensively capped with mannosyl residues (Lemassu and 
Daffe, 1994; Ortalo-Magne et al., 1996), although the amount of mannosyl capping does not 
appear to play a role in selective phagocytosis of virulent mycobacteria (Ortalo-Magne et al., 
1996) as previously thought. 
 
It has been determined that most of the ~205 proteins found in the early growth-phase 
culture filtrate of M. tuberculosis (Sonnenberg and Belisle, 1997) may come from the 
outermost layer of the M. tuberculosis cell envelope (Ortalo-Magne et al., 1995; Lemassu et 
al., 1996). These proteins may be a complex mixture of actively secreted and cell envelope-
associated or cytoplasmic polypeptides (Wiker et al., 1991; Sonnenberg and Belisle, 1997; 
Navarre and Schneewind, 1999; Rosenkrands et al., 2000; Mattow et al., 2003). Most of the 
actively secreted proteins are identified by the presence of a sec-translocase leader or signal 
peptides in their amino acid sequence. However, several proteins were observed in the 
culture filtrate that apparently lacked any translocase recognition sequences and would 
therefore be expected to be restricted to the M. tuberculosis cytoplasm. Examples of 
exported proteins lacking apparent translocase recognition sequences are superoxide 
dismutase (Zhang et al., 1991), alanine dehydrogenase (Andersen et al., 1992), glutamine 
synthetase (Harth et al., 1994) and ESAT-6 (Sorensen et al., 1995). The observation of such 
proteins in the exogenous environment of M. tuberculosis has led to speculation that M. 
tuberculosis might employ other mechanisms of protein export than the known protein export 
systems. Interestingly, many of the exogenous M. tuberculosis proteins (including the 
examples named above) could be functionally linked to virulence and the ability of M. 
tuberculosis to survive the host immune onslaught (Daffe and Etienne, 1999).   
 
 1.4.2 The cell wall core 
 
The structural definition of the cell wall core has been ongoing since the early 1960s and it 
can now be described as a mycolyl arabinogalactan-peptidoglycan complex (mAGP). The M. 
tuberculosis cell wall is composed of an soluble segment composed of long and short free 
fatty acids (lipids), cell wall proteins, phosphatidylinositol mannosides (PIMs), phthiocerol 
containing lipids, lipomannan (LM) and lipoarabinomannan (LAM) all intercalated into the 
lipid environment of the mycolic acids. The mycolic acids, together with arabinogalactan 
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(AG) and peptidoglycan (PG) form the “lower” insoluble segment of the cell wall core (Figure 
1.5) (Daffe and Draper, 1998). 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. The mycobacterial cell wall is a complex structure of various long- and short 
chain fatty acids that lends many unique features to the mycobacteria. This cell wall is 
relatively impermeable to antibiotics. See text for definition of abbreviations. (Picture from T. 
Mahmud, Oregon University) 
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The insoluble fragment of the cell wall core may be essential for the viability of M. 
tuberculosis, while the compounds contained in the soluble fraction may be involved as 
effectors in the tuberculosis disease progression. The PG forms a vast matrix of alternating 
N-acetylglucosamine (GlcNAc) units and modified muramic acid residues (N-acylated with 
glycolic acid, MurNGly) over the M. tuberculosis cell membrane, a double lipid membrane 
similar to that found in most cells (Adam et al., 1969; Petit et al., 1969). The MurNGly 
residues may be specific to mycobacterial cell walls and serve as the site of covalent 
attachment of PG to the galactan region of AG via a special disaccharide-phosphate linkage 
[L-Rhap-(1→3)-D-GlcNAc-(1→P)] (McNeil et al., 1990). The AG is a major cell wall 
polysaccharide of mycobacteria (Besra et al., 1995). The most recent structural evidence 
suggests that AG is composed of a linear stretch of non-branched galactanfuranose (~ 23 
units) with non-branched arabinan chains attached close to the reducing end of the galactan 
chain (Besra et al., 1995). Furthermore, the non-reducing termini of the arabinan chains may 
constitute a branched penta-arabinofuranosyl structural motif at the terminal end where the 
mycolic acids may be located in clusters of four.  
 
The mycolic acids are large α-alkyl branched and β-hydroxylated fatty acids. Mycolic acids 
can be divided into the non-oxygenated alphamycolate, and oxygenated methoxy- and 
ketomycolate structural subclasses and it has been demonstrated that the absence of the 
oxygenated mycolic acids leads to M. tuberculosis cell envelope alteration and increased cell 
wall permeability, resulting in M. tuberculosis attenuation in mice (Dubnau et al., 2000).  
 
Delipidated and proteolytically digested cell walls of M. tuberculosis and M. bovis (also BCG) 
contain non-peptidoglycan poly-L-glutamic acid (Wietzerbin et al., 1975a; Phiet et al., 1976; 
Hirschfield et al., 1990). This polymer may account for as much as 10% of the dry weight of 
the M. tuberculosis cell wall (Hirschfield et al., 1990) but is completely absent from the cell 
walls of avirulent mycobacteria, such as M. smegmatis and M. phlei (Wietzerbin et al., 
1975b). The study by Wietzerbin et al. (1975) also showed that the poly-L-glutamic acid 
content of the M. bovis BCG strains varies between 0.6 and 2%, except in the M. bovis BCG 
Montreal sub-strain where it is completely absent. The exact nature of this polymer is 
unclear, but the study by Wietzerbin et al. (1975) showed that the α-carboxyl group of the L-
glutamic acid residues could be involved in most of the peptide links and that the residues of 
the complete native polymer may be amidated. The function of poly-L-glutamic acid and 
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whether the presence of this polymer could be correlated with mycobacterial virulence is 
unknown.  
 
The soluble region of the cell wall core consists of several lipid compounds that may play a 
role in M. tuberculosis virulence. Trehalose dimycolate (TDM), or cord factor, a mycolic acid-
glucose compound (Noll and Bloch, 1955) has been shown by various studies using mice 
and rabbits to induce granuloma formation and inflammation of lung, liver and spleen tissues  
(Yamagami et al., 2001; Saita et al., 2000). Evidence has also been presented which 
suggests that TDM production elicits an effect on M. tuberculosis morphology (Hunter et al., 
2005). In that study, the virulence of M. tuberculosis isolates could be correlated with TDM 
production, being either rough mycobacterial colonies (high TDM production, virulent M. 
tuberculosis) or smooth colonies (low TDM production, avirulent M. tuberculosis). This 
correlation between virulence and colony morphology has also been demonstrated in other 
infectious mycobacteria (Howard et al., 2006). 
 
The major lipid component in the soluble segment of the M. tuberculosis cell wall core was 
discovered in 1936, and was referred to as a “unsaponifiable wax” (Stodola and Anderson, 
1936). This lipid is phthiocerol dimycocerosate (DIM, C36H72O3), a highly non-polar lipid due 
to the methyl or methylene nature of the C-35 backbone, and the two hydroxy groups that 
are esterified with two mycocerosic acids (composed of 28 methyl or methylene groups). 
Phthiocerol dimycocerosate has been implicated in the virulence of M. tuberculosis due to 
the two independent observations that M. tuberculosis H37Rv transposon mutants, which 
are unable to synthesise DIM were attenuated for growth in the mouse lung (Camacho et al., 
2001; Sirakova et al., 2003). The attenuation of these DIM-less M. tuberculosis mutants 
were ascribed to an increased permeability of the cell wall and a subsequent increase in 
susceptibility to the reactive oxygen and nitrogen response elicited by the host immune 
response.  
 
1.5 TUBERCULOSIS CHEMOTHERAPY: THEN AND NOW 
 
In the previous centuries before Koch identified M. tuberculosis as the etiological agent of 
consumption or phthisis, as tuberculosis disease was then known, treatment usually resulted 
in tales of severe tragedy and/ or disappointment. In many cases, brutal treatment methods 
such as purging through bleeding (panacea) might have actually increased mortality. Other 
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more benign methods included herbology and dietary interventions or the well-known 
“benefits” of rest and climatic prescriptions that aids the body’s defences against M. 
tuberculosis infection. These measures were implemented in sanatoria, especially in Europe 
and the USA, which also had the function of removing and isolating the sick individuals from 
the general population.  
 
During and around the 1840s, it was generally accepted that phthisis was heritable and 
treatment was mainly aimed at diminishing discomfort or to temporarily prolong life in order 
to afford the body time to overcome the disease by itself, since this can occur in some 
patients. During these times, the use of cod-liver oil as treatment was widely applied with a 
high rate of success, as symptoms improved in 63% of patients treated this way. In 18% of 
the patients, the progression of the disease was arrested, while 19% of patients showed 
non-responsive disease progression while on cod-liver oil treatment. Another great benefit of 
this treatment was that it lead to a weight increase in most patients. Other remedies 
favoured in the treatment of phthisis was potassium arsenate (Fowlers’ solution, KH(AsO2)2), 
which was in some cases (especially by phthisiologists such as William Osler, 1845 – 1919) 
promoted over the use of cod-liver oil.  Indeed, in the 1906 play “A Doctors Dilemma” by the 
Irish-British Nobel Laureate George Bernard Shaw, tuberculosis treatment in Britain was 
described as “a huge commercial system of quackery and poison”.   
 
The hypothesis of tuberculosis heritability survived even after Koch’s observation of the 
mycobacterial bacillus, which paved the way for pathogen directed treatment. Koch himself 
was the first person to have investigated medication that had a growth inhibitory effect on M. 
tuberculosis, since he believed that growth inhibition alone would be effective in the 
treatment of the disease. Therefore Koch tested a wide variety of compounds in vitro, which 
included β-naphthylamine, xylidine, fuchsin, gentian violet, methylene blue, quinoline violet, 
aniline yellow, auramine, mercury vapour and gold cyanide. Compounds of gold cyanide 
became the standard regimen for tuberculosis treatment before the advent of streptomycin in 
the 1940s. Interestingly, Koch observed that these compounds would inhibit M. tuberculosis 
growth in vitro, but not in vivo. The reason became clear through the studies of Paul Ehrlich 
(1854 – 1915), who, incidentally, coined the term chemotherapy to describe the antimicrobial 
effect of drugs. Ehrlich observed that gold cyanide was less effective in vivo because of the 
higher affinity of gold cyanide for host enzymes than for M. tuberculosis. 
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However, in the years preceding Ehrlich’s observations and despite Koch’s findings in the 
1890s, compounds of gold cyanide were widely promoted and became the most used 
chemotherapeutic drugs for the treatment of tuberculosis. In 1912 gold cyanide was retested 
in rabbits and given in various dosages to human subjects. Sub-mortal treatment with gold 
cyanide resulted in some successes, which led to the question whether it was the gold or the 
cyanide exhibiting the antimicrobial effect. Adolf Feldt, a German pharmacologist, decided 
that the active ingredient was gold, since gold cyanide was bactericidal in greater dilutions 
than that elicited by potassium cyanide. Interestingly, Feldt also observed the appearance of 
M. tuberculosis strains that were resistant to gold cyanide. These strains were recovered 
from M. tuberculosis infected rabbits that were treated with gold cyanide for only short 
periods. Feldt will also be remembered in history as the creator of gold cyanide compounds 
such as krysolgan and sanocrysin (Figure 1.6), of which the latter became the first line 
antibiotic against M. tuberculosis infection in the years preceding streptomycin. The side 
effects of these compounds were most unpleasant, and included menorrhagia and 
spontaneous abortion (krysolgan); anorexia, diarrhoea and fever (sanocrysin).  
 
 
 
 
 
 
 
 
 
Figure 1.6. Chemical structures of Adolf Feldt’s gold compounds Sanocrysin (sodium 
aurothiosulphate) and the gold (I) complex of 4-amino-2-mercaptobenzoic acid (Krysolgan) 
commonly used as anti-tuberculosis drugs preceding streptomycin.  
  
 1.5.1 Modern chemotherapy 
 
The first practical breakthrough in modern M. tuberculosis chemotherapeutic treatment was 
made in 1943 through the discovery of streptomycin. Albert Schatz, a post-graduate student 
of a prominent soil biologist, Selman Waksman, isolated a compound from Streptomyces 
KrysolganSanocrysin
http://scholar.sun.ac.za
 20
griseus with high antimicrobial activity to gram-negative bacteria but low toxicity to animals 
(Schatz et al., 1944). Schatz named the compound streptomycin (Mistiaen, 2002), a 
derivative of the generic name ‘Streptomyces’ and due to its similarity to streptothricin 
(Schatz et al., 1944). It seemed that the potential and implications of streptomycin in the 
chemotherapeutic treatment of tuberculosis was at first not realised by Waksman, since the 
antibacterial activity of streptomycin on M. tuberculosis was merely mentioned in the results 
in the paper by Schatz, Bugie and Waksman in 1944, as well as in a subsequent paper 
(Jones et al., 1944) and no suggestion or speculation that it might be used in tuberculosis 
treatment was noted. Feldmann and Hinshaw first described the effect of streptomycin on 
infected guinea pigs in preliminary reports in 1944 and again in 1945 (H. Corwin Hinshaw 
Papers, American Philosophical Society; Comroe, Jr., 1978a). The first human to be treated 
with streptomycin was a 21-year old female on 20 November 1944 (Comroe, Jr., 1978). The 
result was, for that time, astonishing in that very shortly after administering streptomycin, the 
progression of the tuberculosis disease was halted, M. tuberculosis was cleared from the 
sputum and the patient healed. Streptomycin was also found to be effective against bubonic 
plague, cholera and typhoid fever. With the advent of streptomycin, the use of all gold 
compounds were scrapped virtually everywhere with immediate effect because the risk to 
the patient exceeded the possible therapeutic efficacy and also because streptomycin 
proved effective to extra-pulmonary tuberculosis. 
 
However, M. tuberculosis strains showing resistance to streptomycin became apparent 
shortly after the introduction of streptomycin as a mono-therapy. In 1943, the Swedish 
pharmacologist Jorgen Lehmann tested Para-aminosalisylic acid (PAS) on M. bovis BCG 
cultures and discovered that PAS inhibited mycobacterial growth in lower concentrations 
than any other compound previously tested (Lehmann, 1964). Lehmann designed PAS as a 
sodium salicylate analog on the basis of previous work by other biologists; principally 
Bernheim (Bernheim, 1940), who hypothesised that sodium salicylate may be essential for 
continued mycobacterial growth. Interestingly enough, the first tests done by Lehmann with 
PAS on mycobacterial cultures were unsuccessful. He quickly realised that Bernheim used 
virulent mycobacteria in his studies, and subsequently found that PAS does not have an 
inhibitory effect on non-virulent mycobacteria, such as it has on virulent strains. Therefore, 
by the end of 1946 physicians had two drugs to combat tuberculosis, which greatly reduced 
the occurrence of drug resistant M. tuberculosis strains. 
 
http://scholar.sun.ac.za
 21
The next breakthrough in tuberculosis treatment came with the re-discovery of isoniazid 
(INH), which was first synthesised by Meyer and Mally in 1912 (Meyer and Mally, 1912). The 
efficacy of INH as an inhibitor of M. tuberculosis was first described in 1952 (Bernstein et al., 
1952). Soon after INH was first introduced as mono-therapy against tuberculosis disease, 
INH resistant M. tuberculosis strains began emerging. But adding INH to PAS and 
streptomycin (so-called triple therapy) resulted in a 90 – 95% cure rate of patients over the 
extremely long continuous treatment periods of 24 months (MRC, 1955). However, through 
triple therapy the emergence of acquired drug resistant M. tuberculosis phenotypes was 
effectively suppressed. Since INH, a host of compounds have been included in the 
chemotherapy of tuberculosis, mainly aiming to reduce the emergence of drug resistant 
phenotypes, shorten therapy duration and lessen toxicity and side effects. 
 
During the early 1960s, ethambutol (EMB) was observed to clear M. tuberculosis in mice 
(Thomas et al., 1961) and subsequently replaced PAS, since EMB was less toxic and 
resulted in a reduction in treatment period to 18 months (Doster et al., 1973). The next 
compound to be introduced was rifampicin (RIF), which is a bactericidal derivative of 
rifamycin from Streptomyces mediterranei (Lancini and Hengeller, 1969). Rifampicin, 
administered in combination with INH, streptomycin and EMB resulted in a cure rate of 
>95% after a treatment period of only 8 – 9 months (Angel et al., 1976; WHO 1976). 
Although known since the 1950s to exert anti-tuberculosis effects (Yeager et al., 1952), 
Pyrazinamide (PZA) was introduced during the 1990s after the observation that similar cure 
rates could be obtained to that of RIF, streptomycin, EMB and INH tetra-therapy in only 6 
months when combined with INH and RIF (Fox et al., 1999).  
 
Currently, treatment of tuberculosis disease involves a two-month combination therapy of 
INH, RIF, PZA and EMB, followed by a four-month combination of INH and RIF (Banerjee et 
al., 1994; Palandez et al., 2003). Various studies have shown that the 6-month regimens 
could be administered three times a week throughout the duration of chemotherapy (Hong 
Kong Chest Service, 1982; Hong Kong Chest Service, 1991), or twice weekly following a 
two-week daily induction phase (Cohn et al., 1990). Failure in cure rates arose, however, 
due to non-compliance or abandonment of treatment. Therefore the WHO endorsed a direct 
observed therapy short-course (DOTS) that aimed to circumvent the cure failures due to the 
above-mentioned problems (WHO, 1994). The DOTS programme has certain drawbacks, 
such as relying on sputum microscopy for diagnosis, but has made an impact on cure rates 
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particularly in first world countries such as the USA where a decline in tuberculosis case 
rates of 7.8% per year over a five year period has been observed (Centres for Disease 
Control and Prevention, 2000).  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Mode of action Target MIC in vitro (mg/ml)
Isoniazid
Mycolic acid biosynthesis 
inhibition; exact mode of action 
unclear but may act through free-
radical intermediates
Cell wall 0.01 - 0.05 
Rifampin
Acts on DNA-dependent RNA 
polymerase thereby blocking 
protein synthesis
Transcription 0.05 - 1.0 
Pyrazinamide
Metabolism inhibition Unknown 6.2 (pH = 5)   to              >400 (pH ? 6.0)
Streptomycin
Protein synthesis inhibition     
thorugh binding to and inhibition     
of ribosomes
Translation 0.5 - 2.5 
Ethambutol
Mode of action unclear, but may 
inhibit arabinogalactan 
biosynthesis 
Cell wall 2.0 - 5.0
p -Aminosalicylic acid 
Unknown, but thought to disrupt 
folate biosynthesis
Folate 
metabolism 1.0 - 5.0
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Figure 1.7. Summary of so-called first-line drugs, which are the drugs of choice for brief 
periods, usually taken in combination of two or more, of which at least two are isoniazid and 
rifampin (WHO-DOTS programme). 
 
 
 1.5.2 Drug Resistance  
 
As mentioned in Section 1.5.1, one of the factors that has confounded the effective 
treatment of tuberculosis was the emergence of M. tuberculosis strains that do not respond 
to existing anti-tuberculosis drug treatment (referred to as drug resistant M. tuberculosis). 
Anti-tuberculosis drugs have been described as a “two-edged sword” which at the same time 
kill M. tuberculosis and also select for drug resistant phenotypes (Johnson et al., 2006)  The 
anti-tuberculosis drugs currently used exert their bactericidal action through the inhibition of 
a variety of essential cellular processes (see Figure 1.7). However, drug resistance is a man-
made problem and seems to be mainly the result of the acquisition of mutations in the 
various genes encoding the targets of the anti-mycobacterial drugs through natural selection 
(Frothingham et al., 2005). The slow doubling time of M. tuberculosis (~ 23 hours) and its 
ability to remain latent for prolonged periods (Wayne, 1994; reviewed in Parrish et al., 1998) 
require that antibiotics must be taken over prolonged periods (a minimum of 6 months). 
During latent periods, micro-organisms enter a metabolically inactive state during which 
drugs that are usually bactericidal only have a bacteriostatic effect (Handwerger and 
Tomasz, 1985). These factors, together with unpleasant side effects and incompatibility with 
other chemotherapeutics, further exacerbates the rise in drug resistance because it leads to 
poor patient compliance during therapy, which promotes the evolution of drug resistant M. 
tuberculosis phenotypes (Gillespie, 2002). 
 
Table 1.2 illustrates the extent of the drug resistant M. tuberculosis phenotypes globally. A 
recent report by the WHO showed that amongst these MDR-TB cases there is a rising 
incidence of so-called extensively drug resistant (XDR) M. tuberculosis infections (Wright et 
al., 2006). Extensively drug resistant M. tuberculosis phenotypes are defined as multidrug-
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resistant M. tuberculosis isolates (resistant to at least INH and RIF) with additional 
resistance to any  fluoroquinolones and at least one injectable second-line drug (such as 
capreomycin, kanamycin and amikacin) (WHO Global Task Force on XDR-TB, 2006), 
allowing these isolates not to be killed by current front- and second-line drugs. Population 
based data in the report by Wright et al. (2006) showed that of the MDR M. tuberculosis 
isolates obtained from the USA (1993 to 2004), Latvia (2000 – 2002) and South Korea 
(2004), 4%, 19% and 15% respectively were XDR M. tuberculosis. In South Africa, 53 cases 
of XDR M. tuberculosis infections have been reported, of which 52 patients succumbed to 
the infection within 25 days (Koenig, 2006), although these cases were all HIV positive.   
Table 1.2. Estimates of individuals infected with MDR-tuberculosis (Dye et al., 2002) 
Country All cases MDR-TB cases % 
Pakistan 273099 26201 0 - 21.6 
Estonia 935 131 10.5 - 17.6 
Latvia 2783 250 7.0 - 11.0 
China (non-DOTS) 650502 49844 6.3 - 9.0 
Russia 97223 5864 4.5 - 7.6 
India 1864390 63136 1.6 - 5.2 
Mozambique 86558 3023 2.4 - 4.6 
China (DOTS) 650502 18520 2.0 - 3.7 
Bangladesh 308271 4351 0 - 3.3 
Peru 54310 1666 2.3 - 3.1 
South Africa 215943 3267 0.6 - 2.4 
USA 15123 183 1.0 - 1.4 
England and Wales 6947 55 0.5 - 1.1 
 
 
These observations highlight the need for new anti-tuberculosis chemotherapeutic 
compounds and strategies to effectively combat the transmission of the new drug-resistant 
M. tuberculosis strains or shorten the standard treatment course. The main objectives for the 
development of new anti-tuberculosis drugs includes a faster mode of action in order to 
shorten therapy, drugs that can counter the current drug resistant M. tuberculosis 
phenotypes and drugs that are non-toxic in order to limit side effects. A further objective is 
the sterilisation of latent or persistent forms of M. tuberculosis (Ormerod, 2005). These 
objectives led to a renewed interest in the biology of M. tuberculosis to find potential and 
unique metabolic factors that might be developed as future targets of drug intervention 
(Cohn et al., 1997; Pablos-Mendez et al., 1998). 
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1.6 GLUTAMINE SYNTHETASE 
 
One of the M. tuberculosis molecules that emerged as a potential drug target is glutamine 
synthetase (GS) (EC 6.3.1.2, also known as L-glutamate: ammonia ligase). This enzyme 
plays a central role in nitrogen metabolism through its dual involvement in both ammonia 
assimilation and glutamine synthesis. Nitrogen is one of the major components of cell 
structures such as proteins, nucleic acids and coenzymes and therefore living organisms’ 
ability to assimilate inorganic nitrogen is essential. Glutamine synthetase is involved in 
nitrogen assimilation under conditions of nitrogen starvation by acting in sequence with 
glutamate synthetase (GOGAT) in the GS/GOGAT pathway (Figure 1.8) (Nolden et al., 
2001). Ammonia is used in the synthesis of glutamine from glutamate and then the amide 
nitrogen of glutamine is transferred to α-ketoglutarate resulting in the formation of glutamate. 
The glutamate molecule may then act as an amino donor in transaminase reactions, using 
ammonia in the synthesis of all amino acids (when the GS/GOGAT pathway is present).  
 
The role of GS in this pathway also serves as a means of an ammonia detoxification of cells, 
which together with CO2 are by-products of urea hydrolysis. High levels of ammonia are toxic 
to most living cells, and there is evidence that the GS enzyme may have evolved to fulfil an 
ammonia-detoxifying role even in the first primitive pre-prokaryotes (Kumada et al., 1993).   
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Figure 1.8. Ammonia incorporation through the synthetic action of glutamine synthetase 
(GS) and glutamate synthetase (GOGAT). 
 
1.6.1 Structure and biochemistry 
 
Glutamine synthetase is found in most living organisms in the form of three different 
isoforms: GS type I (GSI, found only in bacteria), GS type II (GSII, found in prokaryotes and 
eukaryotes) and GS type III (GSIII, some bacterial species). These GS isoforms differ with 
respect to regulation (see Section 1.6.3) and ultra-structure (see Figure 1.9).  
 
Early electron microscopy of E. coli GS (Valentine et al., 1968) as well as the crystal 
structure of unadenylylated Salmonella typhimurium GS (Janson et al., 1984), showed that 
the GS enzyme exists as a petal-shaped dodecameric structure composed of two inverted 
hexameric rings of identical subunits. 
 
 
 
 
 
 
Glutamine 
Glutamate 
GS GOGAT 
ATP 
ADP + Pi -ketoglutarate + NADPH 
Low [Nitrogen] 

4NH
High [Nitrogen] 
Glutamate NADP+  
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Figure 1.9. A visual comparison of GS protein domains shows the high degree of homology 
in functional regions and amino acids implicated in catalytic function. Note the presence of 
an adenylylation site in the GSI enzymes, which is lacking in the other GS classes. (Source: 
van Rooyen et al., 2006)    
 
The molecule has a central channel into which the central loops of each GS sub-unit 
protrude (Figure 1.10). The two hexameric rings are held together by hydrophobic and 
hydrogen bond interactions between the helical N- and C-termini of each eclipsed sub-unit 
(Almassy et al., 1986). These interactions are facilitated by the formation of a “hydrophobic 
hole” by the N-terminal of one sub-unit, into which the C-terminal α-helix (called a “helical 
thong”, see Figure 1.10) of the eclipsed sub-unit on the opposite hexameric ring inserts 
(Almassy et al., 1986).     
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Figure 1.10. Backbone diagram showing the interaction of the C- and N-termini of two 
eclipsed GS-sub-units. The C-terminal helical thong of the red sub-unit can be seen 
protruding into the blue sub-unit, thereby binding the two hexameric rings into a 
dodecameric structure. (Source: PDB http://www.rcsb.org/pdb/home/home.do) 
 
A striking feature of the GS molecule is that the 12 enzymatic active sites are formed 
through the interaction of the C-terminus β-strands of one sub-unit with the N-terminus β-
strands of a neighbouring sub-unit (Almassy et al., 1986).  These sites have been likened to 
a bi-funnel wherein ATP and glutamate bind at the opposite ends and two divalent cations 
bind at the bi-funnel joint. The cation binding sites, n1 and n2, can be occupied by either 
Mg2+ or Mn2+ for catalysis.  These metal ions are each connected by four ligands to the 
protein backbone (Almassy et al., 1986) and may have a regulatory effect on GS activity 
through inducing structural changes on binding. In the less active, or adenylylated state, GS 
prefers Mg2+ to Mn2+ for optimal activity (see Table 1.3 and Section 1.6.3).  The n1 cation 
binding site plays a role in the binding of glutamate and stabilising role active GS (Shapiro 
and Ginsburg, 1968). The n2 cation binding site is involved in phosphoryl transfer (Hunt et 
al., 1975) and interestingly has a 50 times lower affinity for metal ions than the n1 binding 
site (Hunt and Ginsburg, 1980).  
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Three-dimensional structures of M. tuberculosis GS sub-units have revealed that catalytic 
and regulatory amino acid residues may be situated on various mobile loops (Gill et al., 
2002). These include the Glu-327 flap (residues 324 – 329), the Asp-50 latch (residues 50 – 
64) and the Tyr-397 adenylylation loop (residues 388 – 411).  
 
 
Figure 1.11. Structure of a sub-unit (left) and hexameric ring of sub-units (right) of bacterial 
glutamine synthetase (Eisenberg et al., 2000). The helical thong formed by the C-terminal 
can be seen extending down the Z-axis in the representation of a single GS sub-unit. 
 
 1.6.2 Reaction mechanism 
 
The most important reaction catalysed by GS is the biosynthetic reaction that is the ATP-
dependent condensation of glutamate with ammonium to form glutamine: 
 
Glutamate + NH 4  + ATP       Glutamine + ADP + Pi  
 
In this reaction, GS uses either Mg2+ or Mn2+ as co-factor.     
 
The adenylylated form of the GS enzyme (see Section 1.6.3) catalyses the reverse or 
transferase reaction, which is the transfer of a glutamyl moiety of glutamine to 
hydroxylamine: 
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glutamine + hydroxylamine       γ-glutamylhydroxamate + ammonium 
 
In this reaction, the adenylated GS is active in the presence of Mn2+ (Luo et al., 2005), and 
has a pH optimum of 6.9 to 8.0 as the state of adenylylation increases from 0 to 12 
(Stadtman et al., 1970). 
 
The reaction mechanism possibly involves ATP and glutamate binding in their substrate 
sites at opposite ends of the active site in the initiating step (Eisenberg et al., 2000). The γ-
carboxylate group of glutamate attacks the γ-phosphate atom of ATP producing an activated 
γ-glutamyl phosphate intermediate and ADP (Liaw and Eisenberg, 1994). The ADP induces 
the movement of the Asp-50 latch to bind ammonium and subsequently deprotonates it to 
form active ammonia (Alibhai and Villafranca, 1994). In the second step of the reaction 
mechanisms, the ammonia ion attacks the δ-carbon of γ-glutamyl phosphate and forms a 
tetrahedral transition state intermediate. This intermediate is stabilised and protected from 
hydrolysis through the action of the Glu-327 flap, which closes the active site and thereby 
excludes water (Gill and Eisenberg, 2001). The Glu-327 residue accepts a proton from the 
transition state intermediate to form glutamine (Liaw et al., 1995). The glutamine escapes 
the active site at the bottom half of the bi-funnel where glutamate entered in the first step of 
the reaction.   
 
 1.6.3 Glutamine synthetase regulation through adenylylation 
 
One of the main differences between the three GS classes is that GSI can be regulated 
through the reversible esterification of AMP to the phenolic group of a tyr-residue (tyr-405 in 
the M. tuberculosis GS enzyme, Krajewski et al., 2005) in a process termed adenylylation 
(see Figure 1.9 for sequence comparison). The adenylylation and deadenylylation of GS is 
catalysed by the bi-functional GS adenylyltransferase (E.C 2.7.7.42) , encoded by glnE 
(Rhee et al, 1985; Berlett et al., 1998). Adenylylation of GS may proceed at a rate to match 
GS activity (and therefore glutamine production) with cellular glutamine utilisation, the 
enzyme being fully adenylylated in the presence of high glutamine concentrations and fully 
deadenylylated when glutamine levels are low. The mechanism explaining the effect of 
adenylylation has been described from data inferred from crystallographic models of E. coli 
GS (Figures 1.12 A and B), and suggests that the tyr-397 residue is situated on a mobile 
adenylylation loop which is in close proximity to the GS catalytic pocket (Almassy et al., 
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1986; Gill et al., 2002). Adenylylation of tyr-397 causes the adenylylation loop to move to a 
closer position to the glu-327 loop, enabling glu-327 to bind the adenyl group of AMP (Figure 
12 B). This bond immobilises the glu-327 latch disabling the completion of the catalytic 
pocket and changing the affinity of divalent metal ion binding in the catalytic site (Gill et al., 
2002).  In support of this model, a recent report has demonstrated that GS fails to be 
adenylylated when tyr-397 is substituted with either a serine or alanine residue (Luo et al., 
2005). In other bacteria, many of the genes involved in the regulation cascade of GS 
adenylylation (such as PII signalling molecules) are situated in operons in the vicinity of the 
glnA1 gene (Merrick et al., 1995; Schulz et al., 2001; Burkovski, 2003). It is not known if the 
same mechanisms control the GS-adenylylation cascade in M. tuberculosis.   
 
 
Figure 1.12. The mechanism of GS inhibition through the adenylylation of tyr-397 involves 
the movement of the adenylylation loop (yellow) towards the catalytic pocket of GS, where 
the α-carbon of glu-327 binds the adenyl group thereby preventing completion of the active 
site. Intermolecular distances between the participating atoms of glu-327 and tyr-397 
(depicted as ball and stick structures) are shown in Å (Figure from Luo et al., 2005). 
 
  
1.6.4 Regulation through feedback inhibition 
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Glutamine synthetase is also subject to feedback inhibition by several end products of 
glutamine metabolism, namely histidine, tryptophan, AMP, CTP, carbamyl-phosphate, 
glucosamine-6-phosphate, and NAD+, and also by glycine and alanine (Woolfolk and 
Stadtman, 1964). All these compounds interact with different allosteric sites of the enzyme, 
since saturation of the GS enzyme with any one inhibitor only partially inhibits its function, 
whereas mixtures of inhibitors at a physiological concentration, effectively inhibit GS 
enzymatic function up to 90% (Shapiro and Stadtman, 1970). However, feedback inhibition 
is also influenced by the adenylylation state of the sub-units of the enzyme (Kingdon and 
Stadtman, 1967). Fully deadenylylated enzyme appears insensitive to feedback inhibition 
(Shapiro et al., 1967). 
 
Table 1.3 Comparison of the characteristics of deadenylylated and adenylylated GS (Luo et 
al., 2005).  
Characteristic deadenylylated  adenylylated 
Mg2+-dependent biosynthetic activity yes no 
Mn2+-dependent biosynthetic activity no yes 
Mg2+-dependent γ-glutamyltransferase activity yes no 
Mn2+-dependent γ-glutamyltransferase activity yes yes 
pH optimum for Mn2+-dependent γ-glutamyltransferase 
activity 8 6.9 
feedback inhibition sensitivity absent enhanced 
effect of 4,5 M urea none inactivated
  
 
 1.6.5 Glutamine synthetase of M. tuberculosis 
 
The structure of M. tuberculosis GS and many aspects of its physiological role has been the 
subject of various studies. However, there still remain many features unique to M. 
tuberculosis GS of which the mechanisms have not been elucidated. 
   
Glutamine synthetase is encoded by the glnA genes of which four homologues (glnA1, 
glnA2, glnA3 and glnA4) have been identified in the M. tuberculosis genome (Cole et al., 
1998). It is thought that glnA1 encodes a GSI enzyme, while glnA2 encodes a GSII enzyme. 
The glnA3 and glnA4 gene sequences encode probable GSI and GSII enzymes, however 
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the amino acid residues usually associated with GS enzymes are less conserved in these 
protein sequences. It has recently been shown that the above glnA genes encode functional 
GS enzymes, with the GS encoded by glnA1, glnA3 and glnA4 synthesising L-glutamine, 
while the glnA2 GS synthesises D-glutamine and D-isoglutamine (Harth et al., 2005). 
However it was also shown that only glnA1, and not the glnA2, glnA3 and glnA4 genes, were 
able to complement a M. smegmatis glutamine auxotroph, suggesting that the main GS 
encoding locus is glnA1 (Harth et al., 2005). In support of this finding, it has previously been 
demonstrated through transposon site hybridisation studies that a functional glnA1 is 
essential for the growth and survival of M. tuberculosis (Sassetti et al., 2003).  
 
The glnA1 gene is situated in close proximity to the genes encoding the adenylyl-transferase 
(glnE, see Section 1.4.2) and glnA2 (see Chapter 4, Figure 4.1) (Cole et al., 1998). The 
adenylyl-transferase is involved in the reversible inhibition of GSI enzymes (Section 1.6.3) 
and it has been shown (via glnE mutation) that a functional adenylyl-transferase is essential 
for M. tuberculosis survival (Parish et al., 2000).  In this report, the authors speculated that 
glnE mutation resulting in absence of adenylyl-transferase activity could lead to a depletion 
of cellular glutamate through the un-regulated action of GS.  It has also been shown that 
glnA2 may be essential for M. bovis growth in minimal media (Collins et al., 2002). In that 
study, it has also been shown that glnA2 mutants lost the ability to cause infection in guinea 
pigs, however, the role of glnA2 during infection has not been clarified.   
 
 1.6.5.1 Glutamine synthetase is a major exogenous protein of M. tuberculosis 
 
Glutamine synthetase activity is normally limited to the cytosolic fraction of cells, but GS 
activity has been detected in the exogenous environment of infectious mycobacteria, 
specifically M. tuberculosis and M. bovis, including the M. bovis BCG strains (Harth and 
Horwitz, 1994). In M. tuberculosis, GS is one of the most abundant of the approximately 200 
protein species found in the M. tuberculosis culture filtrate (Harth et al., 1994; Sonnenberg 
and Belisle, 1997) suggesting that active GS could be exported to the exogenous 
environment of M. tuberculosis.   
 
This observation led the hypothesis that exogenous GS activity may be a unique feature and 
probably a virulence factor of M. tuberculosis, as other non-infectious mycobacteria such as 
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M. smegmatis, M. phlei, M. fortuitum and M. kansasii do not show this phenomenon 
(Raynaud et al., 1998).  
 
Table 1.4 Comparison of the endo- vs. exogenous GS activity of various bacterial species 
(Harth and Horwtiz, 1994).  
 GS activity 
 Cell extract (A) Culture supernatant (B) Ratio B/A 
M. tuberculosis       
     Erdmann 63.7 28.7 1: 1.2 
     H37Rv 42.3 18.1 1: 2.3 
     H37Ra 36.5 16.4 1: 2.2 
M. bovis BCG 49.6 11.4 1: 4.3 
M. smegmatis 6.3 0.06 1: 105 
M. phlei 6.9 0.06 1: 115 
E. coli DH5α 2.1 ≤ 0.01 ≤ 1: 210 
L. pneumophila 2.1 ≤ 0.02 ≤ 1: 211 
B. subtilis 2.8 ≤ 0.03 ≤ 1: 280 
 
 
In addition, irreversible inhibition of exogenous GS with a non-covalently binding glutamate 
analog such as L-methionine-S-sulfoximine which is specific for GS and is unable to cross 
the mycobacterial cell wall (Harth and Horwitz, 1999), has a bacteriostatic effect on M. 
tuberculosis growth in both liquid culture and in M. tuberculosis infected human monocyte 
cell lines (Harth and Horwitz, 1999). In this study, it was also observed that the bacteriostatic 
effect was obtained in M. tuberculosis and M. bovis cultures only and that L-methionine-S-
sulfoximine (an inhibitor of GS, Manning et al., 1969) had no effect on cultures of other 
mycobacteria that do not exhibit exogenous GS activity.  
 
The mechanism of export and the function that GS fulfils in the exogenous M. tuberculosis 
environment is unknown, although it has been speculated that exogenous GS might play a 
role in delaying lysosome fusion by inhibiting phagosomal acidification (Miller and Shinnick, 
2000). This hypothesis was based on the enhanced survival (up to 6 fold over a 24 hour 
period) of recombinant M. smegmatis (a non-infectious species of the mycobacterial genus) 
expressing M. tuberculosis glnA1 in human macrophages. Previous studies have shown that 
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the expression of M. tuberculosis glnA1 in M. smegmatis yields a recombinant protein 
identical to the native M. tuberculosis GS protein and that this GS activity could also be 
detected in the M. smegmatis transformants’ culture filtrate (Harth and Horwitz, 1997).  From 
this observation, it has been hypothesised that GS is not actively exported by M. 
tuberculosis, and that the high concentration of GS in the exogenous environment of M. 
tuberculosis is due to mycobacterial lysis and the exogenous stability of the GS protein in the 
exogenous M. tuberculosis environment (Tullius et al., 2001).  
 
 1.6.6 Why is exogenous GS essential for M. tuberculosis survival? 
 
The reason for the observed bacteriostatic effect by L-methionine-S-sulfoximine described 
earlier is still unclear, but it is thought that exogenous GS might also be involved in cell wall 
biosynthesis of the pathogenic mycobacteria M. tuberculosis and M. bovis. This hypothesis 
is based on the observation that poly-L-glutamic acid, a polymer unique to the cell walls of 
M. tuberculosis and M. bovis, coincides with exogenous GS activity (Harth et al., 2002). In 
the study by Harth et al. (2002), it was also hypothesised that GS may play a direct role in 
the synthesis of poly-L-glutamic acid, as it was shown that the concentration of this polymer 
decreases if GS is inhibited (Harth and Horwitz, 1999) or glnA1 activity is inhibited (Harth et 
al., 2000). The physiological and functional role and synthesis mechanism of poly-L-glutamic 
acid in the M. tuberculosis cell wall is still unknown. Besides playing a possible role on the 
cell wall integrity of M. tuberculosis through poly-L-glutamic acid synthesis, it was also 
hypothesised that GS might play a role in the disruption of phagosome-lysosome fusion 
through its involvement in nitrogen metabolism and ammonium production (Harth and 
Horwitz, 1994).  
 
 
 
 
 
 
 
 
1.7 PROBLEM STATEMENT 
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Because of the essential role of GS in M. tuberculosis intracellular growth and survival, GS 
has been identified as a potential target for new anti-tuberculosis antibiotics. However, not 
much is known about the evolutionary stability of the GS encoding locus, glnA1, in M. 
tuberculosis or its expression during active disease. Furthermore, other factors may play a 
role in the physiological properties of M. tuberculosis, such as its export and secretion into 
the exogenous environment, which may be unique to M. tuberculosis. These mechanisms 
are still poorly understood and may reveal other areas for potential antibiotic intervention.  
 
1.8 OBJECTIVES OF THE CURRENT STUDY 
 
Objective 1: To investigate the evolution and genetic diversity of M. tuberculosis 
GS and its encoding gene, glnA1.  
 
It is hypothesised that the genome of M. tuberculosis is not stable and continues to evolve 
and that this genomic evolution may impact on strain fitness and virulence (Warren et al., 
2000). There are a number of genetically diverse strains of M. tuberculosis that are known to 
vary in terms of virulence, as some may be more infectious than others (Manca et al., 2001; 
Lopez et al., 2003). In the light of these hypotheses, it is necessary to evaluate the genetic 
stability of glnA1, as mutations in this gene may be reflective of altered GS structure and 
function between the different M. tuberculosis strain families. Such mutations may also 
complicate antibiotic design and contribute to the emergence of resistance. 
 
 Objective 2: To investigate glnA1 expression during active disease  
 
Mycobacterium tuberculosis is a facultative intracellular pathogen that resides within the 
granuloma, a structure formed through the activation of the immune system after infection 
(Schlesinger et al., 1990) where it may be exposed to varying aerobic (Wayne & Sohaskey, 
2001) and toxic (Russell, 2001) conditions not conducive to bacterial growth. Not much is 
known about the mechanisms enabling M. tuberculosis to survive in these conditions. 
Therefore the expression of glnA1 in M. tuberculosis infected human tissues may indicate 
the importance of GS in vivo, as the conditions in the granuloma during active disease may 
differ from conditions created in the laboratory.  
Objective 3: To investigate the regulation of GS synthesis and other factors that 
might be involved in GS secretion and export.  
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Mycobacterium tuberculosis (as well as M. bovis, including the M. bovis BCG strains) is 
unique in having functional GS in its exogenous environment (Harth et al., 1994). Therefore 
we hypothesise that there may be factors unique to M. tuberculosis that might enable the 
mycobacterium to actively or passively transport GS over its cell wall. Understanding these 
mechanisms may identify other unique mechanisms, which can be exploited as possible 
anti-tubercular drug targets. Therefore the regulation of M. tuberculosis GS expression and 
export will be studied in an M. smegmatis host, which does not secrete its own GS (Harth 
and Horwtiz, 1994). Furthermore, the co-regulation of genes situated in gene cluster (glnE; 
glnA2; Rv2223c and Rv2224c) downstream of glnA1 will be investigated to establish their 
functional relationship to GS transport.  
 
 
http://scholar.sun.ac.za
 36
 
 
CHAPTER TWO 
 
 
 
Evolutionary ancestry and stability of M. tuberculosis glnA1 
 
 
 
“Man is the only creature that consumes without producing. He does not give milk, he does 
not lay eggs, he is too weak to pull the plow, he cannot run fast enough to catch rabbits. Yet 
he is lord of all the animals” 
 
Eric Arthur Blair (George Orwell), Animal Farm 
(Born June 25, 1903; died of tuberculosis January 10, 1950) 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Parts of the results presented in the following chapter have been submitted for review 
publication as: ” Evolution and stability of M. tuberculosis glnA1. Hayward, D; van 
Helden, P and I Wiid. Submitted to BMC Evolutionary Biology (2007) 
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2.1 INTRODUCTION 
 
The essential role of the gene encoding glutamine synthetase (GSI-, hereafter referred to 
as GS), glnA1, in the growth and survival of M. tuberculosis has been described in several 
reports (Harth et al., 2000; Lee et al., 2006). These studies made use of methods that disrupt 
GS synthesis, such as either glnA1 mutation or translation inhibition through anti-sense 
technology. These studies imply that other glnA genes (glnA2, glnA3 and glnA4) residing on 
the M. tuberculosis chromosome are unable to complement glnA1 disruption (see Section 
1.6.5). In this regard, a recent study has shown that all the M. tuberculosis glnA1 homologs 
encode functional, but non-essential GS enzymes that are not as abundantly expressed as 
glnA1 (Harth et al., 2005). Therefore glnA1 may be the major GS-producing locus in M. 
tuberculosis, which is similar to observations of glnA1 deletion in other high G+C genome 
mycolic acid containing Actinomycetes, such as Corynebacterium glutamicum. Similar to M. 
tuberculosis, deletion of the C. glutamicum glnA1 results in the complete loss of GS activity 
and subsequent glutamine auxotrophy despite the presence of glnA2 in C. glutamicum 
(Jakoby et al., 1997). Therefore, it appears that glnA2 is unable to complement deletion of 
the C. glutamicum glnA1 and relieve glutamine auxotrophy. This observation, together with 
that of GS export by pathogenic mycobacteria (see Section 1.6.5.1) may all point to GS 
playing other roles in M. tuberculosis pathogenesis, which may not be present in non-
pathogenic mycobacteria. This has been demonstrated by increased survival rates of M. 
smegmatis expressing M. tuberculosis glnA1 in THP-1 macrophages (Miller and Shinnick, 
2000). In that study it was speculated that M. tuberculosis GS might be involved in delaying 
phagosome acidification, thereby delaying lysosome fusion. These differences may be due to 
information contained in the glnA1 and GS-protein sequences and structure.   
 
 2.1.1 Study aims: 
 
2.1.1.1 To study glnA evolution in the Actinobacteria. The ancestry of glnA1 might indicate 
the importance of this locus and why it is the main GS-producing locus in M. tuberculosis. 
This study may also indicate the distribution and importance of other GS encoding loci. 
 
2.1.1.2 To investigate the similarity of the GS sequence between the closely related mycolic 
acid producing CMN-subgroup (Corynebacteria sp., Mycobacteria sp. and Nocardia sp.) of 
the Actinobacteria. The extent of evolutionary change in the GS protein sequence during 
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bacterial diversification may indicate the probability of changes that would allow GS to 
accomplish other functions during M. tuberculosis growth and survival.   
 
2.1.1.3 To investigate the genetic stability of the glnA1 locus and its immediate 5’- and 3’- 
flanking DNA sequences through M. tuberculosis strain diversification. Changes in nucleotide 
sequence may indicate the mutation tolerance of GS and may be of importance for antibiotic 
design and usage.  
 
2.2 RESULTS 
 
 2.2.1 Actinobacteria GS phylogeny 
 
The ancestry of the glnA sequence was investigated through phylogenetic analysis of the 
glnA-like orthologs present in the Actinobacteria (see Section 1.2.1). These orthologous 
protein sequences were obtained through BLAST comparison (Materials and Methods 2.3) of 
the M. tuberculosis H37Rv GS proteins encoded by the glnA1, glnA2, glnA3 and glnA4 open 
reading frames to all available actinobacterial genomes. Sequences of high similarity to M. 
tuberculosis GS I (encoded by glnA1) and GS II (encoded by glnA2) were detected in most of 
the available Actinobacteria genomes (Table 2.1). The GS I and GS II sequences were of 
comparable amino acid length and were more than 60% identical to the corresponding 
sequences in M. tuberculosis H37Rv, the only exceptions being the GS I and GS II 
sequences of Rubrobacter xylanophilus (GS I = 34% similar; GS II = 52% similar) and 
Symbiobacterium thermophilum, which had one GS sequence with 50% amino acid 
homology to M. tuberculosis GS I. The GS protein sequences encoded by M. tuberculosis 
H37Rv glnA3 and glnA4 had lower overall homology to orthologous sequences in the other 
Actinobacteria. One (most notably glnA3) or both of these protein sequences were absent in 
some Actinobacteria. The members of the Micrococcineae suborder (Bifidobacterium 
longum, Leifsonia xyli subspecies xyli, Nocardiodes, Kineococcus radiotolerans and 
Brevibacterium linens) (Stackebrandt et al., 1997) have no glnA3 and glnA4 encoded GS 
protein sequences. The bacteria in the Streptomycineae suborder (S. avermitillis and S. 
coelicolor) have three GS sequences that show the highest homology to the proteins 
encoded by the M. tuberculosis glnA1, glnA2 and glnA4 genes. All members of the M. 
tuberculosis complex had four GS sequences sharing 100% homology to each other (see 
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Table 2.1). Some mycobacteria, such as M. leprae and M. ulcerans, had only glnA1 and 
glnA2 encoded GS orthologs. 
 
The orthologous GS protein sequences obtained by sequence BLAST were aligned 
according to amino acid similarity index using ClustalW software (Materials and Methods 
2.3.1). Phylogenetic analysis of these ClustalW alignments was carried out using the 
program Paup 4.0b4a (Swofford, 1998), with which a consensus tree was generated from  
1000 bootstrapped trees using the majority formula. Branch lengths from the consensus 
trees of all of the above were drawn using the program Treeview 1.5 (Page, 1996). The GS I 
sequence of Symbiobacterium thermophilum was chosen as out-group for the phylogenetic 
reconstruction because S. thermophilum is most closely related to an Actinobacteria 
ancestor (see Figure 1.2). Figure 2.1 shows that the orthologous GS protein sequences are 
clustered into separate clades depending on the encoding glnA gene sequence. In these 
clades, bacteria of the same genus are partitioned into separately evolving lineages that 
resemble accepted phylogenetic trees (see Figures 1.2 and 1.3).  
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Table 2.1 GlnA sequence orthologs and their distribution in the Actinobacteria. The percentage homology to the M. tuberculosis 
orthologs is indicated by means of amino acid identity. The accession number and amino acid (aa) length of the protein sequence is 
indicated for each sequence. Shaded sequence information indicates the same gene.  
 
Identities Sequence acc. nr Identities Sequence acc. nr Idenitities Sequence acc. nr Identities Sequence acc. nr
Acidothermus cellulolyticus  11B 343/475 (72%) YP_872682 474 aa 311/452 (68%) YP_872678 453 aa 103/341 (30%) YP_872678  453 aa 273/445 (61%), YP_873609 446 aa
Arthrobacter sp. FB24 300/475 (63%) YP_947504 474 aa 296/449 (65%) YP_947491 446 aa 97/332 (29%) YP_831086  446 aa 119/379 (31%), YP_831086 446 aa
Bifidobacterium longum  NCC2705 296/475 (62%) NP_696248 478 aa 268/444 (60%) NP_696466 445 aa 92/335 (27%) NP_696466  445 aa     132/449 (29%), NP_696466 445 aa
Brevibacterium linen s BL2 294/470 (62%) ZP_00378605 474 aa 282/452 (62%) ZP_00378066 452 aa 102/350 (29%) ZP_00378066 452 aa 254/452 (56%), ZP_00381218 454 aa 
Corynebacterium diphtheriae  NCTC 13129 319/471 (67%) NP_939986 478 aa 286/444 (64%) NP_940011 446 aa 87/340 (25%) NP_940011 446 aa 129/447 (28%) NP_940011 466 aa
  C. efficiens  YS-314 303/472 (64%) NP_738714 477 aa 297/444 (66%) NP_738737 516 aa  98/331 (29%) NP_738737 516 aa      130/446 (29%) NP_738737 516 aa
  C. glutamicum  ATCC 13032 334/474 (70%) YP_226455 477 aa 293/444 (65%) YP_226471 446 aa 93/318 (29%) YP_226471 446 aa 132/446 (29%) YP_226471 446 aa
  C. jeikeium  K411 340/477 (71%) YP_250482 500 aa 319/445 (71%) YP_250455 448 aa 94/318 (29%) YP_250455 448 aa     133/451 (29%) YP_250455 448 aa
Frankia sp. EAN1pec 316/472 (66%) EAN12723 474 aa 296/451 (65%) EAN12719 452 aa 173/453 (38%) EAN17203 496 aa 246/437 (56%), EAN15827 470 aa
Janibacter  sp. HTCC2649 314/472 (66%) EAP98744 474 aa 315/44 (70%) EAP99396 445 aa 183/432 (42%) EAP99483 446 aa 272/454 (59%), EAP97657 461 aa
Kineococcus radiotolerans  SRS30216 322/472 (68%) EAM74067 474 aa 294/446 (65%) EAM74062 447 aa 77/245 (31%) EAM74062  447 aa 275/450 (61%), EAM72715 460 aa
Leifsonia xyli  subsp. xyli str. CTCB07 293/471 (62%) YP_062980 474 aa 285/446 (63%) YP_061977 445 aa 95/332 (28%) YP_061977 445 aa   122/379 (32%), YP_061977 445 aa
Mycobacterium avium  104 431/478 (90%) YP_881471 478 aa 420/446 (94%) YP_881448 446 aa 350/433 (80%) YP_882016 450 aa 364/461 (78%), YP_882894 468 aa
  M. bovis  AF2122/97 478/478 (100%) NP_855893 478 aa 446/446 (100%) NP_855895 446 aa 450/450 (100%) NP_855562 450 aa 475/475 (100%) NP_856530 457 aa
  M. bovis  BCG str. Pasteur 1173P2 478/478 (100%) YP_978326 478 aa 446/446 (100%) YP_978328 446 aa 450/450 (100%) YP_978005 450 aa 475/475 (100%) YP_978966 475 aa
  M. flavescens  PYR-GCK 403/478 (84%) EAS12379 478 aa 398/446 (89%) EAS12360 446 aa 286/433 (66%) EAS10635 453 aa 338/454 (74%), EAS09445 469 aa
  M. leprae  TN 439/478 (91%) NP_301707 478 aa 418/448 (93%) NP_302123 448 aa 90/333 (27%) NP_302123 448 aa 135/455 (29%) NP_302123 448 aa
  M. smegmati s str. MC2 155 402/478 (84%) YP_888567 478 aa 396/446 (88%) YP_888571 446 aa 280/433 (64%) YP_887864 453 aa 336/451 (74%) YP_886932 457 aa
Mycobacterium  sp. KMS 407/478 (85%) YP_939366 478 aa 398/446 (89%) YP_939374 446 aa 205/432 (47%) YP_936250 437 aa 334/449 (74%) YP_938091 455 aa
  M. tuberculosis  CDC1551 478/478 (100%) NP_336749 478 aa 446/446 (100%) NP_336751 446 aa 450/450 (100%) NP_336385 450 aa 475/475 (100%) NP_337439 457 aa
  M. tuberculosis  F11 478/478 (100%) ZP_01685137 478 aa 446/446 (100%) ZP_01685139 446 aa 450/450 (100%) ZP_01684789 450 aa 475/475 (100%) ZP_01685769 462 aa
  M. tuberculosis  H37Rv 478/478 (100%) NP_216736 478 aa 446/446 (100%) NP_216738 446 aa 450/450 (100%) NP_216394 450 aa 100% 457/457 NP_217376  457 aa
  M. ulcerans  Agy99 430/477 (90%) YP_905364 478 aa 417/446 (93%) YP_905360 446 aa 90/331 (27%) YP_905360 446 aa 139/455 (30%), YP_905360 446 aa
  M. vanbaalenii  PYR-1 411/ 478 (85%) YP_954385 478 aa 395/446 (88%) YP_954396 446 aa 202/432 (64%) YP_953732 442 aa 326/450 (72%), YP_953098 459 aa
Nocardia farcinica  IFM 10152 371/478 (77%) YP_117877 478 aa 372/446 (83%) YP_117870 446 aa 94/331 (28%) YP_117870 446 aa 144/458 (31%), YP_117870 446 aa
Nocardioides  sp. JS614 339/ 472 (71%) YP_923487 474 aa 290/439 (66%) YP_923242 455 aa 95/331 (28%) YP_923242 455 aa 265/449 (59%), YP_923778 464 aa
Propionibacterium acnes  KPA171202 316/473 (66%) YP_055385 473 aa 283/444 (63%) YP_055378 468 aa 102/333 (30%) YP_055378 468 aa   125/407 (30%) YP_055378 468 aa
Rhodococcus  sp. RHA1 384/474 (81%) YP_701142 478 aa 376/446 (84%) YP_701152 446 aa 203/430 (47%) YP_701692 433 aa 150/442 (33%), YP_705251 451 aa
Rubrobacter xylanophilus  DSM 9941 169/484 (34%) YP_643903 443 aa 231/441 (52%) YP_643903 443 aa 101/326 (30%) YP_643809 444 aa 286/448 (63%), YP_645913 455 aa
Salinispora tropica  CNB-440 331/472 (70%) EAU21273 474 aa 311/453 (68%) EAU21297 451 aa 99/339 (29%) EAU21297 451 aa 138/459 (30%), EAU21297 451 aa
Streptomyces avermitilis  MA-4680 335/472 (70%) NP_827182 469 aa 312/452 (69%) NP_827131 453 aa 100/344 (29%) NP_827131 453 aa 296/452 (65%), NP_827901 454 aa
  S. coelicolor A3(2) 339/472 (71%) NP_626450 469 aa 316/452 (69%) NP_626490 453 aa 98/341 (28%) NP_626490 453 aa 290/452 (64%) NP_625889 462 aa
Symbiobacterium thermophilum  IAM 14863 283/475 (50%) YP_074027 471 aa 158/147 (33%) YP_074027 471 aa 55/190 (28%) YP_074027 471 aa 105/320 (32%), YP_074027 471 aa
Thermobifida fusca YX 323/472 (68%) YP_289049 474 aa 311/452 (68%) YP_289043 453 aa 95/342 (27%) YP_289043 453 aa 131/458 (28%) YP_289043 453 aa
marine actinobacterium PHSC20C1 304/471 (64%) EAR23759 478 aa 278/446 (62%) EAR25342 445 aa 100/370 (27%) EAR25918 416 aa      315/449 (70%), EAR26195 455 aa
gln A4
Organism
gln A1 gln A2 gln A3
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Figure 2.1. Phylogenetic reconstruction of GS sequence evolution in the Actinobacteria. 
Branch lengths are proportional to the number of evolutionary events (scale bar equals 0.1 
evolutionary events) and branches with zero length were collapsed. 
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2.2.2 Glutamine synthetase sequence similarity in the closely related CMN subgroup 
 
To study the variation of the glnA1 encoded GS I protein sequence in the closely related 
Corynebacteria, Mycobacteria and Nocardia (CMN) subgroup of the phylum Actinobacteria, 
the GS I protein sequences of all available mycobacteria as well as Corynebacterium 
glutamicum, C. diphtheriae, C. efficiens, C. jeikeium and Nocardia farcinica were compared by 
multiple sequence alignment with ClustalW (Materials and Methods 2.3.1). The GS I protein 
sequences of all the members of the M. tuberculosis complex (M. tuberculosis including the 
H37Rv, F11 and CDC1551 sub-strains, M. bovis and M. bovis BCG Pasteur) were 100% 
similar in every respect. The GS I sequences of the other mycobacteria were very similar to 
the GS I sequence of the members of the M. tuberculosis complex. All sequences were of 
equal length (478 amino acids) with amino acid homology between 84% (M. smegmatis) and 
91% (M. leprae) (Table 2.1). The GS I sequences of the Corynebacteria showed some 
variation in protein length (between 477 and 500 amino acids) and were between 64% (C. 
efficiens) and 71% (C. jeikeium) similar to the M. tuberculosis complex GS I. The GS I 
sequence of N. farcinica had a length of 478 amino acids and was 77% similar to the M. 
tuberculosis complex GS I.  
 
Figure 2.2 shows the ClustalW multiple sequence alignment of the CMN subgroup GS I 
sequences. A high degree of amino acid homology can be observed between all the 
sequences towards the C-terminal, while homology is less pronounced at the N- terminus. 
Some sequence variation has occurred in the Corynebacteria GS I adenylylation and GS 
consensus signatures that differs from the classical signature sequences. In the 
Corynebacteria, leu (L) is substituted with asn (N) in the GS consensus signature (Figure 2.2), 
while val (K) is substituted with arg (R) in the adenylylation consensus sequence (Figure 2.2). 
Leu (L) has been substituted with met (M) in the GS consensus sequence in M. smegmatis. In 
agreement with the phylogenetic reconstruction showing separate GS I sequence evolution 
between slow and fast growing mycobacteria (Figure 1.3), it can be seen that the GS I 
sequences of the fast- and slow growing mycobacteria share greater amino acid homology to 
each other respectively. Similarly, the GS I amino acid sequence evolution could be observed 
in the Corynebacteria, where the sequences of C. efficiens and C. glutamicum share higher 
homology to each other than to that of C. jeikeium and C. diphtheriae. 
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Figure 2.2. Glutamine synthetase protein homology between different mycobacteria. The GS 
consensus signature [FYWL]-D-G-S-S-x(6,8)-[DENQSTAK]-[SA]-[DE]-x(2)-[LIVMFY] is 
highlighted in yellow, the putative ATP-binding region K-P-[LIVMFYA]-x(3,5)-[NPAT]-G-
[GSTAN]-G-x-H-x(3)-S in grey and the adenylylation site consensus sequence K-[LIVM]-x(5)-
[LIVMA]-D-[RK]-[DN]-[LI]-Y where Tyr (Y) is the site of adenylylation in green. Putative active 
site amino acid residues (Eisenberg et al., 2002) are indicated in red. An asterix (*) indicates 
identical sequence. 
M. tuberculosis    ----------------------VTEKTPDDVFKLAKDEKVEYVDVRFCDLPGIMQHFTIPASAFDKSVFDDGLAFDGSSIRGFQSIHESDMLLLPDPETARIDPFR
M. leprae          ----------------------MTEKTSDDVLKLAKDENIEFVDVQFCDLPGIMQHFTIPASAFDKSVFEDGLAFDGSSIRGFQSIHESDMLLFPDPDTARIDPFR
M. avium           ----------------------MTETTPDDVFKLAKDEKVEFVDVRFCDLPGIMQHFTIPVSFFDESVFEDGLAFDGSSIRGFQSIHESDMLLLPDPATAQIDLFR
M. ulcerans        ----------------------MTDKTPDDVFKLAKDDGVEFVDVRFCDLPGVMQHFTIPISFFDEAVFEDGLAFDGSSIRGFQSIHESDMLLLPDPDTAIIDQFR
M. flavescens      ----------------------MAEQTADDIIKLIKDESVEYVDIRFCDLPGVVQHFSIPASAFDESVFEDGLAFDGSSVRGFQSIHESDMMLLPDPATARIDPFR
M. smegmatis       ----------------------MAEKTSDDIFKLIKDENVEYVDIRFCDLPGVVQHFSIPASAFDESVFEDGLAFDGSSVRGFQSIHESDMMLLPDPNTARIDPFR
Mycobacterium KMS  ----------------------MADKTADDIIKLIKDESVEYVDIRFCDLPGVVQHFSIPASAFDESVFEDGLAFDGSSVRGFQSIHESDMMLLPDPETARIDPFR
M. vanbaalenii     ----------------------MAEKTADDIIKLIKDEQVEYVDIRFCDLPGVVQHFSIPASAFDESVFEDGLAFDGSSVRGFQSIHESDMMLLPDPETARIDPFR
N. farcinia        ----------------------MTFSTADEVIQYIKEQDIEYIDIRFSDLPGVQQHFSIPAKAFTADLAEEGLAFDGSSVRGFQSIDESDMLLLPDYSTARIDPFR
C. jeikeium        MCCFYILSQQFEIPTARNGRNTVSFKTAEEVAKYIKDNDVEFVDVRFTDVPGIEQHFTIPASEFDEDAMEEGLAFDGSSVRGFTTIEESDMNLLPDLATAKIDPFR
C. diphtheria      ----------------------MAFTSTEDVIKYIKEENVEFLDIRFTDVPGREQRITIPASMFTEEAAEDGFAFDGSSIRGFTTIDESDMNLHPDIATAMVDPFR
C. effeciens       ----------------------MAFNTPEEVTKFIKDENVEFVDVRFTDLPGIEQHFSIPASALDEDAIEEGLAFDGSSIRGFTTIDESDMNLLPDLATAKIDPFR
C. glutamicum      ----------------------MAFETPEEIVKFIKDENVEFVDVRFTDLPGTEQHFSIPAASFDADTIEEGLAFDGSSIRGFTTIDESDMNLLPDLGTATLDPFR
                                         ::  :.::: :  *:: :*::*::* *:**  *:::**:        ::*:******:*** :*.**** * **  ** :* **
 
M. tuberculosis    AAKTLNINFFVHDPFTLEPYSRDPRNIARKAENYLISTGIADTAYFGAEAEFYIFDSVSFDSRANGSFYEVDAISGWWNTGAATEADGSPNRGYKVRHKGGYFPVA
M. leprae          AAKTLNVNFFVHDPFTLEPYSRDPRNIARKAENYLISTGIADTVYFGAEAEFYIFDSVSFDSRSNGSFYQVDAISGWWNTGAATESDGSPNRGYKVRHKGGYFPVA
M. avium           EAKTLNLNFFVHDPFTLEPYSRDPRNIARKAENYLISTGVADTAYFGAEAEFYIFDSVSFDSRTNGSFYEIDAISGWWNTGSPNELDGSPNRGYKVRPKGGYFPVA
M. ulcerans        EAKTLNLNFFVHDPFTLEPYSRDPRNVARKAENYLISTGIADTAYFGAEAEFYIFDSVAFDSRTNGSFYEVDAISGWWNTGAANEADGGPNLGYKVRPKGGYFPVA
M. flavescens      AAKTLNMNFFVHDPFTREAYSRDPRNVARKAENYLASTGIADTCFFGAEAEFYIFDSVTFDSKINGTFYEVDSESGWWNTGEPFEADGSANRGYKVRPKGGYFPVA
M. smegmatis       AAKTLNMNFFVHDPFTREAYSRDPRNVARKAENYLASTGIADTAFFGAEAEFYIFDSVSFDSKINGTFYEVDSESGWWNTGEPFESDGSANRGYKVRPKGGYFPVA
Mycobacterium KMS  HAKTLNMNFFVHDPFTREAYSRDPRNVARKAENYLISTGIADTCYFGAEAEFYIFDSVTFDSKINGTSYEVDSESGWWNTGEPFEADGSANRGYKVRPKGGYFPVA
M. vanbaalenii     AAKTLNLNFFVHDPFTREAYSRDPRNVARKAENYLASTGIADTAYFGAEAEFYIFDSVSFDSRINGTFYEVDSESGWWNTGEPLEADGSPNRGYKVRPKGGYFPVA
N. farcinia        AAKTLNMNFFVHDPFTREAYSRDPRNIARKAEEYLRSTGIADTAFFGPEAEFYIFDSIRYESNMNGAFYEIESISGSWNTGAEFNPDGTLNRGYKVRNKGGYFPVA
C. jeikeium        KAKTLNVKFFVHDPFTREPFSRDPRNVARKAEQYLASTGIADTCFFGAEAEFYLFDSARFEADTNRAFYELDSVEGWWNRGAEVNPDGTPNLGYKTRMKGGYFPVA
C. diphtheria      KAKTLNMKFFVHDPFTREPFSRDPRNVARKAEQYLASTGIADTCFFGAEAEFYVFDKVSYEIEGNRSHYEVDSDNGWWNRGVDQNLDGTHNRGYKTPFKGGYGQCA
C. effeciens       KAKTLNIKFFVHDPFTREAFSRDPRNVARKAEQFLASTGIADTCNFGAEAEFYLFDSVRYSTDINSGFYHVDTNEGWWNRGRETNLDGTPNTGSKNRLKGGYFPVA
C. glutamicum      KAKTLNVKFFVHDPFTREAFSRDPRNVARKAEQYLASTGIADTCNFGAEAEFYLFDSVRYSTEMNSGFYEVDTEEGWWNRGKETNLDGTPNLGAKNRVKGGYFPVA
                    *****::******** *.:******:*****::* ***:***  **.*****:**.  :.   *   *.::: .* ** *   : **  * * *   ****   *
 
M. tuberculosis    PNDQYVDLRDKMLTNLINSGFILEKGHHEVGSGGQAEINYQFNSLLHAADDMQLYKYIIKNTAWQNGKTVTFMPKPLFGDNGSGMHCHQSLWKDGAPLMYDETGYA
M. leprae          PNDQYVDLRDKMLTNLTNAGFVLEKGHHEVGTGGQGEINYQFNTLLHAADDMQLYKYIVKNTAWQNGKTVTFMPKPLFGDNGSGMHTHQSLWKGGTPLMYDEIGYA
M. avium           PVDHYVDLRDQMLSNLIKAGFSLEKGHHEVGTGGQAEINYKFNTLLHAADDMMLYKYIVKNTAWQNGKTVTFMPKPLFGDNGSGMHTHQSLWKDGSPLMYDETGYA
M. ulcerans        PVDHYVDLRDKMLTNLINAGFSLEKGHHEVGTGGQAEINYKFNTLLHAADDMQLYKYIVKQTAWQAGKTVTFMPKPLFGDNGSGMHTHQSLWKDDTPMMYDETGYA
M. flavescens      PYDHYVDLRDEMATNLQNAGFVLERGHHEVGTAGQAEINYKFNTLLHAADDVLLFKYIIKNTAWQNGKTVTFMPKPLFGDNGSGMHAHQSLWKDGKPLFHDESGYA
M. smegmatis       PYDHYVDLRDQMATNLQNAGFTLERGHHEVGTAGQAEINYKFNTLLAAADDVLLFKYIIKNTAWQAGKTVTFMPKPLFGDNGSGMHAHQSLWKDGQPLFHDESGYA
Mycobacterium KMS  PYDHYVDLRDKMATNLINAGFVLERGHHEVGTAGQAEINYKFNTLLHAADDVLLFKYIIKNTAWQEGKTVTFMPKPLFGDNGSGMHAHQSLWKDGQPLFHDESGYA
M. vanbaalenii     PYDHYVDLRDEMSTNLINAGFTLERGHHEVGTAGQAEINYKFNTLLHAADDVLLFKYIIKNTAWQNGKTVTFMPKPLFGDNGSGMHAHQSLWKDGKPLFHDESGYA
N. farcinia        PYDHYVDLRDKISTKLQDAGFELERGHHEVGTAGQAEINYRFNTLLHAADDLQLFKYIVKNTAWQEGKTVTFMPKPLFGDNGSGMHVHQSLWKDGKPLFHDEAGYG
C. jeikeium        PYDHYQDLRDDMSRNLANAGFKLERAHHEVGTGGQQEINYEFNTLLHAADDLQSFKYIIKNTAWQAGKSATFMPKPLAGDNGSGMHAHQSLWKDGEPLFYDESGYA
C. diphtheria      PYDTLEDLRDEMTLTLRDAGFDIERQHPECGTGSQQEINYRFNTLLHAADDLQTFKYIIKNTAFRNGKTATFMPKPLAGDNGSGMHAHQSLWKDGKPLFHDEVGYA
C. effeciens       PYDQTVDVRDEMVRNLRDAGFHLERFHHEVG-GGQQEINYRFNTLLHAADDIQTFKYIVKNTAALHGKAATFMPKPLAGDNGSGMHAHQSLWKDGKPLFHDESGYA
C. glutamicum      PYDQTVDVRDDMVRNLAASGFALERFHHEVG-GGQQEINYRFNTMLHAADDIQTFKYIIKNTARLHGKAATFMPKPLAGDNGSGMHAHQSLWKDGKPLFHDESGYA
                   * *   *:**.:  .*  :** :*: * * * ..* ****.**::* ****:  :***:*:**   **:.******* ******** ******.. *:::** ***
 
M. tuberculosis    GLSDTARHYIGGLLHHAPSLLAFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGSNPKAKRLEFRSPDSSGNPYLAFSAMLMAGLDGIKNKIEPQ 
M. leprae          GLSDTARHYIGGLLHHAPSLLAFTNPTVNSYKRLVPGYEAPIKLVYSQRNRSACVRIPITGKNPKAKRLEFRCPDASGNPYLAFSAMLMAGLDGIKNKIEPQ 
M. avium           GLSDTARHYIGGLLHHAPSLLAFTNPTTNSYKRLVPGFEAPINLVYSQRNRSACVRIPITGTNPKAKRLEFRCPDSSGNPYLAFSAMLMAGLDGIKNKIEPQ 
M. ulcerans        GLSDTARHYIGGLLHHAPSLLSFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGSNPKAKRLEFRCPDSSGNPYLAFAAMLMAGLDGIKNKIEPQ 
M. flavescens      GLSDMARHYIGGILHHAPSLLAFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGNNPKAKRLEFRCPDSSGNPYLAFAAMLMAGIDGIKKKIEPL 
M. smegmatis       GLSDIARHYIGGILHHAPSLLAFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGNNPKAKRLEFRCPDSSGNPYLAFAAMLMAGIDGIKKKIEPL 
Mycobacterium KMS  GLSDTARHYIGGILHHAPSLLAFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGNNPKAKRLEFRCPDSSGNPYLAFAAMLMAGIDGIKRKIEPQ 
M. vanbaalenii     GLSDLARHYIGGILHHAPSLLAFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGNNPKAKRLEFRCPDSSGNPYLAFAAMLMAGIDGIKKKIEPL 
N. farcinia        GLSDLARHYIGGILHHAPSLLAFTNPTVNSYHRLVPGYEAPINLVYSQRNRSAAVRIPVTGNNPKAKRIEFRAPDSSGNPYLAFAAMLMAGLDGIKKKIEPL 
C. jeikeium        GLSDIARYYIGGILKHAGAVLAFTNPTLNSYHRLVPGFEAPINLVYSQRNRSAAVRIPITGSNAKAKRIEFRAPDPSGNPYFGFAAMMLAGLDGVKNRIEPH 
C. diphtheria      GLSDMARYYIGGILHHAGAVLAFTNPTLNSYHRLVPGFEAPINLVYSQRNRSAAIRIPITGSNPKAKRIEFRAPDPSGNPYFGFAAMMLAGLDGIKNRIEPH 
C. effeciens       GLSDIARYYIGGILHHAGAVLAFTNPTLNSYHRLVPGFEAPINLVYSQRNRSAAVRIPITGSNPKAKRIEFRAPDPSGNPYLGFAAMMMAGLDGVKNRIEPH 
C. glutamicum      GLSDIARYYIGGILHHAGAVLAFTNATLNSYHRLVPGFEAPINLVYSQRNRSAAVRIPITGSNPKAKRIEFRAPDPSGNPYLGFAAMMMAGLDGIKNRIEPH 
                   **** **:****:*:** ::*:***.* ***:*****:****:**********.:***:**.*.****:***.**.*****:.*:**::**:**:*.:***  
 
M. tuberculosis    APVDKDLYELPPEEAASIPQTPTQLSDVIDRLEADHEYLTEGGVFTNDLIETWISFKRENEIEPVNIRPHPYEFALYYDV 
M. leprae          APVDKDLYELPPEEAADIPQAPTQLAAVIDRLEEDHDYLTEGSVFTPDLIETWINFKRENEIEPVNIRPHPYEFALYYDV 
M. avium           APVDKDLYELPPEEAANIPQAPTQLSAVIDRLEEDHEYLTEGGVFTPDLIETWISFKRETEILPVQVRPHPYEFALYYDV 
M. ulcerans        APVDKDLYELPPEEAANIPQAPTQLAAVIDRLEADHEYLTEGGVFTPDLIETWISVKRENEIEPVNLRPHPYEFALYYDC 
M. flavescens      APVDKDLYELPPEEAANIPQAPTSLSAVIDKLEQDHEYLTEGGVFTTDLIETWISYKRENEIMPIQIRPHPYEFSLYYDV 
M. smegmatis       QPVDKDLYELPPDEAAAIPQAPTSLSAVIDKLEEDHEYLTEGGVFTEDLIETWISYKRENEIMPIQIRPHPYEFSLYYDV 
Mycobacterium KMS  APVDKDLYELPPDEAASIPQAPTSLSAVIDRLEEDHEYLTEGGVFTEDLIETWISYKRENEIMPIQIRPHPYEVALYFDV 
M. vanbaalenii     APVDKDLYELPPEEAANIPQAPTSLASVIDRLEEDHEYLTEGGVFTTDLIETWISYKRENEIMPIQIRPHPYEFSLYYDV 
N. farcinia        APVDKDLYELPPEEAKNIPQAPTSLASVIDRLEQDHEYLTEGNVFTEDLIETWIQLKRDNEIAPVNLRPHPYEFELYFDV 
C. jeikeium        APVDKDLYELPPEEAKDIPQAPTSLEASLKALEEDNEFLTEGGVFTDDLIDTYIAYKYDNEIAPVRLRPTPQEFEMYYDC 
C. diphtheria      APVDKDLYELPPEEAASIPQAPTSLEASLKALEEDNEFLTDGDVFTDDLIDAYIKLKYDNEIAPVRLRPTPQEFEMYFDC 
C. effeciens       APVDKDLYELPPEEAASIPQAPTSLEASLKALQEDSDFLTESDVFTEDLIEAYIQYKYDNEITPVRLRPTPQEFELYFDC 
C. glutamicum      APVDKDLYELPPEEAASIPQAPTSLEASLKALQEDTDFLTESDVFTEDLIEAYIQYKYDNEISPVRLRPTPQEFELYFDC 
                   ***********:**  ***:**.*   :. *: * ::**:..*** ***:::*  * :. ** *:.:** * *. :*:* 
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2.2.3 Genetic stability of glnA1 during M. tuberculosis strain diversification 
 
2.2.3.1 Evolutionary diversity of M. tuberculosis clinical isolates 
 
Mycobacterium tuberculosis clinical isolates were typed by IS6110 RFLP genotyping 
methods and were grouped according to similarity index, calculated using the Dice coefficient 
and UPGMA (Unweighted Pair Group Method with Arithmetic mean clustering method, 
GelCompar version 4.0) (Hermans et al., 1995). The GelCompar presentation of the IS6110 
banding patterns (Figure 2.3) shows that the clinical isolates are largely unrelated and 
diverse, although some may be grouped into families according to pattern similarities 
exceeding 65% (Warren et al., 2000a). In this study, 54 M. tuberculosis isolates were 
selected, which included 9 low IS6110 copy (n < 5) and 45 high IS6110 copy number (n ≥ 5) 
M. tuberculosis family groupings, with each having probably independently evolved from a 
mutual ancestral strain (Kremer et al., 1999). Table 2.2 demonstrates that the isolates 
included in this study represent highly prevalent strain families, such as family 29 (Beijing 
families) and family 11 (Richardson et al., 2002; Victor et al., 2004), as well as 
representatives from less prevalent strain families (Richardson et al., 2002).  
 
Table 2.2*: Mycobacterium tuberculosis strain family prevalence in a high incidence setting 
from where the clinical isolates used in the current study were derived. *Adapted from 
Richardson et al., 2002)  
Strain Family % of cases Strain Family % of cases 
1 0.6 17 1.1 
2 3.9 18 2.3 
3 0.4 19 0.4 
4 3.1 20 0.7 
5 0.2 21 2.2 
6 0.9 22 0.5 
7 2.0 23 1.1 
8 0.3 24 1.6 
9 2.3 25 1.6 
10 0.5 26 1.4 
11 19.1 27 0.3 
13 2.1 28 9.7 
14 3.2 29 16.8 
15 1.4 30 0.3 
16 1.5   
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Figure 2.3. GelCompar-generated dendrogram illustrating the extent of genetic diversity 
between the M. tuberculosis clinical isolates included in the glnA1 sequence comparison 
study. Each lane represents a single isolate of M. tuberculosis. The observed banding 
pattern is that of the IS6110 insertion element standard for the classification of M. 
tuberculosis genotypes into the appropriate M. tuberculosis strain families (Van Soolingen et 
al., 1993). The Clinical isolate Number (N), and the M. tuberculosis strain family from which 
the isolate is derived (F) is shown. 
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Table 2.3: Characteristics of the clinical M. tuberculosis isolates used in this study. Included are the South African Western Cape 
(SAWC) database number, strain family and antibiotic susceptibility of these isolates with known sensitivity results. Blank spaces 
indicate that information is not available. (Table continued on next page). 
SAWC Family IS6110_3 
Resistance 
Tested Isoniazid Rifampin Streptomycin Emb Pyrazinamide Ethambutol Kanamycin 
24 21 95 Y Sensitive Sensitive   Sensitive       
75 30 482 Y Sensitive Sensitive   Sensitive       
76 21 95 Y Sensitive Sensitive   Sensitive       
172 120 191 Y Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive 
181 120 191 Y Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive 
245 1 141 Y Sensitive Sensitive Sensitive Sensitive   Sensitive   
355 150 338 N               
464 110 324 N               
483 110 324 N               
550 4 403 N               
567 4 403 N               
598 29 322 N               
603 9 76 Y Sensitive Sensitive           
640 18 121 N               
641 18 121 N               
656 140 381 N               
658 9 76 Y Sensitive Sensitive           
689 7 196 Y Sensitive Sensitive           
709 8 174 Y   Resistant           
713 21 171 N               
740 20 137 N               
742 11 34 Y Sensitive Sensitive           
746 14 374 Y Sensitive Sensitive           
751 11 34 Y Sensitive Sensitive           
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SAWC Family IS6110_3 
Resistance 
Tested Isoniazid Rifampin Streptomycin Emb Pyrazinamide Ethambutol Kanamycin 
753 8 174 Y   Resistant           
769 11 34 N               
839 19 109 Y Resistant Sensitive Sensitive Sensitive   Sensitive   
880 28 266 Y Sensitive Sensitive           
990 19 497 Y Resistant Sensitive Sensitive Sensitive   Sensitive   
1013 11 33 U               
1038 28 266 Y Sensitive Sensitive           
1045 13 79 Y Sensitive Sensitive           
1057 25 133 Y Sensitive Sensitive           
1063 28 288 Y Sensitive Sensitive           
1075 19 109 Y Resistant Sensitive Sensitive Sensitive   Sensitive   
1078 18 125 Y Sensitive Sensitive           
1093 18 125 Y Sensitive Sensitive           
1112 7 553 Y Sensitive       
1127 6 131 N               
1145 2 190 N               
1214 2 190 N               
1236 130 326 Y Sensitive Sensitive           
1320 26 97 N               
1516 16 93 N               
1540 16 93 N               
1543 16 93 N               
1544 16 93 N               
1545 16 93 N               
1634 28 266 Y Sensitive Sensitive           
1649 28 266 Y Sensitive Sensitive           
1670 29 216 N        
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The clinical isolates include some antibiotic-resistant and – sensitive M. tuberculosis 
phenotypes (Table 2.3). Drug sensitivity data of some of the isolates are not known, as 
some of the isolates have not been tested at the time of writing this manuscript.  
 
 2.2.3.2 Sequence comparison of glnA1 from M. tuberculosis clinical isolates 
 
The structural glnA1 gene (1434 bp) and its 5’ and 3’ regions were PCR-amplified 
(Materials and Methods 3.1.2) from purified genomic DNA of the 54 M. tuberculosis 
clinical isolates described above. Oligonucleotides for PCR were designed to overlap by 
46 to 116 bp to allow the accurate intermediate sequences to be constructed from 
incomplete sequencing data (Figure 2.4). Polymerase chain reactions were optimised for 
each oligonucleotide pair and single amplification products were obtained. These 
products were purified and submitted for direct automated sequencing. The complete 
glnA1 sequences constructed in this manner were matched to the publicly available 
genome sequences of the M. tuberculosis H37Rv reference strain, M. tuberculosis 
CDC1551 and M. tuberculosis 210 (F11 clinical isolate) through BLAST comparison. 
Sequence comparisons showed no changes (mutation, deletion or insertion) in the glnA1 
structural gene and surrounding 3’ and 5’ regions in any of the M. tuberculosis clinical 
isolates. The 3’ and 5’ surrounding regions of the glnA1 locus included all the regulatory 
elements described for glnA1 transcription and regulation (Harth and Horwitz, 1997). 
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Figure 2.4. The glnA1-locus (Rv2219 and glnA1 gene loci indicated in bold ) of M. tuberculosis including its’ 5’- and 3’ surrounding 
regions were amplified with 5 PCR-oligonucleotide sets that were designed to amplify DNA fragments 294 bp to 796 bp in length. 
The PCR fragments had overlapping sequences (indicted as boxes) which facilitated the assembly of the full target region (-805bp to 
1181bp).  Priming positions relative to the glnA1 start codon and primer orientations are indicated (arrows, see Materials and 
Methods, Table 4). 
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2.3 DISCUSSION 
 
 2.3.1. Glutamine synthetase evolution in the Actinobacteria  
 
To investigate the evolutionary relationship and origins of the different glnA homologs 
present in the M. tuberculosis genome (glnA1, glnA2, glnA3 and glnA4), the protein 
sequences they encode were investigated through phylogenetic analysis of all the GS 
encoding sequences present in genomes of the phylum Actinobacteria. All the 
Actinobacteria included in this study had GS I (encoded by glnA1) and GS II (encoded 
by glnA2) protein homologs. The phylogenetic reconstruction showed that the GS I 
sequence (encoded by glnA1) may be the most closely related to a actinobacterial GS 
progenitor that underwent a duplication event and diverged into the GS I and GS II 
(encoded by glnA2) sequences during the speciation of most of the members of the 
phylum. An exception was observed in Symbiobacterium thermophilum, a G+C rich 
obligate commensial thermophile that requires co-culture with an associating Bacillus 
strain to provide it with certain metabolites (Ohno et al., 2000), such as carbon dioxide 
(Ueda et al., 2004). Symbiobacterium thermophilum posses only a GS I encoding 
sequence and this sequence might be more closely related to the Actinobacteria GS 
progenitor sequence and might not have undergone duplication into the separately 
evolved GS I and GS II sequences. This observation is supported by the matching GS I 
phylogenetic tree to the actinobacterial phylogeny based on the CTP-synthetase and 
16S rRNA gene sequences (Gao and Gupta, 2005), which suggest that the GS I 
sequence changed with its host organism. These observations are consistent with a 
previous study that investigated the divergence of GS enzymes during prokaryote and 
eukaryote evolution (Kumada et al., 1993). In that study it was shown that GS I (present 
only in prokaryotes, see Section 1.6.1) and GS II may have shared a common pre-
prokaryote ancestor that underwent a duplication event (Kumada et al., 1993). The 
authors further speculated that these enzymes may have become specialised due to the 
central role of this enzyme in amino acid metabolism and nitrogen assimilation during 
speciation. 
 
The role of GS I in bacterial growth has been the subject of various studies, but the role 
of the functionally different GS II enzyme (Section 1.6.1) is not well understood. It has 
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been shown that GS II plays an essential role in ammonia assimilation during nitrogen 
starvation in some Actinobacteria, such as the Frankia species (Tsai and Benson, 1989), 
but in other Actinobacteria, such as M. tuberculosis, conflicting evidence exists which 
suggests that GS II is either essential (Collins et al., 2002) or non-essential (Sassetti et 
al., 2003) for M. tuberculosis growth. Since the GS II enzyme might have been a 
duplication product of a GS I-like enzyme, it can be argued that GS II might play a minor 
role in prokaryotes, but became more specialised during speciation until it became the 
major GS enzyme in eukaryotes, in which GS I was subsequently lost. However, the 
phylogenetic reconstruction also suggests that either GS II or one of the other GS 
enzymes encoded by glnA3 and glnA4 could compensate for the loss of GS I in some 
Actinobacteria such as Rubrobacter xylanophilus. The Rubrobacteriales are 
extremophiles with high resistance to damage caused by ionising radiation (Asgarani et 
al., 2000) and may be one of the deepest branches within the Actinobacteria phylum that 
preceded the emergence of the Bifidobacteriales, Micrococcineae and CMN subgroup 
(Gao and Gupta, 2005). Therefore GS I may have existed in R. xylanophilus, but 
became lost. It is interesting to observe that evidence has been presented that shows 
GS II to be more heat labile than GS I (Hillemann et al., 1993) and probably became lost 
in the extreme habitat of the Rubrobacteriales.  
 
The GS II sequence underwent a further duplication in some Actinobacteria, which may 
have given rise to the GS sequences encoded by glnA3 and glnA4. The evolutionary 
distance between the clades formed by the glnA3 and glnA4 GS sequences suggest that 
the sequences diverged simultaneously at the time of the Actinobacterial speciation. In 
some Actinobacteria, glnA2 diverged only into the GS sequence encoded by glnA4 
(Brevibacterium linens, Kineococcus radiotolerans and Streptomyces sp.), while the 
glnA3 GS sequence is mainly restricted to the more recently speciated members of the 
CMN subgroup. It has been hypothesised that during evolution, non-essential genes 
may undergo change resulting in non-functional truncated products or even be “lost” due 
to the continual and reductive evolution of the bacterial genome, such as that of M. 
leprae and M. ulcerans (Cole et al., 2001; Eiglmeier et al., 2001; Sakharkar et al., 2004; 
Stinear et al., 2007). The absence of glnA3 and glnA4 may indicate that the GS 
enzymes encoded by these genes may have been redundant and therefore were 
deleted from these mycobacterial genomes. In support of this observation it has been 
shown that glnA3 and glnA4 are non-essential for the growth of other mycobacteria such 
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as M. tuberculosis (Sassetti et al., 2003; Harth et al., 2006; Lee et al., 2006). However, 
the possibility that the paralogous GS enzyme sequences encoded by glnA3 and glnA4 
have become specialised and necessary for growth in other Actinobacteria under certain 
conditions cannot be excluded. 
 
2.3.2 Glutamine synthetase I evolution in the high G+C genome content 
actinobacteria 
 
Genes needed for bacterial growth and survival, or essential genes, are mostly retained 
with minor sequence changes in genomes, suggesting that major genetic change in 
essential genes (leading to variation in the amino acid sequence resulting in change in 
enzyme expression or function) may be selected against during evolution (Sassetti et al., 
2003). The importance of GS I during bacterial growth is also reflected in the high 
degree of sequence homology observed between the species of the high G+C 
Actinobacteria CMN sub-group. The homology between actinobacterial GS I protein 
sequences is very pronounced in the conservation of amino acids putatively involved in 
the GS catalytic site and consensus signatures for ATP-binding and adenylylation 
regions. The high degree of homology, especially in amino acids which may play a role 
in the catalytic site structure and ATP- binding and adenylylation signatures, may 
suggest that changes in these sequences may be subjected to selective pressure.  
 
 2.3.3 Evolutionary stability of the M. tuberculosis glnA1 locus  
 
To further study the evolutionary stability of GS I, the glnA1 locus of M. tuberculosis 
isolates has been studied through sequencing. The success of M. tuberculosis as a 
pathogen lies in its ability to adapt to a wide variety of changing environmental 
conditions during host infection. After M. tuberculosis infection, the host immune system 
becomes activated in an attempt to contain the bacterial infection through the formation 
of granulomas (Schlesinger et al., 1990), which are aggregates of immune cells such as 
macrophages and lymphocytes. It has been hypothesised that adaptation to the 
constantly changing granulomatous environment might exert an evolutionary pressure 
resulting in genetic changes in the M. tuberculosis genome (Warren et al., 2002a). 
These changes may impact on the survival fitness of M. tuberculosis strains (Warren et 
al., 2000), which may subsequently have an influence on virulence due to phenotypic 
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and biological variance, causing some strains to be more infectious than others 
(Generozov et al., 2000; Dormans et al., 2004; Petrelli et al., 2004; Janulionis et al., 
2005; Likhoshvai et al., 2006). Genes have been identified of which mutations lead to an 
increase in M. tuberculosis virulence in mice, such as pepD (probable aminopeptidase) 
and umaA1 (mycolic acid transferase) (McAdam et al., 2002). Mutations in other genes, 
such as erp (Berthet et al., 1998), sigF (Chen et al., 2000) and hma (Dubnau et al., 
2000) may lead to M. tuberculosis attenuation in mice. Therefore the granuloma may 
provide M. tuberculosis with an environment that limits spread of the bacilli (Saunders et 
al., 1999) but wherein they may remain viable for extended periods of time during which 
they may undergo significant evolutionary change (Warren et al., 2002a). The 
evolutionary stability, or ability of glnA1 to undergo genetic change during M. 
tuberculosis strain evolution, may be reflected in the glnA1 sequence of separately 
evolved M. tuberculosis strains. It has been shown that disruptions in the M. tuberculosis 
glnA1 gene results in glutamine auxotrophy, but it is not known if polymorphisms in the 
coding sequence or promoter regions may occur that might result in a slight alteration of 
glnA1 activity. Here the glnA1 locus of 54 evolutionary diverse M. tuberculosis clinical 
isolates was sequenced and no change was observed in the glnA1 locus or its 
immediate 5’- and 3’ flanking DNA regions. These strains included highly prevalent and 
less prevalent clinical strain families from high incidence settings in Cape Town, South 
Africa. It has been hypothesised that more prevalent strain families might possess 
increased virulence, or success in infection and causing disease, over less prevalent 
strain families (Richardson et al., 2002). The lack of observed glnA1 genetic diversity 
may imply that the glnA1 DNA sequence is genetically stable and may imply that the 
evolutionary process may select against genetic change that can influence gene activity. 
It should also be noted that assumptions on similar enzyme activity cannot necessarily 
be made from the observation of genetic similarity, since it has been shown that 
variation in gene expression exists amongst different clinical M. tuberculosis isolates 
grown under the same conditions in liquid culture (Gao et al., 2005). In that study it was 
shown that glnA1 expression varied between 10 logarithmically growing M. tuberculosis 
clinical isolates. This observation implies that glnA1 expression (perhaps also enzyme 
activity) may also differ between M. tuberculosis growth in vivo and in vitro.  
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CHAPTER THREE 
 
 
 
MYCOBACTERIUM TUBERCULOSIS GLNA1 EXPRESSION 
REGULATION AND GS EXPORT 
 
 
“In all science, error precedes the truth, and it is better it should go first than last” 
 
Hugh Walpole 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The experimental work (GS precipitation) was carried out in the Division of Bio-
molecular sciences, Stellenbosch University under direction of C. Kenyon, DST.  
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3.1 INTRODUCTION 
 
Structural studies of the gene encoding GS in M. tuberculosis, glnA1, could not identify any 
of the common features necessary for protein export (protein transport across the cell 
membrane to the cell wall) or secretion into the exogenous environment by known bacterial 
systems (Harth et al., 1994; Tullius et al., 2001). However, previous studies have shown the 
presence of GS activity in the M. tuberculosis culture filtrate (Harth et al., 1994), or have 
identified GS in the culture filtrate of M. tuberculosis cultures (Sonnenberg and Belisle, 1997, 
Malen et al., 2007). Structural studies of glnA1 have identified two promoter regions 
upstream of glnA1 that might regulate glnA1 transcription under conditions of nitrogen 
excess, or during nitrogen starvation (Harth and Horwtiz, 1997). It was shown that M. 
tuberculosis glnA1 transcription was induced from a 45 bp upstream σ60-like promoter 
element under conditions of nitrogen excess, while nitrogen limitation resulted in the 
inhibition of the 45 bp upstream promoter region and transcription of glnA1 was initiated from 
a 116 bp upstream promoter region (Harth and Horwitz, 1997). It was shown that 
transcription initiated from either of these promoter regions resulted in mRNA molecules of 
different length, and it has been hypothesised that the un-translated mRNA leader of either 
of the mRNA molecules may encode the signal for GS secretion (Harth and Horwitz, 1997).  
 
Alternatively, it has been hypothesised that GS is released by M. tuberculosis through the 
processes following cell death (Tullius et al., 2003). It was hypothesised that large sec-
secretion signal less proteins, such as GS and super oxide dismutase (SOD) might be 
present in the M. tuberculosis culture filtrate due to leakage from M. tuberculosis or autolysis 
of the bacilli. However, another study has shown that SOD is actively secreted by M. 
tuberculosis by the secA2-dependent secretion system (Braunstein et al., 2003). It was 
shown that this secretion pathway does not require a sec-secretion signal peptide, but it was 
not determined if M. tuberculosis GS might be secreted by the secA2-dependant secretion 
pathway. 
 
3.1.1 Study Aims: 
 
The secretion mechanism of M. tuberculosis GS was studied in a heterologous 
mycobacterial expression host (M. smegmatis). This has been achieved through 
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investigating the sub-cellular compartmentalisation of a recombinant C-terminal tagged M. 
tuberculosis GS in the M. smegmatis expression host. The specific aims were: 
 
3.1.1.1 To investigate if the 116 bp and 45 bp upstream promoter regions of glnA1 
play a role in M. tuberculosis GS secretion 
 
3.1.1.2 To further investigate GS secretion due to glnA1 transcription from the above 
promoter regions, GS sub-cellular distribution in response to varying conditions of 
nitrogen availability would have to be studied. 
 
3.1.1.3 To investigate the role of cell death on M. tuberculosis GS secretion. This will 
be determined in M. smegmatis as expression host during the stationary phase of 
growth. 
 
3.1.1.4 To determine if M. tuberculosis GS export could be mediated by the SecA2 – 
translocase. This will be determined through studying the protein-protein interaction 
of secA2 with GS in an E. coli-based expression host.   
 
3.1.1.5 To determine if GS is exported to the cell wall of slow-growing mycobacteria, 
GS will be studied in the cell wall fractions of M. bovis BCG.  
 
 3.1.1.5.1 To determine if differences in GS distribution are observed in M. 
 bovis BCG. It will be attempted to study these differences in M. smegmatis. 
 This will also be carried out through the stable integration of M. tuberculosis 
 into the M. smegmatis chromosome. 
 
3.2 RESULTS 
 
3.2.1. M. tuberculosis GS export and secretion by M. smegmatis 
 
To determine if the 116bp and 45bp promoter elements of M. tuberculosis glnA1 are 
involved in GS is secretion, glnA1 expression constructs were generated that included either 
both the 116bp and 45bp promoter elements (“glnA1 long” clone, Figure 3.1), or only the 
45bp promoter element (“glnA1 short” clone, Figure 3.1). To allow the detection of the M. 
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tuberculosis GS resulting from these expression constructs, both glnA1 sequences were 
synthesised using an antisense PCR oligonucleotide that encoded a hexa-histidine 
sequence (6x his) and included a stop codon (Figure 3.1). Therefore, both recombinant GS 
proteins would be tagged with a 6x his sequence at the C-terminal (total theoretical 
molecular weight (MW) = 54.39 kDa). The glnA1 “long” and “short” constructs were cloned 
into a mycobacterial expression vector (p19Kpro; Appendix C. 1) that contained a 
hygromycin B-resistance marker that allowed antibiotic selection of recombinant M. 
smegmatis cultures. These M. tuberculosis glnA1 constructs were expressed in M. 
smegmatis cultured to the mid-logarithmic growth phase (OD600 of 0.3 - 0.4) in Kirchners’ 
minimal media alone (representing a low nitrogen medium) or Kirchners’ minimal media 
containing ammonium sulphate ((NH4)2SO4) to a final concentration of 38 mM (high nitrogen 
medium) and hygromycin B. Mycobacterium smegmatis cultures transformed with the glnA1 
“long” and “short” showed comparable doubling times (as measured by OD600 readings) to 
control M. smegmatis transformed with an “empty” expression plasmid in both Kirchners’ 
minimal media or Kirchners’ minimal media containing 38 mM ((NH4)2SO4) indicating that the 
expression of the recombinant C-terminal tagged M. tuberculosis GS did not have an effect 
on the M. smegmatis growth rate.   
 
To study the transport of the recombinant C-terminal tagged M. tuberculosis GS from the 
cytosol to other cellular structures of the M. smegmatis expression host, the M. smegmatis 
cultures expressing the recombinant M. tuberculosis GS proteins were fractionated into its 
sub-cellular fractions (cytosol, cell membrane, cell wall and culture filtrate) through 
differential centrifugation (Materials and Methods 9.1). Culture filtrate proteins were 
concentrated approximately 30x by exclusion centrifugation (Materials and Methods 9.1). 
The protein concentrations of the purified sub-cellular fractions were determined using the 
Bradford methods (Materials and Methods 9.2) and equal amounts of protein (6 μg) from 
each sub-cellular fraction was Western blotted under denaturing conditions (SDS PAGE, 
Materials and Methods 4.1). Recombinant C-terminal tagged M. tuberculosis GS was 
detected on the Western blots using an anti-6x his primary antibody (Materials and Methods 
10.1). 
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Figure 3.1. Genetic and protein sequences of M. tuberculosis glnA1 “long” and “short” clones 
transformed into a M. smegmatis expression host. The upstream promoter regions of glnA1 
are indicated by boxes, with the transcription start sites following each promoter region 
indicated by arrows. The N- as well as modified C- terminal GS amino acid sequence is 
indicated with the corresponding DNA sequence. The glnA1 “long” clone included both 
putative upstream promoter regions (PCR amplified using sense oligonucleotide 1, 
underlined), while the glnA1 “short” construct included only the immediate upstream σ60 
element (PCR amplified using sense oligonucleotide 2). The anti-sense PCR oligonucleotide 
was modified to include a 6x his encoding region followed by a stop codon and a hindIII 
restriction site. 
 
Figure 3.2 shows that during growth in low nitrogen Kirchners’ media, recombinant C-
terminal tagged M. tuberculosis GS (55 kDa) was exported from the cytosol to the cell 
membrane and cell wall fractions of M. smegmatis cultures transformed with the “glnA1 long” 
construct. Under the same growth conditions, a low concentration of recombinant C-terminal 
tagged M. tuberculosis GS could be detected in the cell membrane fraction of M. smegmatis 
cultures transformed with the “glnA1 short” constructs, suggesting that the expression levels 
ggccgcggatacagtaaaggagcattct gtg acg gaa aag acg ccc gac gac gtc ttc aaa ctt gcc aag gac gag 
M   T     E    K     T    P     D    D    V   F   K    L    A   K     D    E 
S.D
aag gtc gaa tat gtc gac gtc cgg ttc tgt gac ctg cct ggc atc atg cag cac ttc acg att ccg gct tcg - - -
K     V   E    Y   V    D    V    R   F   C   D    L   P    G   I     M   Q   H    F    T     I    P    A   S   
94
1
- - - ttc gcg ctg tac tac gac gtc cac cac cac cac cac cac tga agc tt
F    A    L    Y    Y   D    V    H    H    H    H    H   H     *      
(Modified anti-sense oligo 1)
3’
471
gcagacccgataaccaggttcccgttcggcatgccaccggttacgatcttgccgaccatggccccacaatagggccgggg
- 35 - 10
aga
(Sense oligo 1)
5’
116bp promoter region
cccggcgtcagtggtgggcggcacggtcagtaacgtctgcgcaacacggggttgactgacgggcaat ggctccatagcgtc
σ 60 element
atc
(Sense oligo 2)
45bp promoter region
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of the glnA1 “short” construct was low during the M. smegmatis growth conditions used. The 
MW of the recombinant C-terminal tagged M. tuberculosis GS expressed from the M. 
tuberculosis glnA1 “short” construct was similar to that detected in the sub-cellular fractions 
of the M. smegmatis culture transformed with the “glnA1 long” construct, indicating that the 
GS expressed from either of the M. tuberculosis glnA1 “long” and “short” constructs were of 
similar MW. No recombinant C-terminal tagged M. tuberculosis GS could be detected in the 
concentrated culture filtrates of M. smegmatis cultures expressing the glnA1 “long” or glnA1 
“short” constructs, indicating that recombinant C-terminal tagged M. tuberculosis GS was not 
secreted by M. smegmatis during the mid-logarithmic growth phase in low nitrogen Kirchners 
medium. 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Sub-cellular location of recombinant M. tuberculosis GS in logarithmically 
growing M. smegmatis transformants expressing M. tuberculosis glnA1 from either both 
glnA1 upstream promoter regions (glnA1 “long”), or only the immediate upstream promoter 
(glnA1 “short”). These M. smegmatis cultures were grown in either Kirchner’s minimal 
medium (low nitrogen) or Kirchner’s minimal media containing ammonium sulphate to a final 
concentration of 38 mM (high nitrogen medium). The sub-cellular protein fractions included 
the cytosol (CYT), cell membrane (MEM), cell wall (CW) and concentrated culture filtrate 
(CF) proteins.  
 
To investigate whether sub-cellular distribution of recombinant C-terminal tagged M. 
tuberculosis GS expressed from the 45 bp σ60-like promoter element differed from the GS 
glnA 1 ‘short ’ glnA 1 ‘long ’
Normal
CYTCYT MEMMEM CWCW CFCF
55 
55 kDa
kDa
rmal
38 mM (NH4)2SO4
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expressed from the 116 bp promoter region, the M. smegmatis glnA1 expression host was 
cultured in Kirchners medium containing (NH4)2SO4 to a final concentration of 38 mM (high 
nitrogen medium). To minimise the effect of (NH4)2SO4 assimilation during M. smegmatis 
growth, which may influence the expression of the recombinant C-terminal tagged M. 
tuberculosis GS due to lower effective (NH4)2SO4 concentrations, an M. smegmatis start-
culture was prepared in Kirchners media and cultured to a OD600 of 0.2. The M. smegmatis 
culture was collected through centrifugation and inoculated into the same volume of 
Kirchners media, with the added (NH4)2SO4) as the original start-culture and grown to an 
OD600 = 0.3 – 0.4. It was attempted to limit a “temperature shock-response” of the M. 
smegmatis culture during the transfer from the original OD600 = 0.2 start-culture to the 
Kirchners medium containing the (NH4)2SO4) by performing all steps (centrifugation and 
temperature of target media) at 370C. The M. smegmatis cells were collected and 6 g of 
each sub-cellular fraction were collected and Western blotted as before.   
  
Figure 3.2 shows that the expression of recombinant C-terminal tagged M. tuberculosis GS 
was reduced in M. smegmatis cultures expressing both the glnA1 “long” and “short” 
constructs. Contrary to expectations, no recombinant C-terminal tagged M. tuberculosis GS 
could be detected in any of the sub-cellular compartments or culture filtrate of the M. 
smegmatis host strain transformed with the “glnA1 short” construct. Lower concentrations of 
recombinant C-terminal tagged M. tuberculosis GS were observed in the cell membrane and 
cell wall of M. smegmatis host strains transformed with the “glnA1 long” construct. However, 
no recombinant C-terminal tagged M. tuberculosis GS could be detected in the concentrated 
culture filtrates of either M. smegmatis glnA1-expression host, indicating that (together with 
the above observations) increased nitrogen availability caused a down regulation of M. 
tuberculosis GS expression and did not result in the secretion of recombinant C-terminal 
tagged M. tuberculosis GS.   
 
As the method of analysing the culture filtrate fraction described above may have certain 
technical shortcomings, such as masking of the recombinant C-terminal tagged M. 
tuberculosis GS when present in low amounts by other secreted M. smegmatis proteins, it 
was attempted to detect secreted M. tuberculosis GS in concentrated M. smegmatis culture 
filtrates with the -glutamyl transferase assay (Materials and Methods 9.4). The -glutamyl 
transferase assay provides an empirical measure of specific GS activity by a measurement 
of its adenylylated or de-adenylylated catalytic activity in reaction buffer containing Mg2+ or 
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Mn2+ (Stadtman et al., 1979; see Section 1.6.2). Because any effects of the C-terminal 6x-
his tag on the structure, and therefore activity, of the recombinant M. tuberculosis GS could 
not be determined, a copy of a “native” M. tuberculosis, which included a 805 bp region 
upstream and 181 bp region downstream of the glnA1 structural sequence (see Chapter 2, 
Figure 2.4) was cloned into the p19Kpro mycobacterial expression vector (p19KglnA1) and 
expressed in M. smegmatis.  Mycobacterium smegmatis, M. smegmatis expressing “native” 
M. tuberculosis GS and M. smegmatis expressing the recombinant C-terminal tagged M. 
tuberculosis GS was cultured in Kirchners media to the logarithmic growth phase. The 
cytosol fractions and concentrated culture filtrates were purified and assayed for GS activity 
using the -glutamyl transferase assay. Table 3.1 shows that although high specific GS 
activities could be detected in the M. smegmatis expression host cytosol fractions, no GS 
activity could be observed in the concentrated culture filtrates, which supports the hypothesis 
that M. tuberculosis GS is not secreted by logarithmic growing M. smegmatis.    
 
Table 3.1. Glutamine synthetase specific activities (umoles/ min/ mg protein) in the cytosol 
and culture filtrates of M. smegmatis transformants cultured in Kirchners’ media. No GS 
activity could be detected in the culture filtrates of M. smegmatis, M. smegmatis expressing 
M. tuberculosis GS (p19KglnA1) or M. smegmatis expressing recombinant C-terminal 
tagged M. tuberculosis GS (glnA1 “long”), despite high GS activity in the cytosol fractions. 
The OD600 measurements of the M. smegmatis cultures are indicated. All GS activities were 
determined from the average of two independent -glutamyl transferase assays (see 
Materials and Methods 9.4). 
  Cytosol GS  Culture filtrate GS  
Transformant OD600
Reverse 
reaction 
(Mn2+) 
Forward 
reaction 
(Mg2+) 
Reverse 
reaction 
(Mn2+) 
Forward 
reaction 
(Mg2+) 
M. smegmatis 0.412 239.67 2.58 0 0
M. smegmatis p19KglnA1 0.396 253.64 0 0 0
M. smegmatis glnA1 “long” 0.343 171.49 0 0 0
 
 
 
 
 
 
http://scholar.sun.ac.za
 62
3.2.2. Glutamine synthetase secretion by M. smegmatis during the stationary growth 
phase  
 
To investigate the hypothesis that M. tuberculosis GS is present in culture filtrates due to the 
processes following cell death, such as cell lysis, M. smegmatis transformed with both M. 
tuberculosis glnA1-constructs was cultured to the stationary growth phase (OD600 > 1.2) 
under similar conditions of nitrogen availability as described before (Section 3.2.1). Protein 
fractions of the cytosol and culture filtrate were prepared (Materials and Methods 9.1) and 
the presence of recombinant C-terminal tagged M. tuberculosis GS in these protein fractions 
was investigated through Western blotting (Materials and Methods, 10.1) of equal amounts 
of starting material (6g of protein).  
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Detection of recombinant M. tuberculosis GS in the cytosol and culture filtrate of 
stationary phase M. smegmatis cultures. (A) Represents the cytosol and culture filtrate of M. 
smegmatis grown in Kirchners medium, while (B) represents the cytosol and culture filtrate 
of M. smegmatis grown in Kirchners media containing (NH4)2SO4 to a final concentration of 
38 mM. 
 
Figure 3.3 shows that no recombinant C-terminal tagged M. tuberculosis GS expressed from 
the glnA1 “short” construct could be detected in the culture filtrate of M. smegmatis in the 
stationary growth phase under varying nitrogen availability in Kirchners media or Kirchners 
media containing (NH4)2SO4. A slight signal could be detected in the culture filtrate of M. 
smegmatis expressing recombinant C-terminal tagged M. tuberculosis GS from the glnA1 
“long” construct during the stationary growth phase (Figure 3.3 glnA1 long Acf), although this 
signal is less than that detected in the cytosol of the same M. smegmatis culture (Figure 3.3 
Stationary Phase 
BCFBCYT
“glnA1 short” “glnA1 long” 
A CYT ACF
55  kDa 
B CF B CYT ACYT ACF
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glnA1 long Acyt). Therefore it may be possible that M. tuberculosis GS might be present in 
the stationary growth phase culture filtrate due to liberation from the cytosol through cell 
death, although it may only be detectable when expression levels in the cytosol is high. 
 
Intriguingly, Figure 3.3 also shows that the expression of recombinant C-terminal tagged M. 
tuberculosis GS from the glnA1-short construct was up regulated during the stationary 
growth phase of M. smegmatis in Kirchners media and Kirchners media to which (NH4)2SO4 
has been added. This upregulation was not observed in M. smegmatis cultures expressing 
recombinant C-terminal tagged M. tuberculosis GS from the glnA1 “long” construct, where 
almost undetectable amounts of recombinant C-terminal tagged M. tuberculosis GS was 
synthesised during growth in Kirchners media containing (NH4)2SO4 (compare figure 3.3 
glnA1 short Bcyt and glnA1 long Bcyt). This is an unanticipated observation, since it would be 
expected that because the glnA1 “long” construct includes the glnA1 “short” promoter region 
(see Figure 3.1), the same recombinant C-terminal tagged M. tuberculosis GS expression 
would be observed. This difference in recombinant C-terminal tagged M. tuberculosis GS 
may indicate that other regulators of transcriptional activity may be present in the region 
upstream of M. tuberculosis glnA1. 
 
3.2.3. Glutamine synthetase export and the mycobacterial secA2 helper translocase 
 
In Section 3.2.1 it was shown that M. smegmatis could export high concentrations of a 
recombinant M. tuberculosis GS containing a C-terminal 6x his-tag to its cell wall. However, 
no secretion of the protein into the M. smegmatis culture filtrate could be observed during 
mid-logarithmic growth. This finding was substantiated by the lack of GS activity (Section 
3.2.1) in the culture filtrates of M. smegmatis expressing M. tuberculosis GS (in its native 
form). This observation suggests that an export mechanism responsible for the translocation 
of GS from the cytosol to the cell wall may exist, and may also be present in mycobacteria 
other than the slow-growing pathogenic mycobacteria (such as M. tuberculosis, M. bovis, 
including the M. bovis BCG strains, see Section 1.6.5.1).  
 
To investigate whether the translocation of the recombinant M. tuberculosis GS could be 
facilitated by the secA2 transport system described by Braunstein et al. (2003), the genes 
encoding M. tuberculosis secA2 (Rv1821) and GS (glnA1) were cloned into bacterial-2-
hybrid target- and bait expression plasmids (Materials and Methods, Addendum C.5). The 
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vector constructs containing secA2 (pUTsecA2) and glnA1 (pKTglnA1) were simultaneously 
transformed into an E. coli JM109 host strain (Materials and Methods 1.1). Escherichia coli 
transformants containing both vector constructs were selected on LB-media containing X-gal 
and the appropriate antibiotics (Materials and Methods 1.3). Controls included E. coli 
transformed with non-associating vector constructs (pKT25 and pUT18; Addendum C.5), as 
well as associating constructs (pKTZip and pUTZip, Karimova et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. glnA1 and secA2 protein-protein interactions were studied with the bacterial-2-
hybrid system in E. coli as interaction-expression host. The positive control (interacting 
proteins encoded by pKTzip and pUTzip) showed blue colonies on X-gal containing LB 
medium, while the negative control (pKT + pUT) showed white colonies. White colonies 
showing no protein-protein interaction were observed in E. coli transformants expressing M. 
tuberculosis glnA1 and secA2 (pKTglnA1 + pUTsecA2).  
 
pKTglnA1 + pUTsecA2
pKTzip + pUTzip pKT + pUT
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Figure 3.4 show that the positive controls (pKTZip and pUTZip) formed blue colonies on X-
gal containing LB-medium, while the non-associating controls (pKT and pUT) formed white 
colonies. The E. coli transformants containing the pUTsecA2 and pKTglnA1 vector 
constructs formed white colonies, indicating that secA2 and GS does not interact on protein- 
level and that secA2 might therefore not be responsible for M. tuberculosis GS export to the 
mycobacterial cell wall. 
 
3.2.4. Glutamine synthetase in the M. bovis BCG cytosol and cell wall 
 
To investigate whether the observed export of M. tuberculosis GS (as described in Section 
3.2.1) is present in slow growing mycobacteria (such as M. bovis BCG), it was attempted to 
show the presence of recombinant C-terminal 6x his-tagged GS in the sub-cellular fractions 
of M. bovis BCG similar to Section 3.2.1. However, detection of recombinant C-terminal 6x 
his-tagged GS could not be established. The failure to express recombinant C-terminal 6x 
his-tagged GS could not be explained, but it may be due to instability of either the 
hygromycin B antibiotic, or the hygromycin B resistance marker of the plasmid over the long 
duration of culturing times for slow-growing mycobacteria on agar medium. Therefore the 
presence of GS in the cell wall of slow-growing GS-secreting mycobacteria, such as M. bovis 
BCG, was investigated by GS isolation through (NH4)2SO4 precipitation (Materials and 
Methods 9.3).   
 
Glutamine synthetase was isolated from the cell wall and cytosol fractions of a 1.5L M. bovis 
BCG culture. The cell wall fraction was recovered by gentle abrasion of the M. bovis BCG 
cell pellet with glass beads prior to cell disruption through sonication (Materials and Methods 
9.3). After two steps of GS (NH2)4SO4 precipitation, protein samples were analysed by SDS-
PAGE electrophoresis (Materials and Methods 4.1). Figure 3.5 shows that two proteins of 
differing molecular weight (MW) could be purified to single band purity from the M. bovis 
BCG cell wall and cytosol fractions. A higher MW protein (56 - 58 kDa) was associated with 
the M. bovis BCG cell wall, while a lower MW protein (53 – 55 kDa) was detected in the 
cytosol. This was surprising, as GS protein species of differing MW was not observed in the 
cell wall and cytosol fractions after recombinant M. tuberculosis GS expression in the M. 
smegmatis heterologous expression host (Section 3.2.1).  
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This result suggests that GS is exported to the M. bovis BCG cell wall, but that the protein 
may undergo post-translational modification (such as binding of another low MW peptide) 
that does not occur during recombinant C-terminal tagged M. tuberculosis GS export in a 
fast-growing heterologous mycobacterial expression host, such as M. smegmatis, where 
changes in M. tuberculosis GS MW was not observed (see Section 3.2.1).   
Figure 3.5. Two isoforms (proteins of ~54 and ~57kDa) of GS were detected in M. bovis 
BCG Pasteur. The 54 kDa GS isoform is associated with the cytosol (Lane 1), while a 57 
kDa GS isoform is present in the cell wall (Lane 2) of M. bovis BCG Pasteur. Molecular 
weight of the protein standard (Lane M) is indicated.  
 
3.2.5. Integration of the M. tuberculosis glnA1-containing chromosomal domain into  
M. smegmatis. 
 
To investigate the difference in MW observed in the cytosol and cell wall fractions of M. 
bovis BCG, the chromosomal segment of the M. tuberculosis chromosome containing the 
glnA1 locus was stably integrated into the M. smegmatis genome, resulting in an “M. 
smegmatis glnA1 integral” strain able to express an unaltered M. tuberculosis GS in addition 
to its own GS.  
 
The chromosomal segment containing glnA1 and its surrounding sequences was derived 
from an M. tuberculosis cosmid library maintained in E. coli (Bange et al, 1999). Escherichia 
coli colonies were screened with an enhanced chemiluminescent labelled (ECL) probe 
specific for glnA1 (Materials and Methods 8; Materials and Methods 11). The presence of an 
undisrupted glnA1 sequence was determined by a PCR reaction that amplified an 805 bp 
upstream region of glnA1 (therefore containing all necessary promoter elements) and a gene 
50
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M 1 2
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(Rv2224c) located in a gene cassette (containing glnE, glnA2, Rv2223c and Rv2224c) 
downstream of the glnA1 gene (Figure 3.6 A). The stable integration of the selected cosmid 
into the M. smegmatis genome was confirmed by the same PCR screen as described above 
after a few generations of the cosmid-transformed M. smegmatis that had been cultured in 
Middlebrook 7H9 medium without antibiotic selection (Figure 3.6 B).  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. ECL detection of E. coli colonies harbouring the chromosomal region of M. 
tuberculosis that contains glnA1. Two colonies that showed hybridisation of an ECL labelled 
probe complementary to an internal region of M. tuberculosis glnA1 were selected (A). The 
presence of glnA1 and its upstream and downstream regions was determined through PCR 
(Panel B). Through PCR amplification a 796 bp product representing the region immediately 
upstream of glnA1, as well as a 901 bp product representing the region upstream of 
Rv2224c was observed in Colony 1 (Panel B, lane 1) indicating that all the genes between 
and including M. tuberculosis glnA1 and Rv2224c were present in the clone, while Colony 2 
(Panel  B, lane 3) only contained the glnA1 locus.”. Mycobacterium smegmatis (CMS) and M. 
tuberculosis (CMTB) DNA controls included showed the expected sizes of PCR products and 
that no cross-hybridisation PCR products were formed. Lane 2 contains a negative control 
for PCR contamination. 
 
The M. smegmatis glnA1 integral strain was transformed with the glnA1 “long” construct and 
fractionated into sub-cellular fractions (similar to those obtained in Section 3.2.1). However, 
M 1 2 3 C MS C MTB
B.)
A.)
1
2
901 bp
796 bp
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no recombinant C-terminal 6x his-tagged M. tuberculosis GS could be detected in any of the 
fractions (result not shown). To determine if the lack of recombinant C-terminal 6x his-tagged 
M. tuberculosis GS was due to transcriptional down-regulation of glnA1 due to the presence 
of more than two copies of glnA1 (that of M. smegmatis and M. tuberculosis), it was 
attempted to detect the recombinant M. tuberculosis GS in larger whole lysate protein 
preparations by means of dot-blotting (Materials and Methods 10.2). It was also attempted to 
enrich recombinant C-terminal 6x his-tagged M. tuberculosis GS from whole lysates of the 
M. smegmatis glnA1 integral strain transformed with the “glnA1 long” construct through 6x 
his-affinity purification (Material and Methods 9.6). Figure 3.7 shows that anti-6x his antibody 
binding could be detected in whole lysates of the M. smegmatis glnA1 integral strain 
transformed with the “glnA1 long” construct (Figure 3.6 lane 3), as well as affinity purified 
protein samples (Figure 3.7 lane 4). Low background signal of anti-body binding could be 
observed in the M. smegmatis (Figure 3.7 lane 1) and M. smegmatis glnA1 integral (Figure 
3.7 lane 2) whole lysate preparations, probably due to non-specific binding due to high 
protein concentrations.        
 
 
 
 
 
Figure 3.7. Dot-blot detection of recombinant C-terminal tagged M. tuberculosis GS in the M. 
smegmatis glnA1 integral strain. Low levels of background signal were detected in negative 
controls consisting of M. smegmatis (lane 1) and M. smegmatis glnA1 integral strain (lane 2) 
whole lysates. Hybridisation signal were detected in whole lysates of M. smegmatis glnA1 
integral strains transformed with the “glnA1 long” construct (lane 3), as well as affinity 
purified preparations (lane 4) from the whole lysates represented in lane 3. 
 
These results suggest that the recombinant C-terminal tagged M. tuberculosis GS protein is 
in fact expressed, although at low levels in the M. smegmatis glnA1 integral strain. Therefore 
a more sensitive 6x his detection method was employed to detect recombinant C-terminal 6x 
his-tagged M. tuberculosis GS on Western blots (Materials and Methods 10.2) of whole 
lystate proteins, which showed the presence of recombinant M. tuberculosis GS (Figure 3.8 
Panel A, lane 2) in the whole lysate of the M. smegmatis glnA1 integral strain. A low 
concentration of another small molecular weight protein (~ 13 kDa) was observed that was 
1 2 3 4
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not present in the untransformed M. smegmatis integral whole lysate (Figure 3.8 Panel A, 
lane 1), suggesting that the 6x his tag might have been cleaved from recombinant GS sub-
units. A low concentration affinity purified recombinant C-terminal tagged M. tuberculosis GS 
protein was recovered from the M. smegmatis glnA1 integral strain transformed with the M. 
tuberculosis “glnA1 long” construct (Figure 3.8 Panel B, lane 1). The affinity purified protein 
migrated as a single band with a MW of approximately 60 kDa, indicating that in the 
presence of a “native” M. tuberculosis glnA1 copy, recombinant C-terminal tagged M. 
tuberculosis GS may have a larger MW. No corresponding protein could be detected in the 
affinity-purified M. smegmatis glnA1 integral whole lysate controls that was not transformed 
with the M. tuberculosis glnA1 “long” construct (result not shown).  
 
    
 
 
 
 
 
 
 
 
 
Figure 3.8. Recombinant M. tuberculosis GS detection in M. smegmatis glnA1 integral 
strains was detected by anti-6x his colorimetric staining. Panel A shows that 2 protein bands 
(55 kDa – 60 kDa, arrow 1 and 13 kDa, arrow 2) could be detected in the whole lysate of the 
M. smegmatis glnA1 integral strain (Panel A, lane 2) that was not present in the M. 
smegmatis glnA1 integral control whole lysate (Panel A, lane 1). Panel B shows the 6x his 
affinity purified protein migrated as a single band of approximately 60 kDa (Panel B. lane 1). 
Molecular weight is indicated in kDa (Molecular weight marker, Panel A and B, lane M). 
 
3.3 DISCUSSION 
 
The sub-cellular compartmentalisation of recombinant M. tuberculosis GS was investigated 
in a heterologous mycobacterial host that does not secrete its own GS, namely M. 
smegmatis (Harth and Horwitz 1994). However, M. tuberculosis GS is putatively expressed 
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from two alternative promoter sites located 116bp and 45bp upstream of the glnA1 start 
codon, which may regulate glnA1 expression in response to differences in environmental 
nitrogen limitation or abundance (Harth and Horwitz 1994). To allow the investigation of the 
differences in GS expression and translocation using the alternative M. tuberculosis glnA1 
promoter regions, the expression of M. tuberculosis glnA1 in M. smegmatis was carried out 
from either both the promoter regions (116 bp and 45 bp), or only one (45 bp) under 
conditions of variable nitrogen availability. The results have shown that M. tuberculosis GS is 
preferentially expressed under the direction of the 116 bp promoter region during growth in 
Kirchners’ media, while little amounts of recombinant GS was expressed from the 45 bp 
promoter region alone under similar culturing conditions. When environmental nitrogen 
concentrations were increased through the addition of (NH4)2SO4, GS production was 
significantly reduced in both constructs and totally absent when the 116 bp upstream 
promoter region is not present. This suggests that GS synthesis may also be controlled at 
transcriptional level by nitrogen availabiltiy. Down-regulation of glnA1 transcriptional activity 
under conditions of nitrogen excess has also been observed in the closely related 
Corynebacteria (Nolden et al., 2001). This down-regulation of glnA1, as observed in the 
Corynebacteria, may be due to the presence of a tetR-type repressor sequence upstream of 
the glnA1 locus (Jakoby et al., 2000). In that study the tetR repressor protein has been 
identified as AmtR, which is responsible for the repression of gene transcription under 
conditions of nitrogen excess in the Corynebacteria. In another study it was shown that 
AmtR may control the expression of many of the genes involved in nitrogen metabolism, and 
may therefore be a master regulator of nitrogen control in the Corynebacteria (Beckers et al., 
2005). In other prokaryotes (such as Bacillus subtillus), glnA is regulated at the 
transcriptional level by the glnA-specific glnR regulator under conditions of nitrogen excess 
(Wray, Jr. and Fisher, 1993). It is not known whether these mechanisms of nitrogen 
metabolism and glnA1 transcription control are present in M. tuberculosis, as many of the 
genes involved in the GS regulation cascades have been identified through sequence 
homology only. However our results indicate that GS may be regulated by mechanisms 
other than post-translational modification (through adenylylation) under conditions of 
nitrogen excess. In support of this hypothesis, results of a separate quantitative study by our 
group that is investigating glnA1 expression under varying nitrogen conditions, have shown 
that glnA1 may be totally down-regulated under conditions of nitrogen excess (60 mM NH4+ 
added to Kirchners cultures), while being abundantly expressed under conditions of nitrogen 
starvation (3 mM NH4+) (Harper, C.; personal communication). Whether there are 
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transcriptional repressors that could disable M. tuberculosis GS synthesis in M. smegmatis, 
or if the glnA1 promoter region itself plays a role in the down-regulation of transcription is not 
known. 
 
It was also observed that large concentrations of recombinant M. tuberculosis GS are 
translocated from the M. smegmatis cytoplasm to the cell membrane and cell wall. 
Glutamine synthetase had a MW of approximately 55 kDa, indicating that no post-
translational protein modifications, such as N-terminal cleavage, have taken place during GS 
translocation from the M. smegmatis cytosol to the cell wall. Post-translational modification 
of M. tuberculosis GS was not expected, since the GS sequence does not possess an N-
terminal secretion signal peptide necessary for sec-dependant export (Pugsley, 1993) and 
no N-terminal modification of the secreted GS sequence was observed in previous studies 
(Harth and Horwitz, 1997; Sonnenberg and Belisle, 1997). However, a sec-like protein 
export pathway (mediated by a secA2 helper translocase) that does not require the cleavage 
of a N-terminal sec-signal sequence was shown to be present in mycobacteria, including M. 
tuberculosis and M. smegmatis (Braunstein et al., 2003). In the study by Braunstein et al. 
(2003) it was shown that other N-terminal sec-secretion signal sequence lacking proteins 
predominant in the M. tuberculosis culture filtrate, such as SodA, might be secreted through 
the SecA2-dependant mechanism. Since this mechanism might explain the export of 
recombinant M. tuberculosis GS by M. smegmatis, the protein-protein interaction of M. 
tuberculosis GS and SecA2 was investigated in an E. coli-based bacterial-2-hybrid system. 
The results showed that no protein-protein interaction between GS and SecA2 could be 
detected, suggesting that M. tuberculosis GS is probably not exported by this mechanism. 
However, the results presented here show that the mechanism required for GS export is 
present in M. smegmatis, despite the observation of a previous study that showed that M. 
smegmatis does not export its native GS (Harth and Horwitz, 1997). It could also be argued 
that a possible confounding factor in this study was the fact that E. coli was used as an 
expression host and that both proteins were fusion constructs. Subtle alterations in target 
protein folding and structure may influence the recognition and interaction sites between the 
two M. tuberculosis proteins (Baneyx and Mujacic; 2004; Garcia-Fruitos et al., 2005; 
Petersson et al., 2004).  
 
The high concentrations of recombinant M. tuberculosis present in the M. smegmatis cell 
wall may suggest a physical association between GS and the mycobacterial cell wall. This 
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observation is supported by the lack of recombinant GS in the logarithmic growth phase 
culture filtrates of the M. smegmatis expression host, despite the high level of expression 
observed in the cytosol. Furthermore, low concentrations of GS could be detected in the 
culture filtrate of M. smegmatis cultures that had entered the stationary growth phase. It is 
believed that many cytosol - associated proteins are liberated into the bacterial culture 
medium following cell membrane disintegration after cell death (Wiker, 2001). Increases in 
the concentration of such cytosolic proteins have been observed during the entry into the 
stationary growth phase of M. tuberculosis, suggesting extensive lysis of dying bacilli 
(Andersen et al., 1991). Since it could not be determined whether the apparently low 
concentrations of recombinant M. tuberculosis GS detected in the culture filtrate of stationary 
growth phase M. smegmatis cultures were derived from the cytosol, it cannot be argued that 
GS was actively secreted during the stationary M. smegmatis growth phase.   
 
To investigate whether GS is similarly associated with the cell walls of GS-secreting 
mycobacteria, such as M. bovis BCG, GS was isolated through ammonium sulphate 
precipitation from cytosol and cell wall protein preparations of M. bovis BCG. The cell wall 
proteins were prepared by gentle abrasion of the M. bovis BCG biomass that would result in 
the removal of the outermost layer of the cell wall of the mycobacterium. This method of 
gentle mechanical removal of cell wall proteins has been used previously and showed that 
although the outermost layer of the bacilli were removed, minimal lysis of bacilli occurred 
(Ortalo-Magné et al., 1995). The GS proteins from both the M. bovis BCG cytosol and cell 
wall fractions were purified to single band purity which both had γ-glutamyl transferase 
activity. Two GS proteins of differing molecular weight (MW) was observed that were 
restricted to the cell compartment from which they were isolated. A lower MW GS 
(corresponding to the predicted MW of GS sub-units of ~ 54 kDa) was obtained from the 
cytosol of M. bovis BCG. From the cell wall, a higher MW GS sub-unit (~ 58 kDa) was 
isolated. The difference in MW is counter-intuitive, since modifications of exported proteins 
would usually be expected to be of a smaller MW than the cytosolic form due to post-
translational modifications, such as peptide cleavage (Palmer and Berks, 2003). Glutamine 
synthetase subunits of higher MW (56 to 58 kDa) than predicted have been observed in M. 
smegmatis cultures expressing M. tuberculosis glnA1 from a constitutive plasmid construct 
(Harth and Horwitz, 1997). This discrepancy in the observed and predicted MW of GS could 
not be explained, although it was shown that the observed increase in GS MW was not due 
to the adenylylation state or post-translational modifications such as glycosylation or 
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lipidation. In other studies the molecular weight of GS has been determined as 53.57 kDa 
(Gu et al., 2003) or 54 kDa (Rosenkrans et al., 2000). It has been suggested that observed 
differences in molecular weight could be ascribed to transcriptional effects, such as 
transcription from the two alternative M. tuberculosis glnA1 promoter regions (as described 
in Section 3.2.1) that may result in GS of different molecular weight. However, our results do 
not support this hypothesis, since recombinant M. tuberculosis GS expressed from either or 
only one promoter region showed GS of homogenous MW, similar to that of the predicted 
MW (54.39 including the 6x his C-terminal tag). It may therefore be argued that an additional 
polymer responsible for the observed increase in MW was purified together with GS from the 
M. bovis BCG cell wall. This polymer might not be present in M. smegmatis, or have a 
different affinity for M. tuberculosis GS.  
 
A candidate for such an additional polymer may be that of poly-L-glutamic acid. It has been 
shown that GS may be directly involved in the synthesis of poly-L-glutamic acid (Harth et al., 
2000). This polymer has been observed in the cell walls of pathogenic mycobacteria only, 
such as M. bovis (including some of the M. bovis BCG sub-strains; Phiet et al., 1976) and M. 
tuberculosis (Harth et al., 1994), although probably not M. leprae (Melancon-Kaplan et al., 
1988). It has been shown that the poly-L-glutamic acid polymer might be non-covalently 
associated with the peptidoglycan layer of the M. tuberculosis cell wall of which it may 
constitute as much as 10% of the dry weight (Hirschfield et al., 1990). The function of this 
polymer is unknown, although it has been speculated that it might function as an internal 
nitrogen and carbon reservoir (Hirschfield et al., 1990), or in maintaining the integrity of the 
M. tuberculosis cell wall (Wietzerbein et al., 1975). However, it has been shown that 
transcriptional inhibition of M. tuberculosis glnA1 results in a decline in poly-L-glutamic 
formation in the cell wall (Harth et al., 2000), suggesting that active GS is required for its 
formation. Such a hypothesis might explain the observed bactericidal effect of compounds 
such as methionine-L-sulfoximine (MSO) on M. tuberculosis (Tullius et al., 2003). It has been 
shown that MSO cannot cross the M. tuberculosis cell wall into the cytosol (Harth and 
Horwitz, 1997), thereby implying that the compound is exerting its bactericidal effect on the 
GS located in the M. tuberculosis cell wall. Following from these observations it could 
therefore be hypothesised that the poly-L-glutamic acid may be associated with GS during 
its synthesis. The additional MW of this polymer might then explain the observed size 
difference in the larger cell wall associated GS. In addition, the GS observed in the cell wall 
fraction of M. bovis BCG was of one MW, which implies that the poly-peptides associated 
http://scholar.sun.ac.za
 74
with GS may be of equal size. It could not be shown that the recombinant M. tuberculosis 
GS expressed in M. smegmatis is active and therefore it may be argued that poly-L-glutamic 
acid could probably not be synthesised by the recombinant GS after expression in M. 
smegmatis.  
 
To the hypothesis that a difference in M. tuberculosis GS MW may be observed in M. 
smegmatis if a functional M. tuberculosis is present, an M. tuberculosis chromosomal 
fragment containing the glnA1 locus was integrated into the M. smegmatis chromosome. 
The M. smegmatis integral strain was consequently transformed with the glnA1 long 
construct to enable detection of M. tuberculosis GS. Intriguingly, hybridisation signal of anti-
6x his antibody could not be detected in the whole lysates of the M. smegmatis integral 
strain transformed with the “glnA1 long” construct. Dot blots showed that an epitope was 
present in spots of concentrated proteins, which may suggest that transcription rates of the 
“glnA1 long” construct might have been very low due to the presence of three glnA1 genes 
(those of M. smegmatis, M. tuberculosis and the M. tuberculosis “glnA1 long” construct). A 
more sensitive method of 6x his epitope detection (based on colorimetric staining) showed 
the presence of a ~ 60 kDa protein, as well as a ~ 13 kDa product not present in M. 
smegmatis integral control lysates. The identity and MW of the recombinant GS was 
confirmed through affinity purification, which showed a single protein band with a MW of ~ 
60 kDa. This result was intriguing, since it showed that the recombinant M. tuberculosis GS 
produced in the M. smegmatis integral strain had a higher MW than when expressed in M. 
smegmatis without the integrated cosmid (MW ~ 55 kDa).  This observation may imply that 
the recombinant M. tuberculosis may be modified (by addition of another low MW moiety) in 
the presence of a functional copy of M. tuberculosis glnA1, and therefore presumably 
functional M. tuberculosis GS. If this is true, it may also imply that GS does not catalyse the 
addition-event, since the recombinant GS protein may not be active.    
 
The smaller ~ 13 kDa product could not be observed after affinity purification, although it 
cannot be excluded that it may be present in very low and undetectable amounts. This 
product may imply that the C-terminus of M. tuberculosis GS is modified in the M. smegmatis 
integral strain. The consequences of such a C-terminal modification are unknown, since this 
terminus is involved in the dodecamerisation of the GS hexameric rings (see Section 1.6.1). 
However, these results imply that other cis-or trans- acting factors might be involved in GS 
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modification or association. These factors might be located in close proximity to the glnA1 
locus integrated into the M. smegmatis chromosome in the M. smegmatis integral strain.  
 
3.3.1 Conclusion 
 
Although it has been shown that the chemical requisites necessary for the forward catalytic 
reaction of GS, such as ATP (Harth et al., 2000) and ammonium (Clemens et al., 1995), are 
present in the culture filtrate of M. tuberculosis, GS may not necessarily have a specific 
function in the culture filtrate, but may fulfil a integral role in maintaining cell wall integrity 
through the formation of poly-L-glutamic acid.  Although the method of concentrating culture 
filtrate proteins used in this study may not have been effective in enriching low abundance 
proteins, the results of the sub-cellular compartmentalisation of M. tuberculosis GS strongly 
suggest that although M. tuberculosis GS may be exported by M. smegmatis, it is not 
secreted into the culture filtrate, suggesting that GS activity detected in mycobacterial culture 
filtrates by previous studies might be due to other reasons, such as mechanical damage of 
mycobacterial cell walls resulting in a release of the cell wall bound GS. It may however also 
be possible that other factors involved in GS secretion may exist in M. tuberculosis, but not 
in non-pathogenic mycobacteria, such as M. smegmatis.  
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CHAPTER FOUR 
 
 
Operon structure of other genes in close proximity to glnA1 
 
 
 
 
“When it rained down sorrow it rained all over me 
Cause my body rattles like a train on that old SP 
I've got the TB blues 
I've got that old TB I can't eat a bite 
Got that old TB I can't eat a bite 
Got me worried soul I can't even sleep at night” 
 
James Charles (Jimmie) Rodgers, T.B Blues 
(Born September 8, 1897 – died of tuberculosis May 26, 1933) 
 
 
 
 
 
 
 
 
 
 
Note: Some of the results presented in the following chapter were submitted for peer review 
and publication as: ”Transcriptional regulation and essentiality of genes downstream of 
M. tuberculosis glnA1. Hayward, D; van Helden, P; Kenyon, C and  I Wiid to the Journal of 
Bacteriology on 07-07-2007 
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4.1 INTRODUCTION 
 
In Chapter 3 we showed that substantial quantities of M. tuberculosis GS subunits are 
exported over the cell membrane and into the cell wall of a mycobacterial expression host, 
such as M. smegmatis. This result indicated that an export mechanism might exist in 
mycobacteria that aids this export. We hypothesised that retention of GS in the cytosol might 
involve C-terminal modification and that the factor(s) performing this task may be located in 
proximity to the glnA1 locus. Gene clusters in prokaryotic genomes are typically composed 
of functionally related genes which are situated adjacent to each other on the same DNA 
strand with intergenic gaps of no more than 300 bp (Overbeek et al., 1999). Clusters of 
genes adjacently located and transcribed in the same direction are a common feature of the 
M. tuberculosis genome (Cole et al., 1998). Examples of gene clusters containing 
functionally related genes include the genes involved in lactose utilisation (lac), galactose 
utilisation (gal), as well as genes involved in histidine (his) and tryptophan biosynthesis (trp) 
(Lawrence and Roth, 1996). Such gene clusters were also observed in the genome of M. 
tuberculosis, and include examples such as the ESAT-6 gene clusters (Gey van Pittius et al., 
2001), the mce operon and various operons in which the ATP-binding cassette (ABC) 
transporters are situated (Gioffre et al., 2005).  
 
A cluster of four genes is present downstream of the coding sequence of M. tuberculosis 
glutamine synthetase, glnA1 (Figure 4.1). Two of the genes in this cluster, glnE and glnA2, 
were previously shown to be essential for M. tuberculosis growth, since viable deletion 
strains of these sequences could not be established (Parish and Stoker, 2000; Collins et al., 
2002). The other two gene sequences in this arrangement, Rv2223c and Rv2224c, are 
annotated as serine proteases of unknown function. 
 
4.1.1 Study aims 
 
4.1.1.1. To investigate the promoter activity of the intergenic regions of the gene cluster 
downstream of glnA1 
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4.1.1.2. To investigate the two DNA sequences downstream of glnE and glnA2, Rv2223c 
and Rv2224c in terms of protein sequence distribution 
 
4.1.1.3. In silico functional analysis of the proteins encoded by Rv2223c and Rv2224c 
 
4.2 RESULTS 
 
 4.2.1 The chromosomal region surrounding glna1 
 
The genes in the M. tuberculosis chromosomal region surrounding the glnA1 locus were 
retrieved from TubercuList (Materials and Methods 2.1). Figure 4.1 shows the location of 
genes surrounding glnA1 on the M. tuberculosis chromosome, while the predicted functions, 
positions, sizes are summarised in Table 4.1. In Table 4.1 it can be seen that the functions 
of many of the genes are unknown or that a putative annotation has been ascribed due to 
the presence of sequence domains common to known functional protein classes. The 
functions of some genes, namely glnA1, glnE and PanB have been determined 
experimentally (Harth and Horwitz, 1997; Parish and Stoker, 2000; Sugantino et al., 2003). 
The Rv2219A open reading frame (ORF) is situated 199 bp downstream of glnA1 on the 
obverse DNA strand and is annotated as a conserved membrane protein.  The glnE gene 
locus is situated 318 bp upstream of glnA1 on the divergently transcribed negative DNA 
strand. The glnE gene encodes a glutamine synthetase adenylyltransferase, which is 
responsible for the reversible regulation of GS through differential adenylylation of the 
individual sub-units (Section 1.6.3).  The glnE sequence is located in close proximity (48 bp) 
to glnA2, which encodes a GS type II enzyme responsible for the synthesis of D-glutamine 
and D-isoglutamine (Harth et al., 2005). The glnA2 locus is separated by 95 bp from an open 
reading frame, Rv2223c, that may encode a exported protease. The Rv2223c locus is 
located 62 bp upstream of a similar ORF, Rv2224c, also annotated as a putatively exported 
protease-encoding sequence. 
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Figure 4.1. The M. tuberculosis chromosomal domain containing glnA1 
 
 
Table 4.1. Summary of the sizes, functions and products of the genes situated in the immediate chromosomal vicinity of the glnA1   
      locus. 
 
Gene Size Function Product Coordinates Reference
lipB 693 bp (230 aa) lipoate biosyntheis lipoate biosynthesis protein B (EC 6.-.-.-) 2484584 - 2485276
lipA 936 bp (311 aa) lipoate biosyntheis lipoate biosynthesis protein A 2485273 - 2486208
Rv2219 753 bp (250 aa) unknown conserved transmembrane protein 2486235 - 2486987
Rv2219A 423 bp (140 aa) unknown conserved membrane protein 2486994 - 2487416
glnA1 1437 bp (478 aa) glutamine synthesis glutamine synthetase (EC 6.3.1.2) 2487615 - 2489051  (Harth and Horwitz, 1997)
glnE 2985 bp (994 aa) gutamine synthetase regulation glutamine synthetase adenylyltransferase (EC 2.7.7.42) 2489369 - 2492353  (Parish and Stoker, 2000)
glnA2 1341 bp (446 aa) glutamine synthesis glutamine synthetase (EC 6.3.1.2) 2492402 - 2493742
Rv2223c 1563 bp (520 aa) function unknown exported protease (EC 3.4.-.-) 2493837 - 2495399
Rv2224c 1564 bp (520 aa) function unknown exported protease (EC 3.4.-.-) 2495461 - 2497023
panB 846 bp (281 aa) pantothenate biosynthesis 3-methyl-2-oxobutanoate hydroxymethyltransferase (EC 2.1.2.11) 2497742 - 2498587  (Sugantino et al. , 2003)
Rv2226 1542 bp (513 bp) unknown conserved hypothetical protein 2498832 - 2500373
Rv2216 
sucB lipB lipA 
Rv2224 glnA2 Rv2219A 
glnA1 
glnE 
Rv2219 panB 
Rv2226 
Rv2223 
A
B
Ir III: 48 bp317 bp Ir II: 95 bp Ir I: 62 bpIntergenic region (Ir) size:
glnA1 (1434 bp) glnE (2982 bp) glnA2 (1338 bp) Rv2223c (1560 bp) Rv2224c (1560 bp)
2492353 2493742 2495399 2497023
5’ - genome coordinates:
2487615
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  4.2.2 Operon structure and regulation 
 
To investigate the functional relationship between the four genes in the 3’ domain of 
glnA1, the co-expressed of glnE, glnA2, Rv2223c and Rv2224c was investigated 
through reverse transcription (RT) of the intergenic regions linking these genes. It has 
been previously observed that internal promoter elements may reside between genes 
co-expressed as an operon as an additional means of transcriptional control (Torres et 
al., 2001; Matsumoto et al., 2005; Li et al., 2006; Oyamada et al., 2007). Therefore the 
relative promoter activity of the intergenic regions were investigated under conditions of 
varying nitrogen availability.  
 
 4.2.2.1 Reverse transcription  
 
To determine whether the genes described above are transcribed as a single polygenic 
mRNA species, mRNA representing the intergenic regions was amplified through 
reverse transcription (Materials and Methods 3.2) and PCR (Materials and Methods 
3.1.2) from total mRNA prepared from a mid-logarithmic growing M. tuberculosis H37Rv 
culture (Materials and Methods 7.3). To minimise the chance of obtaining PCR artefacts 
from mRNA read-through products (Wernisch et al., 2003), anti-sense PCR 
oligonucleotides were designed that would prime approximately 100 bp into the 5’-start 
of the structural genetic region of glnE, glnA2 and Rv2223c (Materials and Methods 2.2). 
Figure 4.2 shows that RT-products could be obtained for the intergenic regions located 
between glnE and glnA2 (350 bp, lane 4) and glnA2 and Rv2223c (300 bp, lane 3). The 
sizes of the PCR products were similar in size to that obtained using M. tuberculosis 
H37Rv DNA as PCR template. No RT-product could be detected representing the 
intergenic region between Rv2223c and Rv2224c (lane 2). Relative to the control 
reactions, no residual M. tuberculosis H37Rv mRNA could be detected in total mRNA 
samples (negative control, lane 1). Controls in the PCR amplification of cDNA produced 
through RT indicated that there was no contamination of the PCR reaction that could 
have resulted in false positive results. 
 
 
 
 
http://scholar.sun.ac.za
 81
 
 
 
 
Figure 4.2. Co-transcription of the four genes in the chromosomal domain was detected 
through RT-PCR using primers that span the intergenic regions. Lane 1 represents the 
reverse transcription negative control, lane 2; the intergenic region between Rv2224c 
and Rv2223c, lane 3; a 259 bp amplification product of the intergenic region between 
Rv2223c and glnA2 and lane 4; the intergenic region between glnA2 and glnE.  
  
 4.2.2.2 Specific promoter activity of the intergenic regions 
 
To investigate whether promoter activity may be present in the genetic regions 
separating the genes described in 4.2.2.1, the relative promoter activity of the intergenic 
regions between Rv2224c and Rv2223c (ir I, Figure 4.1B); Rv2223c and glnA2 (ir II, 
Figure 4.1B) and glnA2 and glnE (ir III, Figure 4.1B) were determined. These intergenic 
regions were cloned into a promoterless mycobacterial expression vector containing a 
functional lacZ sequence (Materials and Methods 5.1 and Addendum C.3). These 
constructs were transformed into E. coli as plasmid amplification host, and colonies were 
selected from LB-Kanamycin agar plates containing X-gal. All E. coli transformants (even 
E. coli transformed with an insert-less pJEM15 plasmid) were blue on X-gal containing 
LB agar plates. This was also observed in a study by Timm et al. (1994) who concluded 
that white-blue screening should be carried out in a mycobacterial host. All pJEM15 
constructs were transformed into M. smegmatis (Materials and Methods 6.2) as a 
mycobacterial expression host (1). Promoter activity in the intergenic regions resulted in 
measurable β-galactosidase activity in the transformed M. smegmatis cultures.  Figure 
4.3 shows transformed M. smegmatis cultured on mycobacterial agar containing X-gal 
and it can be seen that the M. smegmatis transformed with the pJEM15 constructs 
containing the upstream region of Rv2224c (pJem4Up) and the intergenic sequence 
between glnA2 and Rv2223c (Ir II) formed blue colonies (indicative of  β-galactosidase 
activity). The blue colour of these M. smegmatis colonies were comparable to a positive 
control construct that contains the PAN – IS900 transposase promoter region (Murray et 
al., 1992). In contrast, the M. smegmatis transformed with the pJEM15 constructs 
containing the intergenic regions between glnE and glnA2 (Ir III) and Rv2223c and 
 
M  1 2 3 4
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300 bp 
200 bp 
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Rv2224c (Ir I) were white. These colonies were comparable to a negative control 
consisting of M. smegmatis transformed with an control pJEM15 plasmid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Mycobacterium smegmatis transformed with promoter constructs were plated 
on X-Gal containing mycobacterial agar in the presence of Kanamycin. Mycobacterium 
smegmatis cultures transformed with constructs including the Rv2224c upstream region 
(pJem4Up), the intergenic region between Rv2223c and glnA2 (Ir II) and the positive 
control (pJemPAN) exhibited β-galactosidase activity, while M. smegmatis transformed 
with constructs including the intergenic regions between Rv2223c and Rv2224c (Ir I), 
glnA2 and glnE (Ir III) as well as a negative pJEM15 control showed no activity. Blue 
colonies indicate promoter activity due to the expression of the lacZ, while white colonies 
indicates a lack of promoter activity.    
 
pJem15 neg. control
Upstream promoter Intergenic region 1
Intergenic region 2 Intergenic region 3
pJem4Up r I
r II r III
pJemPAN pos. control
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The β-galactosidase activity of the M. smegmatis transformants were quantitatively 
determined using the ONPG β-galactosidase spectrophotometric assay (Pardee et al., 
1959; Materials and Methods 9.5) during the logarithmic (OD600 = 0.4 – 0.6) and 
stationary (OD600 > 1.2) growth phases under conditions of varying nitrogen availability. 
The β-galactosidase activity could be directly translated to the relative strength of 
promoter activity of the sequences that were cloned at the 5’-end of the lacZ locus 
contained in the pJEM15 plasmid. Figure 4.4 shows the relative promoter activity of the 
5’- regions of M. tuberculosis Rv2224c (pJem4Up), Rv2223c (Ir I), glnA2 and glnE during 
the logarithmic and stationary growth phases of M. smegmatis. In Table 4.2 it can be 
seen that background β-galactosidase activity was detected in the pJem15 negative 
control assays. Since the β-galactosidase activity demonstrates relative promoter 
activity, the data presented in Figure 4.4 were standardised to the β-galactosidase 
activity of the pJem15 negative control assays. The non-standardised means and 
deviations are listed in Table 4.2. β-galactosidase activity could be detected in the 5’-
regions of Rv2224c and glnA2, while the activity for 5’- regions of Rv2223c and glnE 
were comparable to that of the negative control. Promoter activity changed during the M. 
smegmatis stationary growth phase, in that increased β-galactosidase activity  was 
observed in the 5’-regions of all the genes, as slight increase in promoter activity could 
also be observed in the 5’-region of Rv2223c (pJem Ir I, Figure 4.4) and glnE (pJem Ir III, 
Figure 4.4). An up-regulation of promoter activity in the 5’-region of the Rv2224c 
(pJem4Up, Figure 4.4) and glnA2 (pJem Ir II, Figure 4.4) was also observed during the 
stationary phase of M. smegmatis growth.   
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Figure 4.4. Relative promoter activity of the putative promoter regions upstream of 
Rv2224c (pJem4Up), Rv2223c (pJem Ir I), glnA2 (pJem Ir II) and glnE (pJem Ir III) 
during the mid logarithmic ( ) and stationary growth phases ( ) of M. smegmatis.   
 
Plasmid (Promoter) Logarithmic growth Stationary growth 5mM (NH4)2SO4 50mM (NH4)2SO4
pJEM15 0.47 ± 0.21 0.35 ± 0.13 -0.27 ± 0.27 -0.09 ± 0.05
pJEM 4upstream 2.35 ± 0.28 4.79 ± 0.13 2.26 ± 0.16 -0.07 ± 0.02
pJEM irI 0.34 ± 0.06 0.98 ± 0.12 -0.01 ± 0.03 0.88 ± 0.09
pJEM irII 2.87 ± 0.06 3.13 ± 0.64 2.07 ± 0.15 2.3 ± 0.06
pJEM irIII 0.41 ± 0.15 0.99 ± 0.68 0.3 ± 0.88 0.19 ± 0.08
β-galactosidase activity
 
Table 4.2. β-galactosidase activity detected in ribolysed cell extracts of transformed M. 
smegmatis cultures grown to different growth phases and under different conditions of 
nitrogen availability in the logarithmic growth phase. The results represent the means 
and standard deviations of three independent assays. 
 
To study the effect of nitrogen availability on promoter activity, the M. smegmatis 
transformants were grown in Kirchners medium to the mid logarithmic growth phase 
(OD600 = 0.4 – 0.6), collected by centrifugation, and incubated for one growth division (~ 
4 hours) in Kirchners medium in which asparagine was substituted by 5 mM (NH4)2SO4 
or 50 mM (NH4)2SO4 as nitrogen source. Figure 4.5 shows that promoter activity in the 
5’-regions of Rv2224c and Rv2223c were influenced by the nitrogen concentration in the 
growth medium. Promoter activity could not be detected in the 5’-region of Rv2224c 
(pJem4Up, Figure 4.5) at high concentrations of nitrogen availability, but was 
upregulated under conditions of nitrogen starvation. In contrast, promoter activity was 
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upregulated in the 5’-region of Rv2223c (pJem Ir I, Figure 4.5) under high nitrogen 
availability, but was observed to be down regulated under low nitrogen conditions. The 
activity of the glnA2 and glnE 5’-regions remained unchanged during fluctuations in 
nitrogen availability.        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Relative promoter activity  of the putative promoter regions under conditions 
of nitrogen starvation: 5 mM (NH4)2SO4 ( ) or nitrogen excess: 50 mM(NH4)2SO4 ( ). 
 
 4.2.3 In silico analysis of the sequences encoded by Rv2223c and Rv2224c  
 
The results shown in Section 4.2.2 suggest that the expression of the enzymes encoded 
by Rv2223c and Rv2224c in M. tuberculosis may be regulated in conjunction with other 
genes involved in M. tuberculosis GS regulation and metabolism. To gain insight into the 
possible function that the proteins encoded by these ORFs might perform, the amino 
acid sequences of the proteins were analysed using in silico methods (Methods and 
Materials 2.3 and 2.4). Examination of the protein sequences of the Rv2223c and 
Rv2224c and paralogs thereof by means of in silico analysis might impart information 
helpful in determining what the functions of these proteins might be. 
 
 4.2.3.1 Distribution of homologous sequences    
 
The function of the enzymes encoded by the ORFs’ Rv2223c and Rv2224c are 
unknown, however they are annotated as putative exported proteases. To investigate 
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whether protein paralogs with known function may be present in other organisms, the 
amino acid sequences of Rv2223c and Rv2224c were compared by sequence BLAST to 
570 fully sequenced bacterial genomes available on the NCBI genome web-server 
(Materials and Methods 2.3). Both the M. tuberculosis Rv2224c and Rv2223c ORFs may 
encode peptides of 520 amino acids. Figure 4.6 shows that these protein sequences 
share a similarity of 46%. These homologous amino acids are dispersed over the whole 
sequence, with the least homologous region being the amino acid sequences contained 
in the protein N-terminal. Some stretches of conserved amino acid sequences can be 
observed in particular regions of the protein sequence, suggestive of potential enzymatic 
functional sites.    
 
Rv2223c MAAMWRRRPLSSALLSFGLLLGGLPLAAPPLAGATEEPGAGQTPGAPVVAPQQSWNSCREFIADTSEIRTARCATVSVPVDYDQPGGTQA 90
Rv2224c MGMRLSRRDKIARML---LIWAALAAVALVLVGCIRVVGGRARMAEPKLGQPVEWTPCRSSNPQVKIPGGALCGKLAVPVDYDRPDGDVA 87
Rv2223c KLAVIRVPATGQRFGALLVNPGGPGASAVDMVAAMAPAIADTDILRHFDLVGFDPRGVGHSTPALRCRTDAEFDAYRRDPMADYSPAGVT 180
Rv2224c ALALIRFPATGDKIGSLVINPGGPGESGIEAALGVFQTLPKR-VHERFDLVGFDPRGVASSRPAIWCNSDADNDRLRAEPQVDYSREGVA 176
Rv2223c HVEQVYRQLAQDCVDRMGFSFLANIGTASVARDMDMVRQALGDDQINYLGYSYGTELGTAYLERFGTHVRAMVLDGAIDPAVSPIEESIS 270
Rv2224c HIENETKQFVGRCVDKMGKNFLAHVGTVNVAKDLDAIRAALGDDKLTYLGYSYGTRIGSAYAEEFPQRVRAMILDGAVDPNADPIEAELR 266
Rv2223c QMAGFQTAFNDYAADCARSPACPLGTDSAQWVNRYHALVDPLVQ-------KPGKTSDPRGLSYADATTGTINALYSPQRWKYLTSGLLG 353
Rv2224c QAKGFQDAFNNYAADCAKNAGCPLGADPAKAVEVYHSLVDPLVDPDNPRISRPARTKDPRGLSYSDAIVGTIMALYSPNLWQHLTDGLSE 356
Rv2223c LQRGSDAGDLLVLADDYDGRDADGHYSNDQDAFNAVRCVDAPTPADPAAWVAADQRIRQVAPFLSYGQFTGSAPRDLCALWPVPATSTPH 443
Rv2224c LVD-NRGDTLLALADMYMRRDSHGRYNNSGDARVAINCVDQPPVTDRDKVIDEDRRAREIAPFMSYGKFTGDAPLGTCAFWPVPPTSQPH 445
Rv2223c PAAPAGAGKVVVVSTTHDPATPYQSGVDLARQLGAPLITFDGTQHTAVFDGNQCVDSAVMHYFLDGTLPPTSLRCAP 520
Rv2224c AVSAPGLVPTVVVSTTHDPATPYKAGVDLANQLRGSLLTFDGTQHTVVFQGDSCIDEYVTAYLIGGTTPPSGAKC-- 520
 
Figure 4.6. Alignment of the protein sequences of the putative proteases encoded by 
Rv2223c and Rv2224c in M. tuberculosis H37Rv. The homology between the two protein 
sequences was determined as 46%.   
 
Sequences from organisms that share an amino acid similarity higher than 35% to the M. 
tuberculosis Rv2223c and Rv2224c sequences are summarised in Table 4.3. From the 
data presented in Table 4.3, it can be seen that homologous sequences to the M. 
tuberculosis Rv2223c and Rv2224c amino acid sequences are not widely distributed 
through the bacterial species whose genome sequences are available on the NCBI 
sequence-BLAST webpage. Sequence paralogs with a homology higher than 35% were 
only detected in the Actinobacteria.  In bacteria other than the Mycobacteria, one 
sequence paralog per bacterial genome was observed (Table 4.3), while the 
mycobacterial genomes contained paralogous sequences to both Rv2223c and 
Rv2224c.  
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Table 4.3. Rv2223c and Rv2224c paralogs obtained through protein sequence BLAST to all bacterial genomes present on NCBI web 
server. The sequence accession numbers and annotated functions of these sequences together with the percentage of identical 
amino acids contained in each sequence compared to the M. tuberculosis Rv2223c and Rv2224c sequences are indicated. In the 
organisms where only one sequence homolog for either the Rv2223c and Rv2224c sequences could be obtained, a open space was 
left in the column indicating sequence accession number and function, although homology to the paralogous M. tuberculosis 
sequence is shown.  
 
 
Organism Sequence acc. nr. Identities Function Sequence length Sequence acc. nr. Identities Function Sequence length
M. tuberculosis H37Rv NP_216739 520/520 (100%) exported protease 520 NP_216740 520/520 (100%) probable exported protease 520
M. tuberculosis CDC1551 NP_336752 520/520 (100%) proteinase 520 NP_336753 507/507 (100%) putative proteinase 507
M. tuberculosis F11 ZP_01685140 520/520 (100%) hypothetical protein 520 ZP_01685141 518/518 (100%) hypothetical protein 518
M. bovis AF2122/97 NP_855896 520/520 (100%) probable exported protease 520 NP_216740 520/520 (100%) probable exported protease 520
M. ulcerans YP_905359 384/477 (80%) exported protease 522 YP_905357 457/518 (88%) exported protease 518
M. avium YP_881447 375/475 (78%) hydrolase 519 YP_881445 438/520 (84%) putative hydrolase 520
M. leaprae NP_302124 373/479 (77%) possible hydrolase 511 NP_302125 441/520 (84%) possible secreted protease 535
Mycobacterium sp. KMS YP_939375 325/464 (70%) TAP domain protein 508 YP_939376 349/493 (70%) TAP domain protein 511
M. smegmatis YP_888572 320/474 (67%) hydrolase 500 YP_888573 332/492 (67%) protease 510
M. vanbaalenii PYR-1 YP_954397 306/464 (65%) TAP domain protein 505 YP_954398 314/495 (63%) TAP domain protein 516
Rhodococcus sp. RHA1 YP_701153 254/469 (54%) possible proteinase 566 248/474 (52%)
Nocardia farcinica YP_117869 247/467 (52%) Putative hydrolase 555 253/475 (53%)
Arthrobacter sp. FB24 YP_830213 178/467 (38%) TAP domain protein 524 181/476 (38%)
Streptomyces avermitillis  MA-4680 NP_825801 190/488 (38%) protease 533 185/492 (37%)
Thermobifida fusca YX YP_290836 172/463 (37%) putative proteinase 500 192/484 (39%)
Streptomyces coelicolor A3 NP_627738 178/462 (38%) secreted proteinase 539 186/488 (38%)
marine actinobacterium ZP_01131087 178/475 (37%) peptidase 512 175/490 (35%)
Leifsonia xyli supsp. xyli YP_061517 170/480 (35%) peptidase 518 172/487 (35%)
Kineococcus radiotolerans ZP_00616853 179/485 (39%) A/B hydrolase 515 195/483 (40%)
Nocardioides sp. JS614 YP_921618 184/487 (37%) TAP domain protein 521 180/485 (37%)
Janibacter sp. HTCC2649 ZP_00994153 179/501 (35%) puitative secreted proteinase 515 178/481 (37%)
Rv2223c Rv2224c
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Figure 4.7. The phylogenetic reconstruction demonstrating the evolution of the M. 
tuberculosis Rv2223c and Rv2224c protein sequences shows that these sequences 
might be derived from a single ancestral progenitor, but that might have evolved 
separately. The scale bar indicates an evolutionary distance of 0.1. 
 
To investigate whether the Rv2223c and Rv2224c sequence homologs of the 
mycobacteria could have arisen through a duplication event, a phylogenetic 
reconstruction was done using all homologous sequences (Materials and Methods, 
2.3.1). The Kineococcus radiotolerans sequence paralog was chosen as out-group for 
the construction of the phylogenetic tree, since this organism evolved prior to the 
speciation of the other actinobacteria in the Actinobacterial phylogenetic tree (see Figure 
1.2). The phylogenetic tree representing the evolution of the M. tuberculosis Rv2223c 
and Rv2224c sequences is shown in Figure 4.7. It can be seen that an ancestral 
progenitor sequence has diverged into separate clades (Rv2223c homologs and 
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Rv2224c homologs, Figure 4.7) containing different lineages in the mycobacteria. In 
these mycobacterial clades, the slower growing mycobacteria (M. tuberculosis, M. avium 
and M. leprae) and rapid growers (M. flavenscens, M. vanbaalenii, M. smegmatis and 
Mycobacterium sp. KMS) are clustered similar to mycobacterial species diversification 
(see Figure 1.3). Together with the data summarised in Table 4.3, no conclusion could 
be made as to which open reading frame sequence bears the closest relation to the 
progenitor sequence, but that the duplication event might only be present in the 
mycobacteria.     
 
 4.2.3.2 In silico  functional analysis of Rv2223c and Rv2224c 
 
Protein sequence homologs of the M. tuberculosis Rv2223c and Rv2224c sequences 
were detected in all the mycobacterial genomes included in this study.  A high degree of 
protein sequence homology is observed between these sequences from the different 
mycobacteria, with the sequences being identical in the M. tuberculosis strains and M. 
bovis. The sequence homology between the M. tuberculosis strains and the other 
mycobacteria is shown in Table 4.3. The multiple sequence alignment of the 
mycobacterial sequences in Figure 4.8 shows the high degree of amino acid 
conservation in these sequences, particularly with regard to amino acids that might play 
a role in the structural conformation and folding of the final protein product, such as 
cysteines (cys) which may form disulphide bonds through the interaction of thiol side-
groups which may stabilise global protein folding (Creighton, 1975; Baud et al., 1993). 
From the sequence alignment represented in Figure 4.8, it can be seen that the cys 
residues are remarkably conserved in both sequences in all the mycobacterial homologs 
included in this study. All the M. tuberculosis Rv2223c and Rv2224c amino acid 
homologous sequences contain 10 cys residues situated close to or in conserved amino 
acids domains, which may lead to the formation of 5 disulphide bridges in the folded 
protein.   
 
All the mycobacterial sequences aligned in Figure 4.8 possess a typical lipase serine 
protease gly-X1-ser-X2-gly consensus motif, where X1 is usually either tyr or his (Brady et 
al., 1990). The active ser is usually part of a ser - his - asp catalytic triad, which is 
normally close to the enzyme surface but not completely exposed to solvents. Through 
inspection of the sequence alignment in Figure 4.8, gly321, ser232 and gly325 (numbering 
based on the residue position in the M. tuberculosis Rv2223c amino acid sequence) are 
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conserved together with the tyr324 residues through all the sequences. Four conserved 
his (his181, his306, his378 and his488) residues were observed, with his378 and his488 located 
in the most homologous amino acid stretches. A number of conserved asp residues can 
be observed. To determine which his and asp residues may form part of the catalytic 
triad, the amino acid sequences of Rv2223c and Rv2224c were compared to the 
MEROPS database (Materials and Methods 2.4). Through this comparison it was 
determined that his488 and asp461 were the most likely residues participating in the ser - 
his - asp lipase serine protease catalytic triad with ser232 as the likely active ser residue. 
The linear order of nucleophile, acid and his in these potential catalytic triads identifies 
the Rv2223c and Rv2224c proteins as belonging to the α/β hydrolase fold proteins (Ollis 
et al., 1992).  
 
A further in silico analysis was carried out with the aim to predict the position of possible 
enzyme active sites and the functional class to which the enzymes encoded by Rv2223c 
and Rv2224c may belong through protein motif searches using the ExPasy web-server 
(Materials and Methods 2.4). Sequences with a high level of occurrence were excluded. 
Through this search, it was determined that both the protein sequences encoded by 
Rv2223c and Rv2224c may belong to the serine proteases of the tripepidyl-peptidase B 
type (tripeptidyl aminopeptidase (II), tripeptidyl peptidase II or TPP), clan SC, family S33, 
and code S33.006.  The serine lipase active site-sequence (PS00013) pattern was 
located at amino acid position 226 - 235 (InYLGYSyGT) in the Rv2223c sequence, and 
at amino acid position 222 – 231 (LtYLGYSyGT) in the Rv2224c sequence (Figure 4.8). 
A prokaryotic membrane lipoprotein lipid attachment site (PS00013) pattern was 
predicted to be located at amino acid position 21 – 31 (LAAVALVLVGC) in the Rv2223c 
sequence. Lipoprotein lipid attachment sites are usually precursor signal peptides that 
might be recognised by lipoprotein signal peptidases (Class II), which may cut the 
polypeptide upstream of the cys31. No lipoprotein lipid attachment site could be detected 
in the Rv2224c sequence. 
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M. tuberculosis Rv2223c  --------------------------------------------MAAMWRRRPLSSALLSFGLLLGGLPLAAPPLAGATE 36   
M. avium                 --------------------------------------------MTAMSRLRSLSSALLSFGLVLGGTSGVGLPVAGATP 36   
M. leprae                --------------------------------------------MVAMPSLRSLSSALLSLGLLLQPAMTP--PVVGASP 34   
M. vanbalenii            ----------------------------------------------------------MAAMLRAARLIAALAVTAAAQC 22   
M. flavenscens           ----------------------------------------------------------MTAMLRAGPMIAALALISAALS 22   
M. sp. KMS               MRGRDRRQIPHRRRRPAAGHPVPLSGDHSPVTVCLRG---------AYERVGRATMIAMWRVGRGSVLAALALVVAGAVA 71   
M. smegmatis             MRRRRRRHLPDRRRGAPSGHPVLTGGHHRTVAGRSPVGLSARPRGAARATMSAVRRAGRLAMTVGLVLPALMTALVTFGI 80   
M. tuberculosis Rv2224c  -------------------------------------------------VGMRLSRRDKIARMLLIWAALAAVALVLVGC 31   
M. avium                 -------------------------------------------------MGMGLSRRGKSARTLLIWMSIAAVALLLAGC 31   
M. leprae                ----------------------------------MTAAHQEPKPSLAAYVSMALSYRDKIARMLLLGTAIAAVALVLAGC 46   
M. vanbalenii            --------------------------------------------------MAACGAMKLKTGVARSGLLLSLAVLLVAGC 30   
M. flavenscens           -----------------------------------------------------------------------MSALLVAGC 9    
M. sp. KMS               ------------------------MTSATHSRNCSTRPGETAARGGRRRFMAACGAMRLRIGVA---ATVIALPLVAG-C 52   
M. smegmatis             --------------------------------------------------MAACGAMKVRFGLG---ALLAVTVLAAGGC 27   
Clustal Consensus                                                                                         1    
 
M. tuberculosis Rv2223c  EPGAGQTPG--APVVAPQQSWNSCREFIA--DTSEIRTARCATVSVPVDYD-QPG--GTQAKLAVIRVPATGQRFGALLV 109  
M. avium                 EPGAGQTPAPNPPAAAAPQGWGSCSQFVT--DTSDIPTAQCTTVSVPIDYN-NPG--AGQAKLAVIRVPATGQRLGSLLV 111  
M. leprae                E---------QTPSPVPEQNWGNCSVFLS--DTSDIPSARCATVSVPVDYN-NPD--GVHAELAVIRAPATGQRIGSLLF 100  
M. vanbalenii            PTAAAAPVA-VEEPYTAAAVWSSCTPWIA--DVSRIPTAQCGTVAVPVDYA-KPE--GAQAQLAIIKVPASGPRVGVLIV 96   
M. flavenscens           PTASAAPGT-SAEPYTAAAVWDSCTTVLA--DASAVPTARCGTVAVPVDYA-DPG--GAQAHLAVISVPATGPRIGVLVV 96   
M. sp. KMS               PPASATPEGDATQRYGQPPVWGTCQQWG---DASRIPTAQCGTVPVPVNYD-QPD--GAQAQLAVIRVPATGDRIGALMV 145  
M. smegmatis             PVASATPEGDAATPFAAPPVWGGCAQWVA--DPARIPTAQCGTLAVPVDWN-NPDPQGAQAQLAVIRVPASGDRIGALFV 157  
M. tuberculosis Rv2224c  IRVVGGRARMAEPKLGQPVEWTPCRSSNP--QVKIPGGALCGKLAVPVDYD---RPDGDVAALALIRFPATGDKIGSLVI 106  
M. avium                 VRVVVGRAVMSGPKLGQAVEWTPCRAANP--KVKLPAGALCGKLAVPVDYD---HLDGDVATLAMIRFPATGDKIGSLVI 106  
M. leprae                VRVVSGRALMAGPKLGEPVAWAPCRPSNP--AVKLPGGALCGKLAVPVDYD---HHDDDVAALAMIRFPATGDRMGSLVI 121  
M. vanbalenii            SQVVAGRALISVPRPGTPIEWGPCEAGPS-DQVRIPPGAECGMLSVPVDWVRADAPDGEVAQIAVLRIKAAGEKIGSLII 109  
M. flavenscens           SKVVDGNALVSVPRPGTPIDWSPCETGPS-DQKRIPPGSECGMLSVPVDWDNPEDPDGDVAQLAVLRVPATGDRIGSLVV 88   
M. sp. KMS               SNLVDGRAVIAVPRPGTPIQWAPCQAGAPSDESRIPAGAECGLLSVPVDYA---DPDGDVARLAMIRFKATGDRIGSMVI 129  
M. smegmatis             SQVIDGRAIVAVPRPGTPVQWLPCNGGAG-NQTPIPDSAECGMLSVPVDYS---KPDGDVARLAMIRFPATGDRIGSLVI 103  
Clustal Consensus                               1              : 2  :.**:::          * :*::   *:* :.* :.. 19   
 
M. tuberculosis Rv2223c  NPGGPGASAVDMVAAMAPAIADTDILRHFDLVGFDPRGVGHSTPALRCRTDAEFDAYRRDPMADYSPAGVTHVEQVYRQL 189  
M. avium                 NPGGPGGSAVDMVAAMASDMDNSAIRRSFDLVGFDPRGVGHSTPPLRCRTDAEFDAYRREPMVDYSPAGVAHIEQLYRQL 191  
M. leprae                NPGGPGASAVDMVAEMIPGLQRTDIGRHFDLVGFDPRGVGHSTPALRCRTDVEFDAYRTEPMVDYSPAGVAHIEQVYKQL 180  
M. vanbalenii            NPGGPGASAVNTVASMGGALAGSEIGRHFDLVGIDPRGVGHSTPELRCRTDAEFDAFRAEPLADYSPGGVAHIEGVLRDF 176  
M. flavenscens           NPGGPGASAVDTVAGMGAALAGTEIARRFDLVGIDPRGVGHSTPQLRCRTDAEFDAFRTEPMVDYSPAGVAHIEDVLRQF 176  
M. sp. KMS               NPGGPGASAVDTVRGMGAALAETEIGRRFDLVGFDPRGVGHSTPQLRCRTDAEFDAYRREPMVDYSPAGVAQIEGIHQRF 225  
M. smegmatis             NPGGPGASAVDTVAGMGAALAGTEIGQRFDLVGFDPRGVGHSTPELRCRTDAEFDAYRREPMADYSPAGVAHIESLYQQL 237  
M. tuberculosis Rv2224c  NPGGPGESGIEAALGVFQTLP-KRVHERFDLVGFDPRGVASSRPAIWCNSDADNDRLRAEPQVDYSREGVAHIENETKQF 185  
M. avium                 NPGGPGESGIEAALGVVQSLP-KRVRERFDLVGFDPRGVGASRPAVWCNSDADNDRLRTEPNVDYSPAGVAHIEDETKQF 185  
M. leprae                NPGGPGESGIEAALGVVQTLP-KRVRERFDLVGFDPRGVGASRPAVWCNSDADNDRLRSESQVDYSPAGVAHIEDETKQF 200  
M. vanbalenii            NPGGPGKSGKESAAVMAPTLP-EEVRQRFDLVGFDPRGVAESTPAVRCNSDADHDRLRADNVVEYTPEGVAHLENLTKEF 188  
M. flavenscens           NPGGPGKSGVEAAAAMVSTLP-EEVLERFDIVGFDPRGVANSNPAVWCNSDADNDRLRADNVVEYTAEGVAHLESLTKEF 167  
M. sp. KMS               NPGGPGESGVEAAASMLSTVP-QSVRERFDVVGFDPRGVASSTPAVWCNSDADNDRLRADPQVDYSPEGVEYIENETKAF 208  
Msmeg24                  NPGGPGESGVESALSLLPSLP-QEVKERFDIVGFDPRGVASSSPAVWCNSDADNDRLRADPTVEYTPEGVAHLEAETKAF 182  
Clustal Consensus        ****** *. : .  :   :    : . **:**:*****. * * : 3.:*.: *  * :  .:*:  **  :*   : : 60   
 
M. tuberculosis Rv2223c  AQDCVDRMGFSFLANIGTASVARDMDMVRQALGDDQINYLGYSYGTELGTAYLERFGTHVRAMVLDGAIDPAVSPIEESI 269  
M. avium                 AQQCVNRMGTAFLANAGTASVARDMDAVRQALGDEQINYLGYSYGTELGTAYLEKFSNHVRAMVLDGAIDPTVGPVDENI 271  
M. leprae                AQQCVARVGTAFLANVGTASAARDMDIVRLALGDEQINYLGYSYGTELGTAYLERFSDHVRAMVLDGAIDPSVSSIQKDI 260  
M. vanbalenii            AAQCLDRMGAEFLASVGTATAARDMDVVRDALGEDRVNYLGFSYGTQLGAVYAARYPDRVRAMVLDGAVDPSLDPITESL 256  
M. flavenscens           AARCLDRMGPEFLAGVGTATAARDMDVVREALGEDQINYLGFSYGTQLGAVYASRYPQRVRTMVLDGAVDPTLDPITESL 256  
M. sp. KMS               AQQCVDRMGVEFLANVGTAAAARDMDVVRAALGENQLNYLGFSYGTELGAAYAERYPDRVRAMVLDGAVDPSLGPIDESV 305  
M. smegmatis             AQQCLDRMGAPFLANIGTASAVRDMDAVRAALGEHQISYLGFSYGTELGSAYAEAYPDRVRAMVLDGAIDPALNPIDKTI 317  
M. tuberculosis Rv2224c  VGRCVDKMGKNFLAHVGTVNVAKDLDAIRAALGDDKLTYLGYSYGTRIGSAYAEEFPQRVRAMILDGAVDPNADPIEAEL 265  
M. avium                 VGRCVDKMGKKFLANVGTVNVARDLDAIRAALGDDKLTYLGYSYGTRIGSAYAEAYPHNVRAMILDGAVDPNADQIEADL 265  
M. leprae                IGRCIAKMGKIFLENIGTVNVAKDLDAIRAALGDDKLTYLGYSYGTRIGAAYAEAYPQNVRSMILDGAVDPNADPIEADL 280  
M. vanbalenii            VQRCVDKMGTDFLSNVGTESVVKDLDALRAALGDEKLTFLGYSYGTRIGAGYAEEYPQNVRAMILDGAIDPNADPVEADV 268  
M. flavenscens           IQRCVDKMGTDFLANVGTASVVKDLDALRVALGDEKLTYLGYSYGTRIGASYAEQFPQNVRAMVLDGAIDPNADPLEADV 247  
M. sp. KMS               IERCVDKSGKDFLANIGTVNVAKDLDAIRAALGDDKLTYLGYSYGTRIGAAYAEQFPEKVRAMILDGAVDPNADPLQADI 288  
M. smegmatis             VQRCVDKMGTEFLANVGTENVAKDLDAIRAALGDDKLTYLGYSYGTRIGATYAEQFPDKVRAMILDGAIDPNADPVEESI 262  
Clustal Consensus           4: : *  **   **  ..:*:* :* ***:.::.:**:****.:*: *   :  .**:*:****:**  . :   : 107  
 
 
 
 
 
 
 
 
 
http://scholar.sun.ac.za
 92
M. tuberculosis Rv2223c  SQMAGFQTAFNDYAADCARSPACPLGTDSAQWVNRYHALVDPLVQK-------PGKTSDPRGLSYADATTGTINALYSPQ 342  
M. avium                 NQMAGFQTAFNDYATDCARSPGCPLGTDPAQFVNRYHALVDPLVTR-------PGRTADPRGLSYADATTGTINALYTPA 344  
M. leprae                QQMAGFQIAFTDYAADCARSASCPLGTDPSQWVNRYHALIDPLVTK-------PGRTSDPRGLGYADATTGTINALYTPV 333  
M. vanbalenii            NQQAGFQKAFEAYAADCAESVGCPLGTDPAQFVARFHQLVDPLVTR-------PAATSDPRGLGYQDAITGTASGLYSQR 329  
M. flavenscens           TQNTGFQRAFERYAADCAKSAGCPLGTDPTQFVARFHQLVNPLAVR-------PAATSDPRGLGYQDAITGTVSALYSQR 329  
M. sp. KMS               AQQAGFQRAFDAYAADCAKSAGCPLGTDPAQFVARYHQLVDPLVAR-------PAATSDPRGLSYQDAITGTGNALYTPR 378  
M. smegmatis             RQMASFQKAFDAYAADCGKLVGCPLGNDPAQYVNRFHQLVDPLVAR-------PGATSDPRGLSYQDAITGTGNALYSPR 390  
M. tuberculosis Rv2224c  RQAKGFQDAFNNYAADCAKNAGCPLGADPAKAVEVYHSLVDPLVDPDNPRISRPARTKDPRGLSYSDAIVGTIMALYSPN 345  
M. avium                 RQAKGFQDAFNNFAAECAKQPNCPLGTDPAKAVDVYHSLVDPMVDPDNPMVGRPIPTNDPRGLSYSDAIVGTIMALYSPN 345  
M. leprae                RQAKGFQDAFNNYAADCARKLSCPLGADPAKAVDVYHNLVNPLVDPNNPMVSRPAPTKDPRGLSYSDAIVGTIMTLYSPT 360  
M. vanbalenii            RQAAAFQQAFDDYATDCAIDEDCPLGTDPAKAVDVYRSLVWPLVDA-------PADTTDPRGLSYNDAVVGTILPLYSPG 341  
M. flavenscens           RQAAAFQQAFDDYAADCAIDDDCPLGTDPAKAVEVYHSLVWPLVDE-------PAETSDPRGLSYNDAVVGTILPLYSPA 320  
M. sp. KMS               RQAAAFQTAFNDYAADCAKQPDCPLGTDPAKAVEVYKSLVDPLVEN-------PAKTDDPRGLSYSDAIVGTIQTLYSPN 361  
M. smegmatis             RQAAAFQKAFDDYAADCAKSPDCPLGTDPAKAVDVYKSIIDPLVEN-------PAKTRDGRGLSYSDATVGTILPLYSPN 335  
Clustal Consensus         *  .** **  :*::5.    6*** *.:: *  :: :: *:.         *  * * ***.* ** .**   **:   145  
 
M. tuberculosis Rv2223c  RWKYLTSGLLGLQRGSDAGDLLVLADDYDGRDADGHYSNDQDAFNAVRCVDAPTPADPAAWVAADQRIRQVAPFLSYGQF 422  
M. avium                 HWKYLTSGLLGLARGTDAGDLLALADDYQGRDRNGHYSNDQDAFNAVRCVDAPNPTDQASWVSADQKIRQAAPFLSYGPF 424  
M. leprae                HWKYLTSGLLGLQRGTDAGDLLLLADDYNGRDRNGHYTNDQDAFNAIRCVDAPVPTDSASWVSADQQIRQAAPFLNYGQF 413  
M. vanbalenii            YWPYLTSGLLGLQRGTDPGDLLLLADDYQQRDRNGHYKNRQDAFNAIRCVDAVYPTDSAPWVEADRRSREVAPFLSYGPF 409  
M. flavenscens           FWPYLTSGLLGLQRGTDPGDLLLLADEYQRRDRDGHYSNQQDAFTAIRCVDAVFPTDPAVWADADRRSRAAVPFLAYGQF 409  
M. sp. KMS               LWAYLTSGLLGLQRGTDPGDLLTLADEYQRRDASGHYANRQDAFTAIRCVDAPYPTDPAAWVQADRRFREAAPFLSYGPF 458  
M. smegmatis             YWPFLTSGLLGLERGTDAEDLLLLADDYQHRDRNGHYQNMQDAFTAIRCVDDVYPTDPAVWAEADRQIREVAPFFAYGGF 470  
M. tuberculosis Rv2224c  LWQHLTDGLSELVDN-RGDTLLALADMYMRRDSHGRYNNSGDARVAINCVDQPPVTDRDKVIDEDRRAREIAPFMSYGKF 424  
M. avium                 LWHHLTDGLSELVDH-HGDTLLALADMYMRRDAHGHYTNATDARVAINCVDQPPITDRAKVIDEDRRSREIAPFMSYGQF 424  
M. leprae                LWHHLTDGLSELVDH-RGDTLLALADMYMRRDSQGHYTNATDARVAVNCVDQPPITDRAKVIDEDRRSREVAPFMSYGKF 439  
M. vanbalenii            LWRHLTQALTEIKKG-RGDTMLALSDLYMGRDAQGHYSNDTDSRVAVNCVDKPAITDRATLVEQDRRVREAAPFMAYGEF 420  
M. flavenscens           LWRHLTQALGEVKEG-KGDTMLALADLYMERNAQGRYTNSTDVRIAVNCVDKPAITDRATLVEQDRRVRDAAPFMAYGEF 399  
M. sp. KMS               LWRYLTQGLTELEAG-RGDTMLALADLYMRRDAQGHYNNSTDARVAVNCVDRPPVKDRDKIVEQDRKLREVAPFMSYGEF 440  
M. smegmatis             LWRHLTDALTALKKG-DGNLMLALADLYMGRDAKGHYNNSTDVRVAVNCMDKPAIKDKATVVEQDKRLREVAPFMSYGEF 414  
Clustal Consensus         * .**..*  :        :* *:* *  *:  *:* *  *   *:.7:*     *       *:: *  .**: ** * 179  
 
M. tuberculosis Rv2223c  TGSAPRDLCALWPVPATSTPHPAAPAGAGKVVVVSTTHDPATPYQSGVDLARQLGAPLITFDGTQHTAVFDGNQCVDSAV 502  
M. avium                 TGNAPRDLCALWPVPATSAPHAAPPMPAGKVVVVSTTHDPATPYQAGVNLARQLGGPLITYDGTQHTAVFNGDQCVDNAV 504  
M. leprae                TGNAPRDICALWPVPATSMPHPAPPVAPGKVVVVSTTHDPATPYQAGVDLARELSSPLITYDGTQHTAVFNGDQCVDSAV 493  
M. vanbalenii            TGFAPRDLCAMWPVPPTPVVGVASSPGPGKVVVVSTTGDPATPYQAGVNLAQQMDARLITFEGTQHTVVFNGDACVDTAT 489  
M. flavenscens           TGFAPRDVCAMWPVPPTSVVGAATSPGPGKVVVVSTTGDPATPYEAGIALADQLDAQLISFTGTQHTVVFNGDACVDTAV 489  
M. sp. KMS               TGYAPRDVCGLWPVPATSAPRPATSPGPGKVVVVSTTGDPATPYEAGVALARQMGASLITFEGKQHTVVFNGDACVDTAV 538  
M. smegmatis             TGFAPRDVCAFWPVPATSTARPVTGPGPGKVVVVSTTGDPATPYQAGVDLARQMGAALISFDGAQHTVVFNGDACVDTAV 550  
M. tuberculosis Rv2224c  TGDAPLGTCAFWPVPPTSQPHAVSAPGLVPTVVVSTTHDPATPYKAGVDLANQLRGSLLTFDGTQHTVVFQGDSCIDEYV 504  
M. avium                 TGNAPLGTCAFWPVPPTSKPHTISAPGLAPTVVVSTTHDPATPYKAGVDLANELRSSLLTYDGTQHTVVFQGDGCIDNYV 504  
M. leprae                TGDAPLGTCAFWPVPPTSKPHIVSAPGLAPTVVVSTTHDPATPYKAGVDLANQLRGSLLTFDGTQHTVVFQGDSCVDDYV 519  
M. vanbalenii            TGLAPMTTCGFWPVPPTSVPHELDVSGLPPILVISTTNDPATPYQAGVDLARQLDGTLVTFEGTQHTVSLQGDSCIDDIA 500  
M. flavenscens           TGLAPMPTCGFWPVPPTSKPHEISVTGLPPILVVSTTNDPATPYQAGVNLARQLGGALVTFEGTQHTVALQGDSCVDDIV 479  
M. sp. KMS               TGHAPLSTCAFWPVPPTSEPHELDVEGLPPILVVSTTNDPATPYQAGVDLARQLGGTMLTFEGTQHTVVFQGNACVDEIA 520  
M. smegmatis             TGDAPLGTCAFWPVPPTSEPHELKVEGLPPILVVSTTNDPATPYQAGVDLARQLGGTLVTFEGTQHTVVFQGNKCVDDVA 494  
Clustal Consensus        ** **   8.:****.*.             :*:*** ******::*: ** :: . :::: * ***. ::*: 9:*  . 225  
 
M. tuberculosis Rv2223c  MHYFLDGTLPPTSLRCAP 520  
M. avium                 VRYFVAGTPPPASYRCQS 522  
M. leprae                VHYFVDETLLPASLQCQP 511  
M. vanbalenii            VEFLVNSTPPPAGLRC-- 505  
M. flavenscens           VAFLTNSTPPPSGLRC-- 505  
M. sp. KMS               VRFLVDGVVPPNGLRC-- 554  
M. smegmatis             LRFLTDLQSPPGNLAC-- 566  
M. tuberculosis Rv2224c  TAYLIGGTTPPSGAKC-- 520  
M. avium                 TAYLVGGTIPPSGAKC-- 520  
M. leprae                TEYLIGGTTPPSGAKC-- 535  
M. vanbalenii            VRYLVDVTVPPPDTRC-- 516  
M. flavenscens           VPYLIDGSVPPPDTRC-- 495  
M. sp. KMS               ARYLIDVVVPPPDTRCR- 537  
M. smegmatis             ATYLIDVEVPPADTRC-- 510  
Clustal Consensus          ::      * .  10   229  
Figure 4.8. Sequence alignment of the mycobacterial homologs of the M. tuberculosis Rv2223c and Rv2224c 
amino acid sequences. Conserved cys-residues are numbered (1 – 10) and residues potentially involved in the 
formation of the enzymatic active site indicated by rectangular frame in the M. tuberculosis sequence. In the 
Clustal consensus sensus, a asterix (*) represents identical amino acids, a semi-colon (:)conserved and a stop 
(.) semi-conserved. 
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In order to study the N-termini of proteins encoded by Rv2223c and Rv2224c for leader 
peptide signals, protein sequences were analysed on the SignalP leader peptide 
prediction server available on the Centre for Biological Sequence Analysis (CBS) web 
page (Materials and Methods, 2.4). SignalP predictions were made using networks 
based on gram-positive bacterial data. The protein sequence was then analysed for the 
presence of transmembrane helices on the CBS TMHMM server (Materials and Methods 
2.4). The prediction gives the most probable location of trans-membrane helices in the 
sequence and is found by an algorithm called N-best which sums over all paths through 
the model with the same location and direction of the helices. The data generated in this 
way were compared with the hydrophobicity profiles of the sequences, which allows a 
visual probability of membrane spanning and surface exposed protein domains.    
 
The signal peptide prediction identified a possible cleavage site between amino acids 34 
and 35 (AGA – TE) in the Rv2223c protein sequence, which led to the (statistical) 
conclusion that the sequence is a leader peptide signal (Figure 4.9). Analysing the 
protein on the TMHMM server predicted that one trans-membrane helix, consisting of 17 
amino acids from position 13 to 35 relative to the first amino acid, may be encoded in the 
sequence (Figure 4.9).  The total probability that the N-terminus of the protein could be 
found in the cell cytoplasm was predicted as 0.80423. Of the remaining amino acids in 
the protein sequence, it was predicted that the amino acids from position 1 to 12 would 
form the cytoplasmic part of the protein, while the amino acids from position 36 to 520 
would be present outside the cell after cleavage. Similarly, the amino acid sequence of 
Rv2224 may encode one trans-membrane helix (Figure 4.9). It was predicted that the 
first to twelfth amino acid might be present on the cytosol side of the cell membrane, 
while amino acids 13 to 35 might form the trans-membrane helix. The most likely 
enzymatic cleavage site was predicted to present between met41 and ala42. The rest of 
the peptide (amino acids 42 to 520) may be present outside the cell membrane.   
 
This prediction was tested through the analysis of the hydrophobicity profiles of the 
sequences. These profiles are based on the Kyte-Doolittle and Hopp-Woods (Kyte and 
Doolittle, 1982; Hopp and Woods, 1983) scales, which determines the hydrophilicity / 
hydrophobicity of a peptide chain based on the amino acid side groups contained 
therein. On the Kyte-Doolittle scale, values of ≥ 1.6 typically indicates hydrophobic 
membrane spanning protein domains and as can be seen in Figure 4.10, the profiles of 
both the Rv2223c and Rv2224c protein sequences indicates a sharp increase in 
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hydrophobicity of the N-termini to a peak at around position 12 in the amino acid 
sequences. The Hopp-Woods scale shows the hydrophilicity of the peptide. According to 
this scale, a value > 0 would suggest that the particular domain is likely to be exposed 
on the surface of the folded protein. Therefore this result is in concordance with the 
transmembrane helix prediction server profile, which calculated the first amino acids to 
be hydrophillic (therefore more likely associated with the cytosol) followed by a 
hydrophobic peptide. This result furthermore agrees with the result obtained from the 
signal peptide prediction server, as the predicted cleavage site (amino acid 34 to 35) is 
outside the region of the protein (amino acid 36 to 520) predicted to be on the 
exogenous side of the membrane. 
 
Another observation from the Kyle-Doolittle and Hopp-Woods profiles is the positions of 
the putative ser232, his488 and asp461 catalytic triad residues indicated in Figure 4.10. 
These residues may all be situated on the transition cusp between the hydrophobic 
interior and hydrophilic exterior of the protein. Therefore the catalytic site may be 
accessible, but not exposed to the exogenous environment of the enzyme.  
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Figure 4.9.: The hydrophobicity profiles of the proteins encoded by Rv2223c and 
Rv2224c demonstrates that a region near the N-terminus of these proteins may be 
associated with the mycobacterial cell wall, suggesting that the proteins may be 
exported. 
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Figure 4.10. Kyte-Doolittle and Hopp-Woods hydrophobicity and hydrophilicity plots of 
the Rv2223c and Rv2224c sequences. The position of putative active site amino acids is 
indicated on the plots.   
 
 
 
-  Rv2223c - 
ser232 his488 asp461 
ser228 asp463 his490 
- Rv2224c - 
http://scholar.sun.ac.za
 97
4.3 DISCUSSION 
 
In Chapter 3 it was suggested that GS exported to the M. tuberculosis cell wall may be 
post-translationaly modified by as yet unknown mechanisms due to size differences in 
GS sub-units isolated from different cellular compartments of M. bovis BCG. Size 
differences in GS sub-units have been noted before, but not described. One report has 
however shown that differences in GS sub-unit size may not be due to effects such as 
methylation or adenylylation (Harth and Horwitz, 1997). We have shown that GS 
peptides of differing MW is not observed when M. tuberculosis GS was produced 
through glnA1 expression in other non-GS secreting mycobacteria, such as M. 
smegmatis (see Section 3.2.1). Therefore it was hypothesised that M. tuberculosis may 
possess some unique mechanism of GS modification, which may be coupled with GS 
secretion.  
 
4.3.1 Operon structure and promoter activity of the genes located downstream of  
 glnA1  
 
Although the nitrogen-signalling cascade has been extensively studied in 
Corynebacteria, relatively little is known about the influence of nitrogen availability on the 
regulation of M. tuberculosis genes that are thought to be involved in nitrogen 
metabolism. In this study, the co-expression and promoter activity of a cluster of genes 
located downstream of the glutamine synthetase encoding glnA1 sequence in 
mycobacteria was investigated to see if the other two genes of unknown function located 
in this region may play a role in nitrogen metabolism.  
 
Our results show an inverse correlation between the regulation of the promoters 
upstream of Rv2223c and Rv2224c under conditions of nitrogen availability. The method 
of investigating promoter activity used in this study is not quantitative, but the results 
suggest that Rv2224c may be expressed from a promoter with constitutive activity during 
logarithmic growth, while Rv2223c may only be expressed at very low levels. The 
transcription of both Rv2223c and Rv2224c may increase during the later stages of 
mycobacterial growth. However, Rv2223c transcription may be up-regulated during 
conditions of nitrogen excess, while Rv2224c transcription is down-regulated. The 
promoter activity of the Rv2223c upstream region also suggests that Rv2223c 
transcription may be down-regulated during nitrogen starvation. The presence of 
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differential promoter activity was also reflected by the absence of a RT-PCR product 
representing the 62bp intergenic region between Rv2224c and Rv2223c, which suggests 
that these two genes may not be transcribed as a single polygenic mRNA. The 
differential regulation of these open reading frames may suggest that they may have 
different functions, despite being similar in amino acid sequence.  
 
The function of the proteins encoded by Rv2224c and Rv2223c are unknown, but it has 
previously been shown that the expression of Rv2224c may be up regulated during M. 
tuberculosis infection of human macrophages (Dubnau et al., 2002), indicating that the 
protein encoded by Rv2224c may also be necessary during M. tuberculosis 
pathogenesis. Both the proteins encoded by these genes are annotated to have leader 
sequences and may therefore be exported to the M. tuberculosis cell membrane by a 
sec-dependent mechanism. A previous study showed that the Rv2224c protein could be 
detected in M. tuberculosis cell membranes, but not the Rv2223c sequence (Sinha et al., 
2005). The results of the current study suggest that Rv2224c may be constitutively 
expressed during M. tuberculosis growth in culture and under nitrogen starvation, but 
that Rv2223c is expressed during later stages of the M. tuberculosis growth cycle and 
up-regulated under conditions of nitrogen excess. This observation may explain the lack 
of B-galactosidase activity of M. smegmatis transformed with the Rv2223c upstream 
reporter construct grown on X-gal containing agar plates. The absence of Rv2223c in 
the M. tuberculosis membrane fractions may therefore be explained due to culturing 
conditions and it is expected that Rv2223c may locate to the mycobacterial cell wall.     
 
Our results are equivocal about the presence of a promoter in the upstream region of the 
adenylyl transferase encoding glnE locus. There are conflicting reports regarding the co-
expression of glnA2 and glnE as a polygenic mRNA species (Collins et al., 2002; 
Pashley et al., 2006). In this study, RT-PCR products representing the intergenic regions 
of Rv2223c: glnA2 and glnA2: glnE were detected, suggesting that Rv2223c, glnA2 and 
glnE may be co-transcribed as a poly-cistronic mRNA. This mRNA species may be 
present during specific growth conditions, since the promoter upstream of Rv2223c may 
not have constitutive activity. This observation would explain the lack of a longer mRNA 
transcript by Northern analysis, as described in a previous report (Pashley et al., 2006). 
Similar to that report, results from this study showed constitutive promoter activity in the 
intergenic region upstream of glnA2, which is not influenced by conditions of varying 
nitrogen availability. This is also observed in the closely related Corynebacteria, where 
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glnA2 is similarly situated adjacent to the glnE locus and the expression are not 
influenced by nitrogen levels (Nolden et al., 2001). However, this observation does not 
exclude the presence of a glnE promoter, as operons with weaker internal promoters 
that are activated under certain conditions have been detected in M. tuberculosis, such 
as that in the phosphate transport (Torres et al., 2001) and DNA gyrase operon 
(Unniraman et al., 2002). It is believed that these weaker internal promoters may aid the 
enhancement of gene transcription under certain conditions. It could be speculated that 
the up-regulation of the Rv2223c promoter may lead to an increased production of glnA2 
and glnE under conditions of nitrogen excess. This might be a mechanism leading to 
increased synthesis of the glnE-encoded adenylyltransferase necessary to control GS 
activity through adenylylation under conditions of nitrogen excess.    
 
4.3.2 Rv2223c and Rv2224c evolution  
 
The sequence BLAST comparisons of the M. tuberculosis Rv2223c and Rv2224c protein 
sequences against the available bacterial genomes revealed that only the mycobacterial 
species have both sequences encoded by different genes in their genomes. Other 
actinobacterial genomes contain one protein ortholog of these sequences. This 
observation, together with the extensive protein sequence homology between the protein 
sequences of Rv2223c and Rv2224c, suggests that the two genes arose from an 
ancestral progenitor gene by duplication and subsequent evolutionary divergence. It 
could not be determined which M. tuberculosis gene is most closely related to the 
progenitor sequence. Gene duplication is a crucial mechanism of evolutionary innovation 
through increasing both gene number and gene complexity (He and Zhang, 2005). 
However progenitor and duplicate genes (or inparalogs) might undergo evolutionary 
changes at different rates (He and Zhang, 2005). The difference in the rate of 
evolutionary change may result in considerable sequence variation from the progenitor. 
It has been established that in many cases, the sequence least homologous to the 
progenitor sequence retained the original function, and therefore assumptions based on 
homology to the closest relative orthologous sequence may not reflect closest functional 
relative (Notebaart et al., 2005; Aravind et al., 2006).  
 
The function of the proteins encoded by Rv2223c and Rv2224c could not be inferred 
from the sequence BLAST comparisons, since very few sequence orthologs with known 
function could be identified in other bacteria. The specific functions of the homologous 
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genes in all the bacteria used in this study are unknown. Because of the high degree of 
homology surrounding the catalytic serine gly – ser - gly consensus sequence (Brady et 
al., 1990), most of the sequences are annotated as serine proteases. The presence of 
these putative amino acids involved in forming the catalytic triad in regions of the 
sequence that might be exposed to the environment lends support to this hypothesis.  
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CHAPTER FIVE 
 
 
Expression Analysis of Rv2223c and Rv2224c 
 
 
 
 
 
“Science! true daughter of Old Time though art! 
Who alterest all things with thy peering eyes.” 
 
Edgar Allan Poe, Sonnet to Science 
(Born January 19, 1809, died of tuberculosis October 10, 1849) 
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5.1 INTRODUCTION 
 
When the full M. tuberculosis H37Rv genome sequence was first made available by 
Cole et al. in 1998, specific function could only be ascribed to around 40% of the 3 924 
predicted open reading frames. Most of the functions ascribed to these genes were 
based on bioinformatic approaches that depend on sequence similarity to sequences of 
known function in other bacteria, which has been shown in some cases to be incorrect 
(Watkins et al., 2006; Johnston et al., 2003). Another study showed that 9.4% of the 
genomic sequences were specific to mycobacteria and do not have any known 
homologs (Camus et al., 2002).  For example, the importance of Rv2223c and Rv2224c 
in M. tuberculosis growth and survival is unknown. In Chapter 4 it was shown that the 
Rv2223c and Rv2224c open reading frames might encode proteins with functions 
related to GS metabolism. These functions may be involved in the export mechanism of 
M. tuberculosis GS (Chapter 3). 
 
5.1.1 Study aims 
 
5.1.1.1 To express and purify the enzyme encoded by Rv2224c in E. coli.  
 
5.1.1.2 To analyse the phenotype of after inhibition of Rv2223c and Rv2224c in M. bovis 
BCG, which may indicate if Rv2223c and Rv2224c are essential for M. tuberculosis or 
M. bovis BCG growth.  
 
5.1.1.3 To analyse the in vivo expression of Rv2223c and glnA1 in M. tuberculosis 
infected human tissue  
 
 
5.1.1.4 To analyse protein-protein interaction of M. tuberculosis Rv2223c and GS. 
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5.2 RESULTS 
 
 5.2.1 Expression of M. tuberculosis Rv2223c in E. coli  
 
In order to express the enzyme encoded by the M. tuberculosis Rv2223c open reading 
frame for purification and enzymatic studies, the sequence was cloned into a L-
arabinose inducible E. coli expression vector (Materials and Methods 5, Appendix C.7). 
The M. tuberculosis glnA1 sequence was cloned in a similar manner as a control. An E. 
coli araBA and araC deletion strain (Materials and Methods 1.2) was transformed with 
an Rv2223c or glnA1 vector construct and positive transformants were cultured in liquid 
media until an OD600 of 0.3 – 0.4 was reached. Expression of recombinant proteins was 
induced by the addition of various concentrations of L-arabinose (0.002% to 20%; Figure 
5.1) and cells were incubated at 300C or 370C for 4 hours. It was observed that E. coli 
cultures transformed with the Rv2223c construct did not increase in turbidity after the 
addition of L-arabinose. For the detection of recombinant protein, the E. coli 
transformants were disrupted by different methods, such as lysis through osmotic shock, 
ribolisation and sonication. Figure 5.1 shows that recombinant Rv2223c could not be 
detected in whole lysates at the expected size (55 kDa) on a 12% poly-acrylamide gel 
after induction with L-arabinose at a final concentration of 20%, 2% and 0.2% 
respectively. In lanes 1 to 3 (Figure 5.1), M. tuberculosis GS could be observed as a 
single band migrating around 55 kDa. The overnight culturing of transformed E. coli at 
300C did not result in growth in cultures expressing recombinant Rv2223c. No 
recombinant Rv2223c could be detected by Western blot detection (Materials and 
Methods 10) using anti-6 x his-tag antibodies (results not shown).  
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Figure 5.1. Attempted expression of recombinant M. tuberculosis GS (lanes 1 to 3) and 
Rv2223c (lanes 4 to 8) at varying final concentrations of L-arabinose. Expression of 
recombinant GS were induced with 20% (lane 1); 2% (lane 2) and 0.2% L-arabinose 
(lane 3). Rv2223c expression could not be induced with L-arabinose to a final 
concentration of 20% (lane 4); 2% (lane 5); 0.2% (lane 6); 0.02% (lane 7) and 0.002% 
(lane 8).   
 
In order to investigate whether the recombinant Rv2223c protein may have an effect on 
the E. coli expression hosts’ growth, E. coli transformed with the Rv2223c and glnA1 
constructs was cultured on agar media containing L-arabinose to a final concentration of 
0.2% or agar media containing no L-arabinose. Agar plates were incubated at 300C for 2 
days. Figure 5.2 shows that both the Rv2223c and glnA1 transformed E. coli grew on 
agar that does not contain L-arabinose, but that only the E. coli transformed with the 
glnA1 construct grew in the presence of 0.2% L-arabinose. No growth of E. coli 
transformed with the Rv2223c construct could be detected on agar plates containing 
0.2% L-arabinose after 2 days. 
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Figure 5.2. Escherichia coli colonies were observed on solid media when E. coli 
transformed with expression plasmids carrying M. tuberculosis Rv2223c (A) and glnA1 
(B) under conditions where expression of the recombinant proteins were not induced. 
When protein expression was induced through addition of 0.2% L-arabinose, E. coli 
colonies could be observed for cultures expressing recombinant M. tuberculosis glnA1, 
but not Rv2223c.          
 
 5.2.2 Inhibition of Rv2223c and Rv2224c expression in M. tuberculosis H37Rv   
          and M. bovis BCG  
 
The efficacy of antisense oligodeoxynucleotides (ODNs) to inhibit the expression of 
specific gene targets has been shown in various organisms (Lisziewicz et al., 1993; 
Barker et al., 1996; Andratschke et al., 2001). Due to the hydrophobic nature of the 
mycobacterial cell wall, the passage of hydrophilic compounds (Rastogi et al., 1981; 
Rastogi et al., 1989) is prevented. To minimise degradation of ODNs by bacterial 
mechanisms, ODNs were modified by synthesising all inter-nucleoside linkages as 
phosphorothioates, which leads to higher lipophilicity and therefore uptake by 
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mycobacterial cells (Harth et al., 2002). In order to study the effect of Rv2223c and 
Rv2224c translation inhibition on the phenotype of M. tuberculosis H37Rv, BACTEC 
cultures were treated with sequence specific PS-ODNS (Section 5.2.2.1). To overcome 
the limitations of PS-ODN half-life and entry into the mycobacterial cell, a vector based 
anti-sense delivery system was constructed (Section 5.2.2.2). This anti-sense delivery 
system made use of a mycobacterial expression plasmid containing an acetamide 
inducible promoter (Parish et al., 1997). The synthesis of anti-sense mRNA could 
thereby be controlled through the induction of the plasmid promoter.   
 
 5.2.2.1 Rv2223c and Rv2224c inhibition with PS-ODNs 
 
In order to obtain an indication of the importance of Rv2223c and Rv2224c in M. 
tuberculosis H37Rv liquid cultures, M. tuberculosis H37Rv was cultured in BACTEC to a 
growth index of 600 – 700, which represents bacilli in the early logarithmic growth phase 
(Roberts et al., 1983). At this stage, bacilli would still be in homogeneous suspension 
and clumping would be minimal. These actively growing M. tuberculosis H37Rv cultures 
were incubated overnight with PS-ODN to a final concentration of 10 μM before being re-
inoculated into BACTEC (Materials and Methods 1.3.2). Growth of M. tuberculosis 
cultures incubated with PS-ODN complementary to Rv2223c and Rv2224c mRNA were 
compared to control cultures that were incubated with 10 μM of random non-specific PS-
ODN (no BLAST-sequence homology to the M. tuberculosis genome). Figure 5.3 A and 
B shows that gene knockdown of Rv2223c and Rv2224c resulted in a ~ 80% inhibition of 
M. tuberculosis H37Rv growth compared to controls. Growth curves of M. tuberculosis 
H37Rv control cultures treated with non-specific random PS-ODN shows that the PS-
ODN had almost no growth inhibitory effect compared to the Rv2223c and Rv2224c 
specific PS-ODN, as the control cultures grew to a maximum measurable growth index 
of 999. A normal downward trend at the end of the logarithmic growth phase (~ Day 7 – 
8, Figure 5.3 A and B) due to nutritional starvation was also observed. Time to positivity 
for cultures treated with Rv2223c anti-sense PS-ODN was 5 to 6 days (Figure 5.3 A), 
while those of cultures treated with Rv2224c anti-sense PS-ODN was 4 to 5 days. The 
growth curves of both cultures also show that when growth positivity has been reached 
(i.e. the inhibitory effect of the PS-ODN has been overcome), both M. tuberculosis 
cultures grew exponentially.  
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Figure 5.3. BACTEC growth indices of M. tuberculosis H37Rv cultures treated with anti-
sense PS-ODN targeting Rv2223c (A) and Rv2224c (B) compared to control cultures 
treated with non-specific PS-ODN.  
 
 5.2.2.2 Vector-based anti-sense expression 
 
Because the effect of PS-ODNs can be overcome by bacterial nuclease digestion, the 
effects of longer-term gene knockdown of Rv2223c and Rv2224c could not be studied. 
To overcome the limited up-take efficiency and half-life of anti-sense PS-ODN, a vector-
based approach was followed to investigate the mycobacterial Rv2223c and Rv2224c 
knockdown phenotype in M. bovis BCG. Mycobacterium bovis BCG was chosen as 
expression host due its genetic similarity to M. tuberculosis and safety considerations of 
working with M. tuberculosis electro-transformations. Therefore an acetamide-inducible 
mycobacterial expression vector was modified to produce mRNA molecules 
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complementary to Rv2223c (492 bp), Rv2224c (460 bp) and glnA1 (517 bp) (Materials 
and Methods 5.4). Mycobacterium tuberculosis glnA1 was chosen as a control 
experiment due to the known bactericidal phenotype of glnA1 transcription inhibition 
(Harth et al., 2000). 
 
Figure 5.4 shows the M. bovis BCG phenotypes of M. bovis BCG transformed with 
constructs containing a anti-sense clone of glnA1 (pANT-glnA1), Rv2223c (pANT-
Rv2223c) and Rv2224c (pANT-Rv2224c). As a control for plasmid stability and 
phenotypic effect alone, a plasmid construct without any cloned insert (pANT-0) was 
transformed into M. bovis BCG. These M. bovis BCG transformants were selected on 
7H11 mycobacterial culture plates containing hygromycin B and 7H11 agar plates 
containing hygromycin B and acetamide to a final concentration of 0.01%. Table 5.1 and 
Figure 5.4 show that in all transformed M. bovis BCG cultures (Figure 5.4 A – C), 
bacteria grew well in comparison with control cultures (Figure 5.4 D) in the absence of 
acetamide. Upon induction of anti-sense mRNA synthesis by the addition of 0.01% 
acetamide to the solid media, no M. bovis BCG growth could be observed for M. bovis 
BCG transformed with pANT-glnA1, pANT-Rv2223c or pANT-Rv2224c. On the pANT-
Rv2223c and pANT-Rv2224c solid media, one or two M. bovis BCG revertant colonies 
could sometimes be observed. Control cultures of M. bovis BCG cultured on 7H11 
media containing 0.01% acetamide showed that the acetamide content in substituted 
7H11 media had no effect on colony forming units.       
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Figure 5.4. Growth phenotypes of M. bovis BCG cultures transformed with pANT-glnA1 
(Panel A), pANT-Rv2223c (Panel B) and pANT-Rv2224c (Panel C) and cultured on agar or 
agar containing acetamide to a final concentration of 0.01%. No, or very few colonies could 
be observed on agar containing acetamide when compared to controls without acetamide. 
Control cultures included M. bovis BCG transformed with pACE alone (Panel D) and non-
transformed M. bovis BCG  (Panel E).  
 
 
 
 
 
 
E)
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Table 5.1. Colonies of M. bovis BCG transformed with constructs producing anti-sense 
mRNA to glnA1, Rv2224c and Rv2223c formed on 7H11 agar and agar containing 
0.01% acetamide as a inducing agent for anti-sense mRNA synthesis.  
 Colonies per agar plate 
 0% Acetamide 0.01% Acetamide 
pANT-glnA1 33 2 
pANT-Rv2224c 45 3 
pANT-Rv2223c 37 5 
pANT-0 >50 >50 
M. bovis BCG >100 >100 
 
  
 5.2.3 Bacterial-2-hybrid analysis of GS and Rv2223c interaction 
 
Direct protein-protein interaction between M. tuberculosis GS and the putative protease 
encoded by Rv2223c were investigated with an E. coli based bacterial-2-hybrid system. 
The coding sequences of glnA1 and Rv2223c were cloned into two separate target 
vectors that contained the two subunits of the catalytic domain of adenalyte cyclase (see 
Section 3.2.2). Interaction between two cloned target sequences would result in β-
galactosidase activity on X-gal containing LB media, therefore presenting colonies as 
blue or colourless. In Figure 5.5 A, blue colonies indicative of β-galactosidase activity 
could be observed for E. coli colonies doubly transformed with expression plasmids 
containing interacting proteins (pKTzip and pUTzip). Figure 5.5 B shows that this β-
galactosidase activity is only present as background in E. coli colonies transformed with 
non-interacting controls. Figure 5.5 C indicates that, compared to the control 
experiments, no interaction between GS and the protein encoded by Rv2223c could be 
observed. Some background false-positive Lac+ colonies could be observed on both the 
negative and control experiments. These false positive colonies are usually due to 
endogenous upstream promoter mutations occurring at an approximate frequency of 10-7 
to 10-8 (Karimova et al., 1998). The same results were obtained when E. coli 
transformants were cultured at 300C in order to aid recombinant protein expression and 
correct target protein folding.  Both sequences were analysed for E. coli codon-bias.  
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Figure 5.5. Escherichia coli based Bacterial-2-hybrid indicates interacting proteins by β-
galactosidase acitivity (blue on X-gal containing media), as can be seen for positive 
controls transformed with constructs (pKTzip and pUTzip) encoding interacting proteins 
(A). Colonies transformed with constructs (pKT25 and pUT18) encoding non-interacting 
proteins remain white, although some light blue background colonies were observed (B). 
Colouring of colonies transformed with constructs encoding M. tuberculosis GS and 
Rv2223c were comparable to the negative controls (C).  
 
5.2.4 In situ Hybridisation 
 
In order to gain some indication of the importance of Rv2223c during M. tuberculosis 
host infection, the localisation of Rv2223c expression was studied through RNA: RNA in 
situ hybridisation (ISH; Materials and Methods 12) to granulomatous human lung 
biopsies. The expression of M. tuberculosis glnA1 (encoding GS) was investigated by 
the same method as an indication of the distribution of expression of an essential gene.  
 
As shown in Figures 5.6 – 5.9, all infected tissues analysed were positive for glnA1 and 
Rv2223c expression in cellular regions of mature and immature granulomas. The 
highest intensities of glnA1 and Rv2223c positive staining was evident in regions 
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containing high amounts of cellular structures, such as the tissue at the periphery and 
surrounding both immature (non-necrotic) and mature (necrotic) granulomas.  
 
The necrotic granuloma contained giant cells and a lymphocyte cuff (consisting of 
lymphocytes and macrophages) that were positive for glnA1 and Rv2223c expression. A 
transition zone, weakly positive for glnA1 and Rv2223c expression, was seen extending 
into the central region of caseous necrosis that was negative for glnA1 and Rv2223c 
mRNA, as indicated by the blue signal. No positive hybridisation signal of the sense 
mRNA riboprobe of either genes to sections originating from the same tissue samples 
was observed (Negative controls, Figures 5.6 – 5.9), demonstrates that the hybridisation 
of the anti-sense probe was specific to mRNA sequences of M. tuberculosis glnA1 and 
that the hybridisation conditions were sufficiently stringent to ensure specific probe 
binding.  
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Figure 5.6. In situ hybridisation of a M. tuberculosis glnA1 mRNA specific probe in a 
necrotic granuloma. Positive hybridisation (brown signal indicates hybridisation, whereas 
blue indicates the non-binding of the mRNA probe) demonstrated that glnA1 was 
expressed in the lymphocyte cuff (LC) and the transition zone (TZ) surrounding the area 
of caseous necrosis (CN), where no glnA1 expression could be detected. Higher power 
magnification shows that glnA1 was expressed on the periphery of the necrotic region (B 
+ C). The negative control shows that non-specific binding of the probe did not occur in 
these tissues (D).  
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Figure 5.7. Mycobacterium tuberculosis glnA1 is abundantly expressed in non-necrotic 
granulomas and surrounding tissues, as demonstrated by the dark brown hybridisation 
signal (brown signal indicates hybridisation, whereas blue indicates lack of binding of the 
mRNA probe). Higher power magnification of the internal region of the granuloma shows 
even distribution of glnA1 expression, as well as macrophages and lymphocytes, which 
were negative for glnA1 hybridisation. The negative control shows that non-specific 
hybridisation of the probe did not occur.  
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Figure 5.8. Mycobacterium tuberculosis glnA1 expression could be associated with host 
immune cells and structures found in the lung granuloma, such as alveolar macrophages 
and giant cells. Black carbon deposits are indicated on the negative control with an 
arrow. 
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Figure 5.9. In situ hybridisation of a M. tuberculosis Rv2223c mRNA specific probe to a 
necrotic pulmonary granuloma. Positive hybridisation as indicated by brown signal (blue 
signal indicates non-binding of the mRNA probe) demonstrated that Rv2223c was 
expressed in the lymphocyte cuff (LC) and the transition zone (TZ) surrounding the area 
of caseous necrosis (CN), where no Rv2223c expression could be detected. Higher 
power magnification shows that Rv2223c is expressed on the periphery of the necrotic 
region (D). Negative controls indicate that no non-specific binding of the probes occurred 
in the tissues (B and E). 
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5.3 DISCUSSION 
 
 
 5.3.1 The Rv2223c encoded protein may be toxic to E. coli  
 
 
In order to produce recombinant Rv2223c protein in E. coli, the coding sequence was 
cloned into a L-arabinose inducible E. coli hexa-histidine fusion vector. Recombinant M. 
tuberculosis GS has been synthesised stably and in active form in previous studies in E. 
coli (Singh et al., 2004), and therefore M. tuberculosis glnA1 was cloned in a similar 
manner as an expression control experiment. However, E. coli cultures expressing 
recombinant Rv2223c failed to grow after expression induction, even after longer 
incubation periods at low induction agent concentrations (which might allow the E. coli 
host cells time to overcome the growth inhibitory effect), suggesting that the Rv2223c 
protein might be toxic to E. coli. Previous reports have demonstrated that some 
expression vectors might be intrinsically toxic to the hosts, but usually such transformed 
hosts present as small, slow growing colonies on selection plates lacking recombinant 
protein expression inducing agent (Miroux and Walker, 1996). Much of the toxic effects 
of recombinant protein expression in E. coli host strains are ascribed to transcription 
surpassing the cells’ translation ability, resulting in high cytosol concentrations of 
unstable naked mRNAs (Iost and Dryfus, 1995; Makarova et al., 1995). It has also been 
suggested that the cell might invest most of its protein translation capacity into the 
production of the recombinant protein, thereby not synthesising sufficient concentrations 
of normal cellular proteins (Dong et al., 1995). However, through the induction of M. 
tuberculosis glnA1 it has been observed that altering the final concentration of the 
arabinose-inducing agent may control the rate of transcription. The synthesis of the 
recombinant Rv2223c protein has been attempted at various final concentrations with no 
success. From these observations it might be argued that even low levels of the 
Rv2223c protein product itself may be toxic to E. coli cultures. Because the specific 
function and substrate of the Rv2223c protein is unknown, it could not be determined 
why the toxic effect was observed. However, it might be speculated that if the Rv2223c 
protein is expressed in a functional form it might disrupt normal cellular processes. This 
observation might also lead to enable speculation that during the bacterial-2-hybrid 
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studies, non-functional Rv2223c might have been expressed. Therefore the results of 
this study might be considered inconclusive. 
 
 5.3.2 Inhibition of M. tuberculosis and M. bovis BCG Rv2223c and Rv2224c  
 
The use of anti-sense mRNA has been shown to be an effective manner to suppress the 
translation of target gene mRNA (Harth et al., 2000; Li et al., 2007). To study the 
knockdown phenotype of Rv2223c and Rv2224c, anti-sense molecules administered in 
the form of PS-ODNs or expression plasmid based have been done in M. tuberculosis 
and M. bovis BCG. In both cases, a significant effect on viability of the mycobacteria was 
observed. When M. tuberculosis H37Rv was treated with PS-ODNs targeting Rv2223c 
and Rv2224c, a marked reduction in growth was observed compared to control cultures. 
An increase of growth could be observed after the duration of incubation, which may 
indicate that M. tuberculosis may overcome the effect of inhibition, or that some viable 
mycobacteria may have remained in the culture that has not taken up sufficient amounts 
of PS-ODN to cause a death. This result may also indicate that inhibition of Rv2223c 
and Rv2224c may have a bacteriostatic effect that cause slower growth, and not a 
bactericidal effect. 
 
To investigate the longer-term effects of Rv2223c and Rv2224c inhibition, a plasmid 
based anti-sense delivery construct was generated by using an inducible mycobacterial 
expression plasmid. The effects of anti-sense mediated suppression were done in M. 
bovis BCG as expression host (for bio-safety reasons), which is 99% similar to M. 
tuberculosis on a genetic level. To control for the efficacy of this system, control M. bovis 
BCG cultures transformed with anti-sense constructs targeting glnA1 were produced. It 
has been shown that anti-sense mediated suppression of glnA1 has a bactericidal effect 
(Harth et al., 2000). No growth could be observed in M. bovis BCG cultures transformed 
with the anti-sense constructs targeting Rv2223c, Rv2224c and glnA1. This effect was 
stable over months, suggesting that the effect of Rv2223c and Rv2224c inhibition may 
be bactericidal and that the inhibition could not be overcome to allow growth, suggesting 
that the proteins encoded by Rv2223c and Rv2224c may be essential for M. bovis BCG 
growth. Because of the lethal phenotype shown by mycobacterial cultures treated with 
either method of anti-sense mediated gene suppression, the levels of mRNA could not 
be determined by methods such as reverse transcription- or real-time PCR. At the 
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present time, a plasmid-based anti-sense delivery approach has not been used to inhibit 
mRNA translation in mycobacteria. The results of this study shows that long-term effects 
of gene inhibition could be studied by using inducible expression plasmids as vectors for 
anti-sense encoding DNA sequences. Also the use of longer anti-sense mRNA 
sequences to increase specificity for target molecules may not influence the efficacy of a 
plasmid-based anti-sense construct. 
 
These results also suggest that all the genes in the genetic cassette downstream of 
glnA1 may be essential. In Chapter 4 it was shown that a polygenic mRNA species 
containing the coding information for Rv2223c, glnA2 and glnE might be present under 
some growth conditions. However, the methods employed in this study should not affect 
the translation of glnA2 and glnE, because it was shown that only the regions of double 
stranded mRNA are degraded (Robbins et al., 1998; Thonberg et al., 2004). Also, glnA2 
may have a promoter sequence (see Chapter 4), which suggests that a ribosomal 
binding site should also be present. Therefore translation of the glnA2 and glnE genes 
might not be affected by the breakdown of Rv2223c due to RNase H activity (Thonberg 
et al., 2004).  
 
 5.3.3 In situ hybridisation of Rv2223c and glnA1 in M. tuberculosis infected tissue   
 
The importance of Rv2223c for M. tuberculosis growth (as discussed in Section 5.3.2) 
was further investigated in human tissue derived from pulmonary M. tuberculosis 
infection. The precise micro-environment inside the granuloma is unknown, but it is 
assumed that M. tuberculosis might be exposed to varying aerobic (Wayne and 
Sohaskey, 2001) and toxic (Russell, 2001) conditions not conducive to mycobacterial 
growth. The mechanisms enabling M. tuberculosis to survive and proliferate in these 
conditions are still poorly understood, but some genes encoding virulence factors, or 
factors that enable M. tuberculosis to infect and adapt to the host environment, have 
been identified (Triccas and Gicquel, 2000). Disruption of these virulence genes result in 
M. tuberculosis attenuation, while complementation of the disrupted genes restores 
virulence. Many of these genes may be involved in intermediary metabolism (Cole et al., 
1998), which not only enable M. tuberculosis to subsist on alternative energy sources 
(Segal, 1984; Segal and Bloch, 1956), but also enter a state of metabolic inactivity or 
latency under conditions of low oxygen tension (Wayne and Hayes, 1998).  
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Various studies have attempted to elucidate which genes are essential for M. 
tuberculosis survival under different growth conditions in vitro or in animal models (Li et 
al., 1998; Camacho et al., 1999; Rodriguez et al., 1999; Ravn et al., 1999). The 
expression of most of the genes investigated under those conditions has not been 
correlated with expression in humans during infection, which may differ (Florczyk et al., 
2001; Mariani et al., 2000). Glutamine synthetase has also been implicated in the 
virulence of M. tuberculosis (Tullius et al., 2003) due to its potential contribution to cell 
wall homeostasis through poly-L-glutamic acid synthesis and/ or involvement in altering 
the pH and ammonia concentration of host cell phagoctes (Harth et al., 1994). It has 
been shown that the activity of the glnA1 may vary between evolutionary different M. 
tuberculosis strains grown in vitro under similar conditions (Goa et al., 2005), although it 
is assumed that glnA1 may be active in the early stages of M. tuberculosis growth due to 
observed GS activity in such cultures (Harth et al., 1994). Localisation of glnA1 
expression in M. tuberculosis induced host granulomas may suggest the importance of 
GS in vivo during active growth and survival of M. tuberculosis, since the conditions in 
the granuloma during disease may differ substantially from controlled in vitro conditions. 
Therefore comparing the distribution of Rv2223c expression in the same tissues with 
that of glnA1 might give an indication of the importance of Rv2223c during M. 
tuberculosis host infection. Previous studies have shown that the activity of some genes 
may be influenced by host factors by virtue of showing transcriptional activity only in host 
macrophages and granulomas, but not in vitro (Ramakrishnan et al., 2000). Therefore 
the distribution of glnA1 and Rv2223c expression during active M. tuberculosis disease 
was investigated through in situ hybridisation of a glnA1 specific mRNA probe to human 
pulmonary granuloma tissue, as well as other forms of lung diseases where M. 
tuberculosis may be involved, such as sarcoidosis.  
 
In situ hybridisation showed a high level of glnA1 and Rv2223c expression in cells 
associated with immature non-necrotic granulomas, suggesting that during the active 
stages of infection GS and the enzyme encoded by Rv2223c may be required for 
survival during the initial phase of the host immune response. As the granuloma 
matures, a necrotic centre develops which may either calcify or become caseous 
(liquefied). The central area of caseous necrosis is a-cellular, although it is thought (by 
virtue of the presence of intact M. tuberculosis genomic DNA) that M. tuberculosis might 
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survive in these zones in a dormant or metabolically inactive state of persistence 
(Fenhalls et al., 2002a). In the mature granuloma, positive ISH binding signal for glnA1 
and Rv2223c was observed in the lymphocyte cuff and the transition zone up to the 
periphery of caseous necrosis. No hybridisation signal was observed in the caseous 
necrosis regions of the granuloma. It is unknown if M. tuberculosis is viable or just 
metabolically inactive in caseous regions, but a previous report has shown that nutrient 
and oxygen limiting conditions, such as that found in the central necrotic region of a 
granuloma, had a suppressing effect on gene expression (Hu et al., 1998). Therefore the 
observed lack of glnA1 or Rv2223c expression in the necrotic granuloma could suggest 
that transcriptional activity of these genes are more repressed in restricted areas of the 
granuloma, although it would not imply that functional GS or Rv2223c protein is also 
absent. These results are in agreement with previous studies that demonstrated an 
increased survival of recombinant M. smegmatis expressing high levels of M. 
tuberculosis GS from an expression plasmid in THP-1 macrophages (Miller and 
Shinnick, 2000). The reason for the increased M. smegmatis survival has not been 
determined, though the study by Miller and Shinnick disputed the role of GS in delaying 
phagosome acidification and subsequent lysosome fusion. In a later study, it was 
demonstrated that a glnA1 M. tuberculosis mutant generated through allelic exchange 
was incapable to grow in THP-1 macrophages and infection of M. tuberculosis-
susceptible guinea pigs (Tullius et al., 2003). In that study it was suggested that active 
GS was essential for intracellular growth and virulence of M. tuberculosis due to its 
central role in glutamine production and potential involvement in the detoxification of the 
ammonium-rich environment of M. tuberculosis in host cells. These results also give a 
further indication that the protein encoded by the Rv2223c gene may be important for 
the survival of M. tuberculosis. Intriguingly, we previously showed (see Chapter 4) that 
the expression of Rv2223c might be up regulated during the abundance of nitrogen 
(possibly in the form of ammonia). It has long been hypothesised that the production of 
ammonia by intracellular M. tuberculosis might play a role in the inhibition of phagosome 
maturation, possibly through influencing phagosome pH (Clemens et al., 1995). 
Therefore the results of the current study may also reflect that high concentrations of 
ammonia may be present in exogenous environment of intracellular M. tuberculosis, 
which may cause an up regulation of Rv2223c expression.  
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It was also observed that the amount of positive riboprobe-binding signal for both genes 
are very abundant in the human lung tissues used. It is unknown if all the cells 
surrounding the granulomas are infected by M. tuberculosis, since ZN staining of 
infected lung tissue generally shows a few scattered bacilli in these tissues. This 
abundant presence of M. tuberculosis gene expression has been detected before in 
granulomas using ISH (Fenhalls et al., 2002a), and it may be argued that the ISH 
technique is oversensitive due to non-specific binding of the riboprobes. However, the 
apparent absence of M. tuberculosis in these regions may also be due to the ability of 
mycobacteria, such as M. tuberculosis (Chandrasekhar and Ratnam, 1992; Wang and 
Chen, 2001) and M. paratuberculosis (Wall et al., 1993), to enter an altered growth-
phase dependent state during which they lose their acid-fastness (Gillespie et al., 1986). 
The report of Wall et al. suggests that cell wall deficient (and therefore non-acid-fast) 
mycobacteria may be in the non-metabolically active stationary growth phase. It is 
possible that mRNA of certain genes may still be present in detectable amounts in 
stationary growth phase or dormant mycobacteria (Smeulders et al., 1999; Hu and 
Coates, 2001). Therefore ZN staining may not readily detect an abundance of M. 
tuberculosis bacilli in infected host tissues and their associated cells (Ulrichs et al., 2005) 
that may be detected through in situ hybridisation techniques (Hulten et al., 2000a; 
Hulten et al., 2000b) and DNA-DNA hybridisation techniques (Fenhals et al., 2002b). 
 
 5.3.4 Mycobacterium tuberculosis GS and Rv2223c may not physically interact 
 
 
The bacteria-2-hybrid system was designed that two complementary components (T25 
and T18; Ladant et al., 1989) of the Bordetella pertussis adenylate cyclase are 
expressed as target - and bait fusion proteins from two independent expression plasmids 
in an E. coli adenylate cyclase-deficient strain (Karimova et al., 1998). Expression of T25 
and T18 alone cannot reconstitute adenylate cyclase, but co-expression as fusion 
proteins to interacting proteins results in functional dimerisation and therefore cAMP 
synthesis. Cyclic AMP regulates the transcription of the lac and mal operons, and 
thereby enabling E. coli to ferment lactose and maltose, which is therefore easily 
detectable on indicator media (Ullmann et al., 1979; Danchin et al., 1981). To investigate 
whether GS and the Rv2223c protein may interact through direct protein-protein 
interaction, coding sequences were cloned into the T25 and T18 fusion vectors and 
transformed into a adenylate cyclase-deficient E. coli strain. Because the protein product 
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of Rv2223c potentially possesses a N-terminal leader peptide that might be cleaved by 
the SecA encoded bacterial translocase protein export system (Economou and Wickner, 
1994), this protein was cloned as a C-terminal T18-fusion protein, while glnA1, which is 
considered leader-peptideless (Harth and Horwitz, 1997) was cloned as a N-terminal 
T25-fusion protein. However, functional complementation of β-galactosidase activity 
could not be observed in E. coli transformants harbouring both fusion vectors, implying 
that GS and Rv2223c do not physically interact.    
 
A limitation of the bacterial-2-hybrid system is that other factors confounding protein-
protein interaction, such as steric hindrance or correct peptide folding could not be 
controlled for. The T25 (224 amino acids) and T18 (114 amino acids) fusion tags were in 
the correct proximal arrangement to associate. The reciprocal influence the GS (474 
amino acids) and Rv2223c (518 amino acids) fusions have on the 3D-structure of the 
T25 and T18 peptides are unknown. Changes in 3D structure of either protein might 
influence the binding affinity between the two interacting proteins. Also, it is unknown if 
position of the N- and C- termini of the target and bait-proteins would facilitate the 
association of T25 and T18.  
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CHAPTER SIX 
 
 
 
Conclusion 
 
 
 
“Ours is essentially a tragic age, so we refuse to take it tragically” 
 
David Herbert Richards (DH) Lawrence, Lady Chatterley’s Lover 
(Born September 11, 1885, died of tuberculosis February 2, 1930) 
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6.1 FINAL CONCLUSIONS AND FUTURE PROSPECTS 
 
In this study it was shown that M. tuberculosis GS may be an attractive target for the 
development of new antibiotics, since it is widely expressed during M. tuberculosis host 
infection, and that its encoding sequence, glnA1, is an essential gene and arguably does 
not tolerate evolutionary change. This implies that the GS encoded by glnA1 should be 
homogenous in all M. tuberculosis strains and that resistance to antibiotics due to 
changes in the enzyme may not readily occur. Other genes, such as the putative 
exported proteases encoded by Rv2223c and Rv2224c, may be involved in GS export 
regulation. Although the function of the proteins encoded by these genes was not 
delineated, this study showed that inhibition of the synthesis of the gene products may 
be lethal to M. tuberculosis. Therefore these genes, which are not widely distributed in 
the Bacterial Kingdom, may also be exploitable for antibiotic intervention and in fact be 
better targets than GS, which also occurs in the host.   
 
Future prospects include an extended study of Rv2223c and Rv2224c, and other factors 
involved in the regulation of nitrogen metabolism. There are several signalling and 
effector molecules involved in the regulation of GS and GOGAT in the actinomycetes 
that differs from other systems, such as E. coli (Burkovski, 2003a). These systems are 
poorly described in M. tuberculosis and might reveal novel mechanisms and pathways of 
regulation, since not all of the genes encoding the factors involved in the control of GS 
and GOGAT are present in M. tuberculosis (reviewed in Burkovski, 2003b) . Such a 
study may further the knowledge of how M. tuberculosis adapts to its host environment, 
since nitrogen (in the form of ammonia, for instance) may play a important role in host-
immune response evasion (Clemens and Horwitz, 1995). The deeper understanding of 
the expression and control of the M. tuberculosis GS may lead to new interventions 
which again would contribute the control and alleviation of the burden of the tuberculosis 
disease. 
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MATERIALS AND METHODS 
 
 
 
 
“Don’t go around saying the world owes you a living; the world owes you nothing – it was 
here first” 
 
Mark Twain (1835  -1910) 
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1. BACTERIAL STRAINS AND CULTURING METHODS 
 
 1.1 Bacterial strains and culture media 
 
Escherichia coli JM109 (ATCC 53323) was used as a host for all cloning experiments. 
Mycobacterium tuberculosis H37Rv (reference strain, ATCC 25618), M. bovis BCG sub-
strains Pasteur (ATCC 35734) and Montreal (ATCC 35746, a gift from Dr. Marcel Behr, 
Montreal General Hospital, Montreal, Canada) and M. smegmatis mc2155 (ATCC 700084; 
Snapper et al., 1990) were routinely used as study material and heterologous mycobacterial 
cloning and expression hosts. 
 
E. coli was grown on solid or liquid Luria-Bertani (LB) agar (Appendix A.2.4) or liquid 
(Appendix A.2.3) medium as described by Sambrook et al. (1989). Mycobacterial strains 
were grown at 37C for 2 days with shaking (200 rpm, M. smegmatis) or 14 days with stirring 
(M. tuberculosis and M. bovis BCG) in Middlebrook 7H9 Mycobacterial medium (Appendix 
A.2.5) supplemented with ADC (Appendix A.2.1) and containing 0.05% (v/v) Tween 80 
(Sigma). For transformant selection and -galactosidase activity detection on solid media, M. 
smegmatis cells were grown on Middlebrook 7H11 Mycobacterial agar (Appendix A.2.6) 
supplemented with OADC (Appendix A.2.7) and 0.001% (w/v) 5-bromo-4-chloro-3-indolyl--
D-galactopyranoside (X-gal, Appendix A.3.26).   
 
 1.2 Escherichia coli strains for protein expression 
 
For the expression of recombinant M. tuberculosis proteins in E. coli, the E. coli TOP10 
strain was used which is capable of transporting L-arabinose, but not metabolizing it 
(Guzman et al., 1995). This was important in the protein expression studies as the level of L-
arabinose will be constant inside the cell and not decrease over time. The E. coli TOP10 
strain is araBADC-. It has both araBA and araC deleted, and the gene for araD has a point 
mutation in it, making it inactive (Invitrogen). 
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 1.3 Culturing methods 
 
All bacterial strains were cultured at 370C. Starter cultures were prepared by spreading a 
bacterial suspension on LB agar media (Appendix A.2.4) containing a final concentration of 
5 g/ ml of the appropriate antibiotics (Appendix A.1) when required (see Table 1).  
 
Table 1. Cloning and expression plasmids used in this study. All plasmids used in 
mycobacterial expression applications were E. coli shuttle plasmids. The selection markers 
are indicated. See Appendix C for plasmid maps.  
Plasmid (see App. C) Bacterial Host  Selection marker Reference 
pGemt-Easy E. coli Ampicillin Promega 
pJEM15 E. coli / Mycobacterial Kanamycin Timm et al., 1994 
p19Kpro E. coli / Mycobacterial Hygromycin B De Smet et al., 1999 
PBAD/gIII E. coli Ampicillin Invitrogen 
pKT25 E. coli Kanamycin Karimova et al., 2000 
pUT18 E. coli Ampicillin Karimova et al., 2000 
pACE E. coli / Mycobacterial Hygromycin B De Smet et al., 1999 
 
 
Liquid cultures were prepared by inoculating a single bacterial colony into the appropriate 
liquid media (Table 2). Liquid cultures of mycobacteria were incubated with constant stirring 
with a magnetic stirrer-bar, while E. coli was cultured with constant shaking in an incubator 
on a orbital shaking platform to allow even aeration and minimise coagulation. Kanamycin 
(50 g/ ml, Roche), Ampicillin (50 g/ ml; Roche, Appendix A.1.1) and Hygromycin B (50 g/ 
ml for E. coli; 100 g/ ml for mycobacteria, Roche) were added to bacterial liquid cultures 
when antibiotic selection was required.  All work on M. tuberculosis H37Rv was performed in 
a Biosafety Level III facility. Culture growth was monitored by spectrophotometric 
measurement of culture turbidity at a wavelength of 600 nm (OD600 value).  
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Table 2. Bacterial strains and culture media used in this study 
 
 
 
  1.3.1 Blue/ white colony selection 
 
In order to screen for -galactosidase activity in transformed bacterial cells, transformed M. 
smegmatis or E. coli cells were selection-plated onto agar-indicator plates containing 5 g/ 
ml (10 g/ ml Hygromycin B for mycobacterial cultures) of the appropriate antibiotic, 0.001% 
(w/ v) X-Gal (Appendix A.3.26) and 0.2 mM isopropyl --D-thiogalactopyranoside (IPTG, 
Appendix A.3.15). Colonies that had -galactosidase activity were blue when cultured on X-
gal-containing indicator plates. 
 
  1.3.2 Mycobacterial culture using BACTEC 460TB system 
 
A 5 ml M. tuberculosis H37Rv culture was prepared in Middlebrook 7H9 medium (Appendix 
A.2.5) enriched with ADC (Appendix A.2.1). At a culture density of approximately A600 = 0.6, 
100 μl of the M. tuberculosis starter culture was inoculated into a BACTEC 12B medium vial 
(Libonati et al., 1988). Cultures in BACTEC were grown until an appropriate growth index 
(GI) of 500 was reached. This culture was used as starter culture for BACTEC evaluation of 
antisense oligonucleotides on M. tuberculosis. Sterility of mycobacterial cultures was 
monitored on 7H9 broth/bacteriological agar plates and by Ziehl-Neelsen acid fast staining 
(Section 1.4). The starter cultures above represented M. tuberculosis in exponential phase of 
growth. Five hundred micro litres of starter culture was added to a sterile 1.5 ml eppendorf 
Organism Culture Media 
Liquid Solid 
Mycobacteria: 
1.) 7H9 Broth + 10% (v/ v) ADC 
supplement  
2.) Kirchners minimal media  
7H11 Agar + 10% (v/v) 
OADC supplement 
  M. tuberculosis 
  M. bovis BCG 
  M. smegmatis 
Escherichia coli:    
  DH5α 
Luria Berthani (LB media) LB Agar   TOP10 (∆araBA and  
∆araC; Invitrogen)     
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tube containing a sterile micro stirrer bar. The culture was brought to a final concentration of 
10mM Phosphorothioate-linked 18-mer antisense oligonucleotide and the culture stirred for 
72 hours, which represents 3 doubling times for M. tuberculosis. After 72 hours, 100ul of 
cultures were added to a fresh BACTEC vial and the growth monitored every 24 hours (one 
doubling time for M. tuberculosis). Phosphorothioate oligonucleotides (Table 4) with no 
BLAST sequence homology (Section 2.3) to the M. tuberculosis genome sequence 
(Tuberculist, Table 3) were used as controls to evaluate the effect of such oligonucleotides 
on mycobacterial growth. 
 
 1.4 Ziehl-Neelsen (ZN) staining of mycobacterial cultures 
 
This method could be used to selectively stain mycobacteria in tissue samples as well as 
from liquid cultures. The method depends on the presence of mycolic acids. Briefly, cells 
were immobilised on a microscope slide with fixing solution (supplied by SAMAR) and 
incubated at 100°C on a hot plate for 30 min. Slides were stained with carbol-fuchsin 
(Diagnostic Media Products) for 10 min with intermittent flaming (boiling must be prevented). 
Thereafter samples were destained through rinsing with 5% acid-alcohol (Appendix A.3.1) 
and counterstained with methylene blue (Diagnostic Media Products). The slides were rinsed 
with H2O and allowed to dry. Thereafter samples were viewed under a light microscope at 
100x magnification and oil immersion. Figure 1 shows typical results of ZN-staining, where 
acid-fast bacteria stains pink to red, and non-acid-fast bacteria stains blue to black) 
 
 
Figure 1. Ziehl-Neelsen stained M. smegmatis culture showing the mycobacterial bacilli (red) 
and what may be non-mycobacterial contaminant bacilli (blue bacilli indicated by arrows).  
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2. BIO-INFORMATICS 
 
Bioinformatics and computational biology involve the use of computer-based techniques for 
the analysis of biological data to solve biological problems at the molecular level. Bio-
informatics were used here for DNA and protein sequence alignment, gene finding, protein 
structure alignment, protein structure prediction, prediction of gene expression, protein-
protein interactions, and the modelling of evolution. 
 
 2.1 Sequence retrieval 
 
Annotations and descriptions of individual genes of Mycobacterium tuberculosis and protein 
sequences were obtained from the Pasteur M. tuberculosis database (Table 3). The DNA or 
protein sequences were used in various applications (Figure 2). 
 
 2.2 Oligonucleotide design 
 
Oligonucleotides for PCR (Section 3) were designed to be homologous to unique sequences 
flanking the genomic area to be amplified, and were carefully designed to make the PCR 
reaction as specific as possible. All oligonucleotides for PCR used in this study were 
designed using DNA sequence data obtained from the Pasteur Tuberculist website (Table 
3). Once the sequence to be amplified was identified, PCR oligonucleotides were designed 
using DNAMAN software (Lynnon Biosoft). Primers were between 18 and 24 bases, with a 
GC content of 50% – 60% (see Table 4). The melting temperature (Tm) representing the 
temperature, at which the oligonucleotide/ DNA template duplex dissociates, was restricted 
to a difference of within 20C of each oligonucleotide pair. Melting point temperature was 
calculated as described in Equation B.2. 
 
When oligonucleotides were designed with internal restriction enzyme (RE) recognition sites, 
these oligonucleotides were checked for self-annealing sequences using Primer Premier 
software (Premier Biosoft International). This software predicts binding energy and non-
homologous bases in the PCR oligonucleotide that may cause mispriming and/or non-
specific binding. The sequence of each oligonucleotide was checked for binding specificity 
by sequence BLAST (Section 2.3) on the Tuberculist website. All oligonucleotides were 
synthesised by Integrated DNA technologies (IDT, USA). All oligonucleotides longer than 30 
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bp were quality checked by MALDI-TOF analysis (IDT, USA) to ensure truncated synthesis 
products were not present.    
 
  2.2.1 Phosphorothioate antisense oligonucleotides (PS-ODNs) 
 
Eighteen-mer PS-ODNs (University of Cape Town) targeting the mRNA sequence of 
Rv2223c and Rv2224c (Table 4) were designed using the same M. tuberculosis genome 
sequence data (Tuberculist) and software (DNAMAN) as in Section 2.2. As a negative 
control, a PS-ODN was designed that does not have a sequence homolog in the M. 
tuberculosis genome.  
 
 2.3 Sequence comparisons 
 
Basic Local Alignment Search Tool (BLAST) searches identified homologous DNA and 
protein sequences through the comparison of a known sequence (obtained from the Pasteur 
Tuberculist web-site, Table 3) to either M. tuberculosis genomic data, or the genome 
sequences of other bacteria available on the National Centre for Biotechnology Information 
(NCBI, Table 3) or the Institute for Genomic Research (TIGR, Table 3). The BLAST-program 
compares nucleotide or protein sequences to sequence databases and calculates the 
statistical significance of matches. BLAST can be used to infer functional and evolutionary 
relationships between sequences as well as help identify members of gene families. 
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Table 3. Web-site address and authors of the various software applications used in bioinformatic approaches. The superscript 
reference numbers refers to Figure 2.  
Application Software or Web-page Software author or Web-page addresses  
Sequence retrieval (1) Tuberculist M. tuberculosis H37Rv genome database http://genolist.pasteur.fr/TubercuList/ 
   
Oligonucleotide design (2) DNAMAN ver. 4.1 Lynnon BioSoft 
  Primer Premier ver. 5.0 Premier BioSoft International 
   
Sequence comparison Clustal W multiple sequence alignment tool (3) http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi 
  BioEdit sequence alignment editor ver. 5.0.9 North Carolina State University 
  PAUP ver 4.0 beta 10 phylogenetics software (4) Sinauer Associates, Inc Publishers 
  TreeView ver. 1.6.6 phylogenetic tree editor http://www.ebi.ac.uk/clustalw/ 
  Bacterial genomic BLAST (5) http://taxonomy.zoology.gla.ac.uk/rod/rod.html 
 M. smegmatis genomic DNA data  http://www.tigr.org 
  GelCompar ver 4.0 (6) Applied Maths, Kortrijk, Belgium 
   
Protein structure and 
function analysis 
Hydrophobicity profiling (9) http://www.cbs.dtu.dk/services/TMHMM-2.0/ 
ExPasy Protein motive searches (8) http://au.expasy.org/ 
  CBS Signal peptide prediction server (10) http://www.cbs.dtu.dk/services/SignalP/ 
  CBS TMHMM transmembrane helices prediction ver. 2.0 (11) http://www.vivo.colostate.edu/molkit/hydropathy/index.html 
 
 
 
 
 
 
 
http://scholar.sun.ac.za
 134
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Retrieved DNA and protein data were analysed and manipulated with various bioinformatic software applications. These 
applications were used in PCR oligonucleotide design, as well as predicting the possible structure and function of an non-described 
polypeptide (such as Rv2223c and Rv2224c) from amino acid sequences. The superscript numbering refers to Table 3, where the 
software or online web-site addresses of the various applications are described.  
 
 
 
 
Oligonucleotide design
Sequence comparison
Functional analysis (protein)
Structural analysis (protein)
Clustal W Phylogeny
BLAST
GelCompar
Putative active site residues
Protein motif searches
Hydrophobicity
Signal peptide prediction
Transmembrane helix prediction
Sequence retrieval
(2)
(1)
(3)
(5)
(4)
(6)
(7)
(8)
(9)
(10)
(11)
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Table 4: List of PCR oligonucleotides, including the length of the amplification product (fragment length), the theoretical annealing 
temperature (Tm, see Equation B.2), the chromosomal priming coordinates, internal restriction enzyme sites (RE sites, underlined in 
the oligonucleotide sequence), the application for which the amplification product was used as well as a Chapter reference. 
 
Name Sequence (5' - 3') Frag size Tm Genome Coordinate RE site Section 
AI FI CACGGTCAGTAACGTCTGC 550 bp 55 2487524 none 2.2.3.2 
AI RI TCCACCTCGTAGAAGGAGC   55 2488081 none 2.2.3.2 
AI FII TTCGATTCGGTGAGCTTC 574 bp 57 2488029 none 2.2.3.2 
AI RII GCCGCTTGTAGGAGTTCA   57 2488602 none 2.2.3.2 
AI FIII ACGACGAGACGGGTTATG 294 bp 54 2488483 none 2.2.3.2; 5.2.4 
AI RIII ATCAGCATGGCCGAGAAC   54 2488768 none 2.2.3.2; 5.2.4 
AI FIV TGGTCTATAGCCAGCGCA 597 bp 56 2488633 none 2.2.3.2 
AI RIV GAGATGATTGCCAAGCGG   56 2489229 none 2.2.3.2 
glnA Up F AGATGGACACGGTGGAGT 796 bp 55 2486860 none 2.2.3.2; 3.2.5 
glnA Up R CTTTACTGTATCCGCGGC   55 2487605 none 2.2.3.2; 3.2.5 
Long F CCCGATATCCAGGTTCCCGTTCGGC 1622 bp 82 2487425 EcoRV 3.2.1; 3.2.5 
Short F CGTCTGCGCAACACGGGATCCCTG   80 2487552 BamH1 3.2.1 
glnA16his R AAGCTTCAGTGGTGGTGGTGGTGGTGGACGTCGTAGTACAGCGCGA 1495 bp   2489047 HindIII 3.2.1; 3.2.5 
GS pKT25 F CATTCTGCAGCGGAAAAGACGCCCGAC 1425 bp 56 2487619 Pst I 3.2.2; 5.2.3 
GS pKT25 R GAGTCCTGGTACCTCGTAGTACAGCGCGAA   56 2489044 Kpn I 3.2.2; 5.2.3 
SecA2 pUT18F ATTCGCGCATGCGACGATGGCGGCCATGTG 570 bp  98 2067667  Sph I 3.2.6 
SecA2 pUT18R CGCGCACTCTAGACTCGTCGGCGGCAA   90 2068237  Xba I 3.2.6 
Rv2224c utF GGCCTTCCATCTCTGTAGG 901 bp 60 2497834 none 3.2.5 
Rv2224c utR AGCCCACAAGAACCAACG   56 2496933 none 3.2.5 
ir II RNAF CGTGACGGCGTATTTAATC 290 bp 56 2495515 none 4.2.2.1 
ir II RNAR GGCAGCTGTTCCAACTCTG   60 2495225 none 4.2.2.1 
ir III RNAF ATGGCAACCAGTGTGTGG 259bp 56 2493922 none 4.2.2.1 
ir III RNAR ACCGAGACGTCTGTGAA   52 2493663 none 4.2.2.1 
ir IV RNAF CGAGAATTGCCGTCCAGT 295 bp 56 2492578 none 4.2.2.1 
ir IV RNAR GGGTCAACTAATCCGAGCC   60 2492283 none 4.2.2.1 
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(Table 4 continued from previous page) 
 
Name Sequence (5' - 3') Frag size Tm Genome Coordinate RE site Section 
ToUp irF GGCCTTCCATCTCTGTAGG 247 bp 58 2497834 none 4.2.2.2 
ToUp irR CAGCCCACAGGTACCAACGCCACGGC   58 2496932 Kpn I 4.2.2.2 
ToIr IF CGGTGGGATCCCAGGGCGACAGCTGCA 288 bp 58 2495552 Bam H1 4.2.2.2 
ToIr IR CGAGCAGGTACCCGAAGGACAGCAG   58 2495336 Kpn I 4.2.2.2 
ToIr IIF ACGGGGCCCAACACACTGCGGTGT 203 bp 58 2493943 Apa 1 4.2.2.2 
ToIr IIR AACCGGATCCGGACGAAGCGGATGT   58 2493680 Bam H1 4.2.2.2 
ToIr IIIF CAAGGGCCCGGAGTGGGCGAACTA 157 bp 58 2492466 Apa 1 4.2.2.2 
ToIr IIIR GCTGGGTACCGAGTTTGGTCACGAC   58 2492335 Kpn I 4.2.2.2 
GS Ex F GCATTCCATGGCGGAAAAGACGCCCGAC  1425 bp 56 2487619 Nco I 5.2.1 
GS Ex R AGTCCTTCTAGATCGTAGTACAGCGCGA    56 2489044 Xba I 5.2.1 
Ex2224 f GCAGCACCATGGGCATGAGGCTGT CTC 1575 bp 56 2497022 Nco I 5.2.1 
Ex2224 r GTTTCGTCGACCCGGTAGCACTTGGCGCCG   56 2495447 Sal I 5.2.1 
Rv2223 PS-ODN CGTAGCTGTATCCGAGGT -- -- 2494700 none 5.2.2.1 
Rv2224 PS-ODN GCCGTACGAGTAGCCCAG -- -- 2496334 none 5.2.2.1 
PS-ODN negative GGGTGCCGTACGAGTAGCCCAGGT -- -- -- none 5.2.2.1 
pACE glnA1 F CCACGGATCCGACATGTTGC 571 bp 64 2487825 Bam H1 5.2.2.2 
pACE glnA1 R GCATCGATTTCAACTGGTAGT   58 2488300 Cla 1 5.2.2.2 
pACE Rv2224c F ACAGGATCCGTTCGATGGTCATAAA 460 bp 51 2496709 Bam H1 5.2.2.2 
pACE Rv2224c R CACCATCGATAATCATTGCC   58 2496286 Cla 1 5.2.2.2 
pACE Rv2223c F GTGGGATCCATGCGAAGTTGGC 492 bp 66 2495122 Bam H1 5.2.2.2 
pACE Rv2223c R  ACATCGATACCTAACCGTTCCAG   62 2494676 Cla 1 5.2.2.2 
RV pUT18 F ATTCGCGCATGCGACGATGGCGGCCATGTG 1550 bp 56 2495403 Sph I 5.2.3 
RV pUT18 R CGCGCACTCTAGACTCGTCGGCGGCAA   56 2493853 Xba I 5.2.3 
Rv ISH F CACGTCGAACAGGTCTACCG 120 bp 64 2494859 none 5.2.4 
Rv ISH R CTAACGCTTGGCGAACCA   56 2494739 none 5.2.4 
SP6 ATTTAGGTGACACTATAG -- 48 -- -- Materials and 
Methods 12.5 T7 TAATACGACTCACTATAGGGAGA -- 64 -- -- 
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  2.3.1 Phylogenetic trees 
 
In order to evaluate the evolutionary relationship between sequences, similar DNA or protein 
sequences from various bacteria were identified through BLAST searches. These 
sequences were aligned by Clustal W (Table 3), which produces biologically meaningful 
multiple sequence alignments of divergent sequences by calculating the best match for the 
selected sequences, and lined them up so that the identities, similarities and differences can 
be seen. Non-homologous DNA or amino acid stretches were removed from the Clustal W 
alignments using the BioEdit sequence alignment editor (Table 3). The edited Clustal W 
alignments were saved as a text (.txt) file and analysed by bootstrapping resampling using 
Phylogenetic Analysis Using Parsimony (PAUP) software. The PAUP software required a 
user-defined run-code to specify operation parameters (Figure 3), such as resampling 
number of the sequence data sets. An outgroup-sequence was specified, which was 
selected based on the relationship of the organism from which the sequence originated to M. 
tuberculosis. Using these parameters, the PAUP software constructed a preliminary tree 
(alignment.tre), which was resampled 1000 times by bootstrapped analysis (nreps = 1000). 
The consensus trees were drawn using the Treeview (Table 3) software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The user-defined run-code required for the PAUP software defines the Clustal W 
data input (alignment.txt), an data out-group as well as the number of resampling (nrep) to 
be done. The software saves the generated data as a phylogenetic tree (alignment.tre), 
which can be viewed and manipulated using Treeview software. 
; 
endblock; 
 
begin paup; 
 
log file = C:\PAUP\alignment.txt; 
 
set criterion = distance; 
 
outgroup USER DEFINED [/ONLY]   ; 
 
bootstrap file=C:\PAUP\alignment.tre nreps=1000 bseed=15 search=Nj; 
 
gettrees file=C:\PAUP\alignment.tre; 
 
contree all/strict=no majrule=yes LE50=yes file=C:\PAUP\alignment.tre; 
 
gettrees file=C:\PAUP\alignment.tre; 
 
describe / chglist=yes Brlens=yes; 
 
savetrees file=C:\PAUP\Trees\ alignment.tre brLens=yes; 
 
log stop; 
 
end; 
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 2.4 Functional and structural analysis 
 
Protein sequence data was used for the identification of putative active site amino acids and 
protein motif searches. Structural data such as hydrophobicity profiles, the presence of 
export signal peptides and transmembrane helices could be obtained using computational 
algorithms embedded in specialised software (see Table 3). In all these applications, amino 
acid sequences were entered in either raw or FASTA format for the software to be able to 
function.  
 
3. POLYMERASE CHAIN REACTION (PCR) 
 
The PCR technique provides a rapid means of exponentially amplifying a specific target 
region of DNA flanked by unique regions to which PCR oligonucleotides are designed. 
These oligonucleotides prime the DNA-polymerase mediated 5’ – 3’ synthesis of two 
complementary strands of the desired DNA segment, effectively doubling its concentration 
with every round of amplification. Products of PCR reactions were analysed by gel-
electrophoresis (Section 4.2). 
  
 3.1 Reaction conditions 
 
The different Taq-DNA polymerases used in this study necessitated the preparation of 
different reaction mixtures for optimal enzyme function. Due to the nature and length of 
some of the DNA PCR target sequences, stabilisers such as DMSO were added to a final 
concentration of 2% - 4% to some reactions. All PCR amplification reactions were performed 
in a GeneAmp PCR system 2400 (Perkin Elmer). To control for contamination, all PCR 
procedures included a reaction where template DNA was omitted.  
 
     3.1.1 Long Range PCR 
 
The Expand Long Range PCR (Roche) was used when amplification products exceeded 
1000 bp, or where the target sequences were non-amplifiable by the conventional PCR 
method due to fragment length (Section 3.1.2). Reaction mixtures contained 100 ng of M. 
tuberculosis H37Rv DNA template, 25 pmols of each oligonucleotide primer (Table 4), 1x 
Reaction Buffer 3 (Roche), and 5 U Expand Long Range Taq DNA polymerase (Roche). The 
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Taq DNA polymerase has proofreading ability and therefore does not create 3’- adenine 
overhangs on amplification products. Deoxyribonucleic acid products synthesised using this 
Taq – DNA polymerase cannot be used in TA-cloning (Section 5) applications without 
preparation prior to cloning. Cycling conditions included an initial 2 min Taq activation and 
DNA denaturation step at 94°C, followed by 30 cycles at 94°C for 30 sec, 30 sec at the 
required oligonucleotide pair Tm (Table 4) and elongation at 68°C for a time of 1 min per Kb 
to be amplified. Adding DMSO to a final concentration of not more than 2% increased primer 
specificity should too many spurious products form.  
 
Long oligonucleotides that were engineered to include a hexa-histidine encoding sequence, 
stop codon and RE site (Table 4) had regions of lower homology to the target DNA 
sequence. Therefore, after the initial denaturation step, 10 cycles of PCR were done using 
50°C as annealing temperature. For the remaining 20 cycles, an annealing temperature of 
60°C was used.    
 
     3.1.2 Routine PCR 
 
For the amplification of PCR products up to 1000 bp, HotStart Taq-polymerase (Qiagen) was 
used. The Taq-polymerase included in this system is a non-proofreading DNA polymerase 
that synthesises DNA fragments with 3’- adenine overhangs which could be directly used in 
TA-cloning applications (Section 5). Each reaction contained 25 pmol of each 
oligonucleotide (Table 4), 100 ng DNA template, 10 μM of each dNTP, 1x reaction buffer 
(supplied), 20 mM MgCl2, 1x Q-solution (supplied additive that enables efficient amplification 
of GC-rich templates), 1U Taq-polymerase and sterile dH2O to a final volume of 50 μl.   
 
 3.2 Reverse transcription (RT) PCR 
 
The PCR amplification of mRNA was divided into two steps, consisting of cDNA first-strand 
synthesis (reverse transcription) and subsequent PCR amplification of the RT-synthesised 
cDNA. Each 50 μl RT reaction contained 200 ng purified mRNA (Section 7.3); 50 pmol of 
reverse PCR oligonucleotide; 200 mM of each dNTP (Qiagen); 2.5 mM 1,1-bis(p-
chlorophenyl)-2,2,2-trichloroethane (DTT, Merck); 10 U RNase inhibitor (Invitrogen) and 1 U 
of Titan reverse transcriptase enzyme mix (Roche) in a 1 x final concentration reaction buffer 
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(Roche). Coding-DNA synthesis was carried out at 500C for 1 hour. Controls for the RT 
reaction included a RT reaction wherein mRNA template was omitted. 
 
The PCR amplification of the cDNA was done as described in Section 3.1.2. A control PCR 
reaction was included with 200 ng of purified mRNA to control for DNA contamination.  
 
4. ELECTROPHORESIS   
 
Proteins and DNA were routinely fractionated by gel electrophoresis. The gel acts as a 
molecular sieve that separates DNA fragments according to size in an electrical field.    
 
 4.1 SDS-PAGE electrophoresis 
 
Protein samples were routinely fractionated under denaturing conditions in a 7.5% – 15% 
(depending on the molecular weight of the proteins) poly-acrylamide resolving gel (Table 5). 
The reagents specified in Table 5 are sufficient for the preparation of two 7 x 10 cm gels, 
0.75 mm – 1 mm thick. The ammonium persulphate and TEMED were added to the 
acrylamide solution just prior to pouring the gel. The acrylamide solution was poured into a 
Protean II gel-cast assembly (BioRad) and overlaid with a thin layer of hydrated iso-propanol 
to prevent the top of the gel from dehydrating. The acrylamide gel was allowed to polymerise 
for 30 min at RT.  
 
After the resolving gel has polymerised, the iso-propanol was decanted and the acrylamide 
gel surface rinsed with ddH2O to remove all iso-propanol. The ddH2O was decanted and the 
top of the gel carefully blotted with Whatman 3M blotting paper to remove excess dH2O 
immediately before the 3% stacking gel solution (Table 5) was added. The gel comb was 
positioned into the stacking gel, and the gel was allowed to polymerise for approximately 30 
minutes. At least 1 cm of stacking gel was present between the bottom of the loading wells 
and the resolving gel. After the stacking gel has polymerised, the casting assembly was 
dissembled, the gel comb removed and the gel was placed in the Protean II electrophoresis 
apparatus as described by the manufacturer. 
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Table 5. Component reagents for the preparation of acrylamide gel grades (%) for two 0.75 
mm mini-slab assemblies.  
Component  3% 7.5 % 10% 12% 15% 
Acrylamide/ bisacrylamide (40% 
stock) 650 µl 2.5 ml 3.33 ml 4.0 ml 5.0 ml 
1.5 M Tris-HCl (pH 8.8) 417 µl 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
10% SDS 50 µl 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
H2O 3.9 ml 4.85 ml 4.0 ml 3.35 ml 2.35 ml 
TEMED 10 µl 10 µl 10 µl 10 µl 10 µl 
10% (w/v) ammonium persulphate 50 µl 50 µl 50 µl 50 µl 50 µl 
 
 
Gel electrophoresis was carried out in SDS-PAGE running buffer (Appendix A.3.21). Prior to 
loading, protein samples were denatured for 10 minutes at 950C in 1x reducing buffer 
(Appendix A.3.20) and subsequently snap-cooled on ice to prevent protein refolding. 
Loading wells were carefully rinsed with glycine running buffer and approximately 6 µg (see 
Section 9.2 for determination of protein concentration) of protein was loaded onto the wells. 
Seven µl Rainbow molecular weight marker (Amersham, UK), or 7 µl pre-stained protein 
marker (Inqaba Biotechnologies) was loaded in the outside lanes. The gel was 
electrophoresed at 80V (constant voltage) until the loading buffer dye migrated 
approximately 1 cm into the resolving gel. Thereafter the gel was electrophoresed at 200V 
(constant voltage) until the loading buffer dye had just migrated off the gel. Thereafter the 
protein samples were visualised through 20 min Coomassie staining (Section 4.1.1), or 
Western blotted onto a Nylon membrane for anti-body detection of specific proteins (Section 
10).   
 
  4.1.1 Coomassie staining of SDS-PAGE gels 
 
Following SDS-PAGE electrophoresis, the acrylamide gel was placed in a dish containing 
Coomassie stain (Appendix A.3.9) to completely cover the gel. The gel was stained at RT for 
a minimum of 30 min, but not longer than 3 hours, by gentle agitation on an orbital shaker. 
After staining, the Coomassie stain was decanted and the gel rinsed once with destain 
solution (Appendix A.3.11). This was replaced by another volume of destain solution and the 
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gel was allowed to destain at RT by agitation on a orbital shaker. The destain solution was 
changed regularly (approximately 3x) until the background was clear. Alternatively, gels 
were destained overnight by incubation at 40C in a large volume (approximately 50 mL) of 
destain solution.  
 
 4.2 Agarose gel electrophoresis 
 
Deoxyribonucleic acid samples were analysed by electrophoresis in TBE (Appendix A.3.23) 
agarose gels. Gels (5 cm x 10 cm) were prepared by the suspension of agarose powder at a 
concentration of 0.8% - 1.2% m/v (depending on DNA fragment length to be resolved) in 1x 
TBE buffer. The suspension was gently heated until the agarose was completely dissolved. 
Ethidium bromide was added to a final concentration of 10ug/ml (Appendix A.3.12) and the 
agarose was poured into the casting apparatus. Samples were prepared for electrophoresis 
by the addition of a 1x loading dye (Appendix A.3.17). The gel was run at 100 V (constant 
voltage) until the dye front reached approximately 2 cm from the end of the gel. The DNA 
was visualised on a transilluminator and photographed. 
 
5. CLONING 
 
All cloning steps were done essentially as described by Sambrook et al. (1989). Target DNA 
sequences generated by PCR were cloned either by T/A ligation into a suitable cloning 
vector (such as pGemt-Easy, Promega), or restriction enzyme digestion and subsequent 
sticky- or blunt-end ligation into a similarly RE-digested plasmid.  
 
All T/A cloning was performed using the pGemt-Easy cloning vector system (Promega), 
which is supplied in a linear form containing T-overhangs. Reactions were prepared in a 10μl 
total volume according to the manufacturers instructions (Promega). One μl of T4 ligase was 
added to a reaction containing 3 μl purified DNA insert, 5 μl 2x ligation buffer (supplied) and 
1 μl (50 pMoles) linearised pGemt-Easy vector. Ligation was done O/N at 40C.  
 
5.1 Plasmid and insert preparation by RE-digestion 
 
In order to facilitate directional cloning or sub-cloning into bacterial host-specific expression 
vectors (Table 2), target DNA (insert and vector) had to be prepared through restriction 
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endonuclease (RE-) digestion. Various restriction endonucleases or combinations thereof 
were used depending on the fragment to be cloned. Briefly, RE reactions were prepared in a 
solution containing a 1x final concentration of the required RE-buffer, target DNA (insert or 
vector) and 10 U RE/ ug DNA. Restriction enzyme digestions were incubated at 370C for a 
minimum of 1 hour, followed by insert and linearised plasmid DNA recovery through gel-
electrophoresis or mini-prep purification (Section 7.2)   
 
 5.2 Partial RE-digestion 
 
In some instances where a specific RE recognition site was not unique and it was necessary 
to digest DNA at only one specific restriction site, partial RE digestion was carried out. All 
following steps, unless stated otherwise were carried out on ice. A 100 μl reaction mixture 
containing DNA (4 – 10 μg final concentration) and 1x of the appropriate RE buffer was 
prepared on ice. The reaction mixture was divided into 5 reaction tubes, such that reaction 
tube 1 contained 30 μl, tubes 2 to 4 contained 20 μl each, and tube 5 contained 10 μl 
reaction mixture. The appropriate RE was added to a final concentration of 3 U per μg DNA 
to reaction tube 1. For the following steps it was necessary to use each pipette tip only once 
between steps. Ten μl of the mixture from reaction tube 1 was transferred to reaction tube 2. 
The tube was gently mixed and 10 μl was then transferred to reaction tube 3. This serial 
dilution was repeated so that the five reaction tubes finally contained 20 μl of the reaction 
mixture. The five reaction tubes were then incubated at the appropriate RE working 
temperature for 15 min. The reactions were stopped by 10 min RE inactivation at 650C. 
Samples were then fractionated by electrophoresis (Section 4.2) and subsequently purified 
from the gel (Section 7.2.2).         
 
 5.3 Removal of 5’ phosphate groups from linearised vector DNA 
 
For sticky- or blunt-end ligation of the RE digested vector to a DNA fragment, the phosphate 
groups of 5’ DNA overhangs of the vector were removed by treatment of the RE digested 
vector DNA with shrimp alkaline phosphatase (SAP; Roche). The phosphatase reaction was 
carried out in a 1x SAP reaction buffer with 0.5 U of SAP per μg DNA. The reaction mixture 
was incubated at 370C for 1 – 2 hours, followed by a 15 min inactivation of the enzyme at 
650C. 
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Five units of T4 Ligase (Promega) were added to 50 ng of prepared vector mixed with the 
required amount of insert DNA to a molar ratio of 3:1 (Equation B.1) in a 1x ligation buffer 
(Promega). The ligation reaction was incubated O/N at 40C to ensure maximum vector to 
insert ligation. Recombinant constructs were purified by phenol/chloroform extraction 
(Section 7.2.3) and resuspended in H2O to a final volume 10 μl. Two µl of the purified vector 
construct mixture was used for electro-transformation (Section 6.1.1 and Section 6.2.1).   
 
 5.4 Preparation of antisense clones 
 
To produce expression plasmid-based antisense mRNA to mycobacterial gene-transcripts, 
460 bp – 570 bp DNA sequences complementary to the target sequences were synthesised 
through PCR (Section 3.1.2). Forward and reverse PCR oligonucleotides (see Table 4) were 
designed to include suitable RE-recognition sites to allow directional cloning of the target 
DNA sequences into the MCS of the acetamide inducible vector, pAce (Appendix C.2). The 
forward PCR oligonucleotide also included a ATG codon as a transcriptional initiator 
sequence, while the reverse PCR oligonucleotide included a translational stop-codon (TGA 
or TAG) in addition to the RE-recogntion sites. Through directional cloning, the target 
sequence was cloned in the antisense direction, which would therefore produce an mRNA 
molecule complementary to the mRNA transcript of the mycobacterial target gene.  
 
6. PREPARATION OF COMPETENT CELLS AND ELECTRO-TRANSFORMATION 
 
6.1 Escherichia coli 
 
Escherichia coli cells (all strains in Section 1 were prepared in the same manner) from a 
frozen stock culture were streaked onto a LB-agar plate (Section 1.1) containing 50 μg/ml 
tetracycline (Appendix A.1.4) and the culture was incubated at 37OC O/N. A single colony 
was inoculated into 50 ml LB-media (Appendix A.2.3) containing 50 μg/ml tetracycline and 
cultured O/N at 37OC in a shaking incubator. One litre LB-medium containing 50 μg/ ml 
tetracycline was pre-warmed to 370C and then inoculated with 10 ml of the O/N starter 
culture.  This culture was incubated at 370C in a shaking incubator until the OD600 reached 
0.5 – 0.8. The culture was cooled for 30 min on ice and all subsequent steps were strictly 
performed at 40C. 
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The E. coli cells were collected by 15 min centrifugation at 1150 x g (40C). The culture 
supernatant was removed and the cells were washed 3 times with 1 ℓ sterile 10% (v/v) 
glycerol. Following each wash, the biomass was collected by 15 min centrifugation at 1150 x 
g (40C). Finally, all washed E. coli suspensions were pooled and collected by 20 min 
centrifugation at 1150 x g (40C). The cells were re-suspended in sterile 10% (v/v) glycerol to 
a final volume of 2 – 3 ml. Fifty-μl aliquots of the final E. coli suspension were used 
immediately or flash frozen in liquid nitrogen and stored at -800C. 
 
6.1.1 Electro-transformation 
 
Frozen stocks of competent E. coli cells were placed on ice to thaw. Two μl of purified 
plasmid construct (Section 7.2) were gently mixed with the 50 μl thawed competent cell 
suspension. This mixture was carried over to a 0.2 cm electroporation cuvette (BioRad, pre-
cooled to 40C) and incubated on ice for 1 min. The Gene Pulser (BioRad) was set to a 
constant voltage of 2.5 kV, a capacitance of 125 F, a secondary capacitance of 25 μF, and a 
resistance of 200 Ω. The cuvette was mounted in the Gene Pulser chamber and pulsed 
once. One ml of freshly prepared SOC medium (Appendix A.2.10) was added to the 
contents of the cuvette and mixed. The cell suspension was transferred to a sterile micro-
centrifuge tube and incubated at 370C for 1 hour with vigorous shaking. One hundred μl of 
the electro-transformed cell suspension was plated on selection plates containing 50 μg/ml 
of the required antibiotic (Table 1) and cultured at 370C O/N. 
 
6.2. Preparation of mycobacterial competent cells 
 
Mycobacteria were cultured in ADC-enriched 7H9 mycobacterial medium (Section 1) to an 
OD600 of approximately 0.5. Cultures were routinely checked for contamination by ZN-
staining (Section 1.4). The mycobacterial cells were collected through 10 min centrifugation 
at 1150 x g (40C) and washed 3x with 10% glycerol the same as with E. coli cells (Section 
6.1). One hundred μl aliquots of the final suspensions were made. Electro-competent M. 
bovis BCG cells were used fresh as it was observed that transformation efficiency was 
greatly reduced if -800C stocks were used. Electro-competent M. smegmatis cells were used 
fresh, however -800C stocks were still electro-competent although slightly less efficiently 
than fresh preparations.   
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6.2.1. Electro-transformation 
 
Competent (mycobacterial) bacilli were kept on ice during all preparations. Two μl of purified 
plasmid construct (Section 7.2) was gently mixed with 100 μl competent bacilli suspension. 
This mixture was carried over to a sterile 0.2 cm electroporation cuvette (BioRad, pre-cooled 
to 40C) and then incubated on ice for 1 min. The Gene Pulser (BioRad) was set to a constant 
voltage of 2.5 kV, a capacitance of 125 F, a secondary capacitance of 25 μF, and a 
resistance of 1000 Ω. The cuvette was mounted in the Gene Pulser chamber and pulsed 
once. One ml of freshly prepared OADC enriched 7H9 medium (Appendix A.2.5 and 
Appendix A.2.7) was added to the contents of the cuvette and mixed. The cell suspension 
was transferred to a sterile micro-centrifuge tube and incubated at 370C for 3 hours (fast-
growing mycobacteria) or 4 hours (slow-growing mycobacteria) with vigorous shaking. The 
mycobacterial cells were collected by 30 s centrifugation in a Eppendorf bench-top 
microfuge at maximum speed (RT), resuspended in 100 μl OADC-enriched 7H9 and plated 
on selection plates containing 100 μg/ ml of the required antibiotic (Table 1). Cultures were 
incubated at 370C until growth appeared (~ 2-3 days for fast-growers; ~ 21 days for slow-
growers). 
 
7. NUCLEIC ACID PURIFICATION 
 
7.1 Plasmid preparations from E. coli cultures 
 
7.1.1 Mini-prep plasmid DNA purification   
 
Small-scale purification of plasmid DNA from E. coli cultures was essentially carried out with 
the Promega DNA mini-prep system following the manufacturers instructions with slight 
modifications. E. coli cells were collected by 10 min centrifugation at 1150 x g (40C) and 
resuspended in 200 µl Resuspension Buffer (provided) followed by the addition of 200 µl 
Lysis Buffer (provided). The lysis-suspension was neutralised with 250 µl Neutralising Buffer. 
The DNA-containing lysate was cleared of cellular debris by centrifugation at 15 000 x g for 5 
min (RT). The DNA in the cleared lysate was immobilised on a purification column (provided) 
and washed with 700 µl 70% ethanol (RT). Excess ethanol was removed from the 
purification column by a 2min centrifugation at 15 000 x g (RT). Immobilised DNA was eluted 
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into a sterile 1.5 ml micro centrifuge tube through the addition of 50 µl dH2O (650C) to the 
column and a 1 min centrifugation at 15 000 x g (RT). 
 
7.1.2 Maxi-prep plasmid DNA purification 
 
Large-scale isolation of recombinant plasmid DNA from E. coli was carried out following the 
protocol essentially as described by the manufacturer of the Nucleobond Kit (Machery-
Nagel) with slight modifications. Briefly, a starter culture was prepared by selecting a clonal 
colony of electro-transformed E. coli from selection agar plates (Section 1) and inoculation 
into 10 ml LB media (Appendix A.2.3) containing the appropriate antibiotic to a 50 µg/ml final 
concentration (Table 1). This inoculum was incubated O/N in a 37°C shaking incubator. One 
ml of the starter culture was inoculated into 100 ml sterile pre-warmed LB medium containing 
the appropriate selection antibiotic to a 50 µg/ml final concentration and cultured O/N at 
370C in a shaking incubator. The cells were collected by centrifugation at 1150 x g (40C) and 
resuspended in 4 ml S1 buffer (supplied) pre-cooled to 4oC. The cells were lysed by the 
addition of 4 ml S2 lysis buffer and gentle mixing by inversion. To allow complete E. coli cell 
disruption, the mixture was incubated for 5 min (RT) followed by neutralisation of the lysis 
mixture by the addition of 4 ml buffer S3 (supplied). The mixture was incubated at 40C for 5 
min.  
 
The bacterial lysate was cleared by filtration (provided or Whatman No. 2 filtration paper). 
Plasmid DNA was immobilised from the filtrate in a pre-equilibrated (2 ml N2 buffer) 
Nucleobond AX 100 column by gravity flow through. The column was washed twice with 5 ml 
buffer N3. Plasmid DNA was eluted from the column with 2 ml buffer N5 and precipitated 
with 0.7 volumes of iso-propanol (equilibrated to RT). The plasmid DNA was immediately 
collected by 30 min centrifugation at 15 000 x g (40C) and washed with ice-cold 70% 
ethanol. Plasmid DNA was collected after 10 min centrifugation at 15 000 x g (40C). The 
70% ethanol was aspirated and the plasmid DNA allowed to dry (650C). Finally, the plasmid 
DNA was resuspended in either TE buffer (Appendix A.3.24) or dH2O depending on further 
applications. Plasmid DNA was quantified using the Nanodrop system (Inqaba 
Biotechnologies).         
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7.2 DNA preparations 
 
  7.2.1 Mini-column DNA purification 
 
Polymerase chain reaction amplified DNA was purified using the Promega SV-column 
system. The manufacturer’s instructions were essentially followed and briefly involved mixing 
the PCR reaction with an equal volume of membrane binding solution (supplied). The DNA 
was immobilised on a SV DNA binding column (supplied), washed twice at RT with a 70% 
ethanol solution and dried by a 5-min centrifugation at top speed in a microfuge. To elute the 
DNA, 50 μl nuclease free dH2O (Promega), pre-warmed to 650C, was added to the column. 
The DNA was collected through 1 min centrifugation at 15 000 x g (RT). The DNA was 
quantified with the Nanodrop DNA quantification system (Inqaba Biotechnology).    
 
7.2.2 Purification of DNA from TBE agar 
 
Deoxyribonucleic acid products were recovered from mixtures of DNA molecules of differing 
size through electrophoresis in a 1% TBE agar gel (Section 4.2). The desired DNA 
fragment(s) were excised from the gel and purified using the Promega mini-prep system. 
Briefly, the excised gel fragment was weighed and DNA binding buffer (supplied) was added 
to a final volume of 1 µl/mg of TBE agar. This preparation was incubated at 650C until the 
TBE agar gel was completely melted. The solution was loaded onto a SV column (supplied) 
and DNA was purified using the same procedure as described in Section 7.2.1.      
 
7.2.3 Plasmid DNA purification by chloroform/ isoamylalcohol extraction 
 
The phenol/ chloroform purification method was followed to enrich or purify small quantities 
of target DNA, or small DNA fragments that are not retained by the DNA purification matrices 
of most purification systems (usually DNA fragments smaller than 100 bp). Briefly, DNA 
samples were made up to a volume of 100 μl or greater to which an equal amount of 
chloroform/ isoamylalcohol (24:1) was added. The suspension was carefully mixed and 
centrifuged for 30 min at 40C. The aqueous layer was recovered to which a 1/10 volume of 3 
M NaAc (pH 5.5) was added. Two volumes of 95% ethanol (–200C) was added and DNA 
precipitated at –200C O/N. Precipitated DNA was collected after 30 min centrifugation at 15 
000 x g (40C). The supernatant was carefully aspirated and the DNA precipitate washed 
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once with 70% ethanol (-200C) to remove all excess salt and then allowed to air-dry. The 
pellet was resuspended in 10 μl nuclease free dH2O (Promega) pre-warmed to 650C.        
 
7.3 Ribonucleic acid (RNA) isolation and purification      
 
Mycobacterium tuberculosis was cultured in 7H9 liquid media (Section 1) to an OD600 of 0.6. 
The cells were collected by 15 min centrifugation at 1150 x g (4oC), the culture supernatant 
was discarded, and the bacterial pellet suspended in 0.85 ml TRIZOL (Gibco BRL) per 10 ml 
original M. tuberculosis culture. The bacterial suspension was lysed in a BioLab riboliser at 
speed setting 6.5 for 45 sec using conical 2.0 ml centrifugation tubes filled with 0.5 mm glass 
beads to a equal volume of the original cell pellet. This step was repeated twice with a 1 min 
cooling on ice between the steps. After the final cycle, samples were incubated for 5 mins at 
RT to allow complete dissociation of nucleoprotein complexes.   
 
Chloroform was added to each sample at 0.2 ml per 0.75 ml TRIZOL before 
homogenisation.  Samples were mixed by low speed vortexing for 15 sec to allow mixing of 
the phases, followed by 5-min incubation at RT. Aqueous and organic phases were 
separated by 15 min centrifugation at 15 000 x g (40C). The aqueous phase was recovered 
and nucleic acids precipitated by the addition of 0.5 ml iso-propanol per 0.75 ml TRIZOL 
originally used and 10 min incubation at room temperature. Precipitated nucleic acids were 
collected by 10 min centrifugation at top speed in a micro centrifuge (4oC). The supernatant 
was carefully aspirated and the nucleic acid pellet washed once with 1 ml ice cold 70% 
ethanol. The ethanol was removed and the sample was left to air-dry at room temperature.   
 
The nucleic acid precipitate was resuspended in 80 μl nuclease free H2O to which 10 μl of 
10x DNAse buffer, 40U RNAse Inhibitor and 25U DNAse was added (the total volume of the 
reaction was 100 μl).  The reagents were mixed and incubated for 30 min at 37OC.  The 
reaction was stopped by a 10-min incubation at 65OC. Total mRNA was recovered by a final 
purification step using a RNA Miniprep clean-up kit (Qiagen) essentially following the 
manufacturers instructions. Three hundred and fifty μl Buffer RLT (supplied) was mixed with 
the 100 μl reaction and then 250 μl 95% ethanol was added. This mixture was loaded onto 
an RNeasy mini column, which was assembled in a 2 ml collection tube (supplied). The 
column assembly was centrifuged for 15 sec at 15 000 x g (RT). The RNeasy mini column 
was assembled into another 2 ml collection tube (supplied) and 500 μl Buffer RPE (supplied) 
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was added to the mini column. The mini column assembly was centrifuged for 15 sec at 15 
000 x g (RT). The flow-through was discarded and another 500 μl RPE was added to the 
mini column. The mini column assembly was centrifuged for 2 min at 15 000 x g (RT) and 
the mini column was assembled in a 1.5 ml collection tube (supplied). The mRNA was eluted 
from the mini column by adding 50 μl nuclease free ddH2O and 1 min centrifugation at 15 
000 x g (RT). Ribonucleic acid was quantified using the Nanodrop system (Inqaba 
Biotechnologies).  
 
8. COLONY BLOTTING 
 
To identify E. coli colonies harbouring M. tuberculosis H37Rv genome library cosmids 
containing target library inserts, the E. coli clones were spread onto LB-agar plates 
containing Ampicillin (50 g/ml, Roche) and allowed to grow at 37C for 16 h.  Bacterial 
colonies were transferred to dry Hybond-N+ membrane filters (Amersham) by placing the 
membrane (does not require prior treatment) onto the colonies and incubating for one 
minute (room temperature). Orientation of the disc with respect to the colonies on the LB-
agar was marked by simultaneously piercing the membrane and agar with a syringe needle 
dipped in India ink (local stationery store). The membrane was then placed, colonies facing 
upwards, on Whatmann 3MM paper soaked in 10% SDS (m/ v) for 5 min. The membrane 
was subsequently transferred to Whatmann 3MM paper saturated with denaturing solution 
(Appendix A.3.7) for 10 mins. Thereafter the membrane was placed for 5 mins on Whatmann 
3MM paper soaked in neutralising solution (Appendix A.3.8). Finally the membrane was 
rinsed in 2x SSC (pH 7.0, Appendix A.3.22) on an orbital shaker for 3 mins. The DNA was 
fixed to the membrane by baking for 2 hours at 800C in a vacuum oven.   
 
Colonies harbouring cosmids with the M. tuberculosis genomic region that contains the 
glnA1 to Rv2224c ORFs were identified by ECL direct nucleic acid labelling and detection 
(Amersham, UK). After baking, the membranes were pre-hybridised in ECL hybridisation 
buffer (supplied) for 1 hour at 420C with gentle agitation. Thereafter the membranes were 
probed by the addition of an ECL labelled probe (10 ng/ml; Section 11), which was 
complementary to an internal region of Rv2224c (Table 4) to the ECL hybridisation buffer.  
Probe hybridisation was carried out at 42C with gentle agitation for 4 hours. After 
hybridisation, the membrane was washed for 20 min with gentle agitation in 2 – 5 ml Primary 
Wash buffer (pre-heated to 420C, Appendix A.3.19) per cm2 membrane. A further 20 min 
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wash was carried out under the same conditions with fresh Primary Wash buffer. Thereafter 
the membrane was washed twice in an excess volume of 2x SSC for 5 min at RT with gentle 
agitation. The ECL-hybridisation positive clones were visualised by autoradiography on 
Kodak X-ray film. Following agar plate orientation, corresponding positive colonies were 
picked (as the cosmid sizes are around 40 000 kb, positive clones were obtained with a 
frequency of  1:300) and positive clones were confirmed by PCR of the gene used as probe 
(Rv2224c, as well as glnA1 that are situated downstream, see Chapter 4, Figure 4.1). 
Finally, the isolated cosmids were sequenced on an automated sequencer using T3 and T7 
sequencing primers to confirm the correct DNA region as well as to determine the exact start 
and stop of insert DNA.   
 
9. PROTEIN PURIFICATION AND ACTIVITY ASSAYS 
 
 9.1 Cell fractionation 
 
In order to monitor the expression of recombinant hexa-histidine tagged proteins, crude 
protein extracts were prepared from host cultures (E.coli, M. smegmatis, M. bovis BCG). 
Briefly, cultures were collected by 20 min centrifugation at 1181 x g (4°C). The cell pellet 
was resuspended in pre-cooled phosphate buffered saline (equal to 2x the cell pellet) 
containing 1 mM Phenylmethylsulphonylfluoride (PMSF, Roche) and carried to a sterile 2.0 
ml Apex tube. The Apex tube was prepared with glass beads (0.5 mm diameter) of an 
approximately equal volume to the cell pellet. These preparations were stored at -800C or 
used immediately. The mixture was ribolysed for 45 sec at speed setting 6.5 in a FastPrep 
riboliser (Bio101) and centrifuged at 15 000 x g for 2 min (RT). The cleared lysate was 
aspirated and stored in SDS-PAGE denaturing loading buffer (Appendix A.3.20) at -800C or 
used immediately for acrylamide gel electrophoresis and Western Blotting (Section 10) 
 
To monitor the distribution of recombinant hexa-histidine tagged proteins amongst cellular 
compartments, a more refined cell fractionation was performed (Figure 4). For this purpose, 
the expression host-cells were grown in Kirchners medium (Appendix A.2.2) and, after cell 
collection, the cleared culture supernatant was first sterilised by filtration through a 0.22 μm 
syringe filter unit with low protein affinity (Millipore, USA) and then the proteins were 
concentrated using Amicon Ultra centrifugal filter devices with a >15 kDa exclusion 
(Millipore, USA). The cell pellet was resuspended in PBS containing 1 mM PMSF pre-cooled 
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to 4°C and ribolysed as described before.  The resulting lysate was cooled on ice for 5 min 
and then centrifuged for 10 min at 15 000 x g (40C). The pellet was retained for cell wall 
protein isolation. 
 
 
Figure 4. Flow diagram describing the method of bacterial fractionation into different sub-
cellular compartments.  
  
The resulting cleared lysate was collected and centrifuged for 1 h at 100 000 x g (4°C) in a 
Beckmann ultra-centrifuge to collect the membrane fraction (visible as a thin orange 
coloured film at the bottom of the centrifuge tube). The supernatant contained the cytosol-
associated proteins. The membrane fraction was washed once by re-suspension in 200 μl 
PBS (pH 7.0) containing 1 mM PMSF and collected by ultra centrifugation as before. 
 
Cell wall associated proteins were extracted from the lysate pellet by first washing the pellet 
twice in PBS (4°C) containing 1 mM PMSF to remove any residual cytosol proteins. The 
pellet was collected by 15 min centrifugation at 15 000 x g (40C) and resuspended in a 1x 
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volume SDS-PAGE reducing loading buffer (Appendix A.3.20) and incubated for 10 min at 
1000C. The suspensions were cleared by 15 min centrifugation at 15 000 x g and the 
supernatant used in SDS-PAGE electrophoresis and Western blotting (Section 10). 
 
 9.2 Protein concentration determination 
 
Protein concentrations were determined with the Bradford method (Bradford, 1976) using 
the BioRad Protein Assay. The dye reagent was prepared by diluting dye with ddH2O (1:4) . 
Five dilutions of a bovine serum albumin (BSA) standard were prepared in a linear range of 
0.2 to 0.9 mg/ ml in ddH2O. A blank reaction was also prepared by mixing equal volumes of 
ddH2O with suspension buffer (PBS-PMSF) or culture media (if the culture media used did 
not contain protein-based supplements). Samples were prepared by mixing 10 μl of sample 
with 10 μl ddH2O. Twenty μl of each BSA standard and protein sample preparation was 
mixed with 980 μl diluted reaction dye. The reaction was incubated for 5 min at room 
temperature and then read at 595 nm using a spectrophotometer. A standard curve was 
prepared and the sample concentrations were inferred from the standard curve.      
 
 9.3 Glutamine synthetase purification 
 
Glutamine synthetase was purified from M. bovis BCG Pasteur essentially as described by 
Shapiro and Stadtman (1970) with slight modifications. Mycobacterium bovis BCG was 
cultured in Kirchners medium (Appendix A.2.2) and when cultures reached an OD600 > 1.0, 
the bacteria were pelleted by 10 min centrifugation at 10 000 x g at 4oC. The cells were 
resuspended in 30 ml Resuspending Buffer A (RBA, Appendix A.3.13) and vortexed gently 
(approx 400-500 rpm) 3 times for 1 min each with 5 millimetre diameter glass beads (enough 
to be equivalent to the biomass volume). This step was carried out to remove the cell 
surface GS. The cells were collected by 10 min centrifugation at 10 000 x g at 40C. The 
supernatant was retained for purification of the cell surface GS, while cytosol associated GS 
was purified from the cell pellet.  
 
  9.3.1 Cell lysis and removal of nucleic acids  
 
For the preparation of cytosol GS purification, the cell pellet was resuspended in 50 ml RBA. 
The cell suspension was sonicated (CupSonics) for a total of 15 minutes at a 50% duty 
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cycle. These cycles consisted of a 1 sec on cycle, followed by a 0.1 second off cycle at 
maximum power. After every minute of sonication, the cell suspension was cooled on ice for 
1 min. After sonication, the suspension was centrifuged for 10 minutes at 10 000 x g (40C). 
The protein concentration of the supernatant was determined spectrophotometrically using 
Equation B.5. The supernatant proteins were adjusted to a 20 – 30 mg/ ml final 
concentration with RBA. To precipitate nucleic acids from the supernatant, a 10% v/ v of a 
10% m/ v streptomycin sulphate solution was added to the supernatant. This suspension 
was stirred for 15 min (40C) using a magnetic stirrer and then centrifuged at 20 000xg for 10 
minutes (40C). The supernatant was retained. 
 
  9.3.2 First ammonium sulphate precipitation 
 
Glutamine synthetase was purified from the supernatants of the cell wall surface and cytosol 
GS preparations by ammonium sulphate precipitation. The pH of the suspension was 
adjusted to 5.15 with 0.5 M sulphuric acid (H2SO4) and stirred for 15 min (at 40C). The 
precipitate was collected by 15 min centrifugation at 20 000 x g (40C). The supernatant was 
retained to which a 30% volume of a saturated solution of ammonium sulphate [(NH4)2SO4] 
pre-cooled to 4oC was added. The pH was adjusted to pH 4.6 with 0.5 M H2SO4 and stirred 
for 15 min at 40C. The suspension was centrifuged at 20 000xg for 15 min and the pellet 
resuspended in 50 ml RBA. The pH of the suspension was adjusted to pH 5.7 with 1 M 
ammonium hydroxide (NH4OH) by titration until all the acid-ammonium sulphate precipitate 
was evenly suspended. After the precipitate was resuspended it was stirred for 8-12 hours 
(4oC), ensuring that the pH remained at pH 5.7. The presence of GS activity was determined 
in the supernatant as well as the precipitate by the γ-glutamyl transferase assay (Section 
9.4). 
 
  9.3.3 Second ammonium sulphate precipitation 
 
Glutamine synthetase was precipitated from the cleared supernatant by a second round of 
(NH4)2SO4 precipitation as described above, except that the pH was adjusted to pH 4.4 with 
0.5 M H2SO4. After centrifugation at 20 000 x g for 15 min (40C), the pellet was resuspended 
in 20 ml RBA. The pH of the solution was then adjusted to 5.7 with 1 M NH4OH and 
incubated at 40C for a further 8 - 12 hours with stirring. The suspension was centrifuged at 
20 000 x g for 10 minutes and the cleared supernatant was retained. The presence of GS 
http://scholar.sun.ac.za
 155
was determined in the supernatant, as well as the precipitate, by the γ-glutamyl transferase 
assay (Section 9.4). 
 
Glutamine synthetase purity was then determined through SDS-PAGE gel electrophoresis 
(Section 4.1). If there were still large amounts of other proteins in the sample, GS was 
precipitated in a third round of (NH4)2SO4 precipitation, as described in Section 9.3.2, except 
that 10% by volume of a saturated (NH4)2SO4, pre-cooled to 40C, was added to the 
supernatant and the pH was adjusted to pH 5.15 with 0.5 M H2SO4. The suspension was 
centrifuged for 15 min at 20 000 x g (40C), the supernatant was retained and the pH was 
adjusted to 4.4 with 0.5 M H2SO4. The solution was equilibrated at this pH for 15 minutes 
and then centrifuged at 20 000 x g for 10 minutes (40C). The pellet was resuspended in 5 ml 
RBA (pH 5.7) and centrifuged at 20 000 x g for 10 minutes (40C). To increase purity this step 
could be repeated several times without any significant loss in GS activity. The enzyme was 
stored at 40C in RBA (pH 7.0). 
 
 9.4 γ-glutamyl-transferase activity assay 
 
Glutamine synthetase activity was assayed using the transferase assay. This reaction gives 
a colour reaction that can be measured spectrophotometricly.  For each sample, an assay 
series was prepared consisting of 1 blank reaction and two duplicates of an Mn2+, Mg2+ and 
Mn2+ + Mg2+ combination. Reactions were prepared as in Table 6.  
 
Table 6. The reactions comprising the transferase assay of GS activity. All reagents in the 
assay were prepared as described in Addendum A.3.14. Hydroxylamine and Na-arsenate 
were prepared fresh before each reaction. 
REAGENTS BLANK (μl) Mn (μl) Mg (μl) Mn/ Mg (μl) 
Imidazole buffer 390 230 230  190  
Glutamine 80  80  80 80  
Hydroxylamine 40  40  40  40  
MnCl2.4H2O 40  40  - 40  
MgCl2.6H2O - - 40  40  
Na- ADP - 60  60  60  
Na-arsenate - 100  100  100  
Total volume of assay 550  550  550  550  
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The reaction was started by the addition of 50 μl of the GS enzyme preparation to each 
reaction preparation. Reactions were incubated at 37ºC for 30 min, where after the reaction 
was stopped by the addition of 900 μl stop mix (Addendum A.3.14.7). The addition of the 
stop mix resulted in a colour change of the reaction. The reaction was centrifuged at 15 000 
x g for 2 min (RT) to pellet residual ferric chloride. The cleared supernatant was decanted 
into a 1 ml plastic spectrophotometer cuvette (Merck) and read at a wavelength of 540 nm in 
a spectrophotometer.  
 
 9.5 -Galactosidase assays 
 
-Galactosidase activity was quantitatively assayed as described (Pardee et al., 1959; Timm 
et al., 1994) using sonicated total cellular extracts of M. smegmatis transformed with 
different pJEM constructs (Appendix C.3). The M. smegmatis cellular extracts were prepared 
by sonication for a total time of 5 minutes (15 sec bursts with 30 sec intervals) at 4.5 setting 
in a Misonix sonicator and using a micro tip probe. Protein concentrations of sonicated 
extracts were determined spectrophotometrically using the BioRad protein concentration 
assay (Section 9.2). The assay is based on the -galactosidase substrate o-nitrophenyl--D-
galactoside (ONPG) and one unit of -galactosidase is defined as producing 1 Mole o-
nitrophenol per minute from o-nitrophenyl--D-galactoside at 280C, pH 7.0 (1 Mole/ ml o-
nitrophenol has an optical density at 420 nm of 0.0075). -Galactosidase activity was 
determined using 6.6ug of protein and 30 min reaction incubation at 280C. All activity assays 
were performed in triplicate. The units of -galactosidase activity were calculated as 
described by Timm et al. (1994) and Berthet et al. (1998) (see Equation B.4).   
 
 9.6 MagnaHis affinity purification of 6x his-tagged proteins 
 
The MagnaHis protein purification system (Promega) was used for small-scale purification of 
6 his-tagged proteins. This system makes use of paramagnetic pre-charged nickel particles 
and are effective under non-denaturing or denaturing (by addition of urea to a final 
concentration of 6 M) conditions. Hexa-histidine-tagged protein were purified from whole cell 
lysates that were prepared either by sonication (see Section 9.5) or ribolisation (see Section 
9.1). Thirty l of MagnaHis Ni-particles were added to 1 ml of cell lysate and mixed by 
inversion (room temperature). The suspension was incubated at room temperature for 2 min, 
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where after the Ni-particles were collected using a locally produced magnetic stand (Cor 
Wytenburg). The supernatant was removed by aspiration and 200 l of Binding/ Wash buffer 
(supplied) added to the Ni-particles. The Ni-particles were resuspended by inversion and the 
suspension was incubated at room temperature for 2 min. The Ni-particles were collected 
using the magnetic stand and the supernatant removed by aspiration. This wash-step was 
repeated three times using 200 l of Binding/ Wash buffer. To elute proteins, 100 l 
MagnaHis Elution Buffer (supplied) was added. The Ni-particles were resuspended using a 
pipette and incubated at room temperature for 2 mins. There after the Ni-particles were 
collected using the magnetic stand and the supernatant (containing eluted proteins) 
removed by aspiration. Proteins were analysed by SDS-PAGE electrophoresis (Section 4.1) 
or Western blotting (Section 10).           
 
10. WESTERN BLOTTING 
 
Protein samples were fractionated according to molecular size by SDS-PAGE 
electrophoresis (Section 4.1). A Hybond-P PVDF membrane (Amersham, UK) was cut to the 
size of the poly-acrylamide gel and re-hydrated by rinsing in 95% methanol until the 
membrane was a homogeneous light-grey colour. Since the membrane has high affinity for 
proteins, it was carefully handled with tongs and wearing nitrile gloves at all times. The 
methanol treated membrane was pre-soaked; together with 2 x Western blot pads (BioRad) 
and 2 x Whatman 3M blotting paper sheets (prepared to the size of the Western bolt pads) in 
Western blot transfer buffer (Appendix A.3.25) for 15 min. The gel was taken from the 
electrophoresis apparatus and soaked in Western blot transfer buffer for 5 min. The blotting 
apparatus (BioRad Protean II) was assembled in the order prescribed by the manufacturer. 
The assembly of the blotting apparatus was carried out in a shallow tray filled with transfer 
buffer to avoid drying of the membrane. 
 
The assembly was slotted into the transblotter and the reservoir was filled with Western blot 
transfer buffer pre-cooled to 40C. A frozen ice pack (supplied with trans-blotting apparatus) 
was inserted into the trans-blotter (to keep the transfer buffer cool) and a magnetic stirrer 
was added to the apparatus reservoir (prevents buffer hot spots during transfer). Trans-
blotting was carried out for 1 hour at a constant voltage of 150 V in a cold room (40C). The 
trans-blotting apparatus was disassembled and the membrane was blocked O/N in a BSA-
Tween 20 blocking solution (Appendix A.3.2) at 40C. The transfer of the pre-stained protein 
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molecular weight marker (Fermentas), which was used during SDS-PAGE electrophoresis, 
served as a visual indicator of successful protein transfer. Following transblotting, the 
membrane was blocked overnight at 40C in a 2% BSA solution prepared in PBS-T (Appendix 
A.3.18). Specific proteins were detected through antibody mediated ECL detection (Section 
10.1) or nickel-NTA conjugated colorimetric assays (Section 10.2).  
 
 10.1 Chemiluminescent Western detection  
 
The blocked membrane was carefully rinsed once in phosphate buffered saline/ Tween 20 
(PBS-T) buffer (Appendix A.3.18). The primary anti-hexa-histidine antibody (Invitrogen) was 
diluted 1: 5 000 in PBS-T buffer and added to the membrane in a clean plastic petri-dish. 
The membrane was incubated at RT in the primary antibody preparation for an hour with 
gentle agitation. The primary antibody preparation was decanted (can be stored at –200C 
and re-used) and the membrane was quickly rinsed once in PBS-T buffer and then washed 
twice for 15 min each in PBS-T buffer with gentle agitation. The membrane was then 
incubated for one hour in a 1:10 000 PBS-T dilution of horseradish-peroxidase (HRPO) 
linked secondary antibody (Invitrogen) at RT with gentle agitation. Thereafter the secondary 
antibody preparation was decanted; the membrane quickly rinsed once in PBS-T and 
washed three times for 15 min each in PBS-T with gentle agitation. The HRPO-linked 
secondary antibody detection was performed through ECL (Section 11.1). 
  
 10.2 Colorimetric Western detection 
 
The blocked membrane was transferred into 20 mL PBS-T (Appendix A.3.18) buffer to which 
2 l HisDetector Nickel-HRP (Promega) was added. This membrane was incubated at room 
temperature for 1 hour with gentle agitation. Following the hybridisation, the membrane was 
washed three times for 5 min each with PBS-T. Thereafter the membrane was developed by 
a 10 min to 15 min incubation in 10 mL TMB Membrane Substrate (Promega) at room 
temperature. The reaction was stopped by rinsing the membrane in ddH2O.   
 
 
 
 
 
http://scholar.sun.ac.za
 159
11.  DIRECT ENHANCED CHEMILUMINESCENCE LABELING (ECL) OF DNA PROBES 
 
Chemiluminescent labelling (Amersham) was carried out essentially as recommended by the 
manufacturer. The DNA (PCR products and purified as in Section 7.2.1) to be labelled was 
diluted to a concentration of 10 ng/ μl with sterile dH2O. One hundred ng DNA (10 μl) was 
denatured by 5 minutes incubation at 950C in a solid-state heating block and then snap-
cooled on ice for 5 min. The tube was briefly spun to collect the condensate. An equal 
volume of DNA labelling reagent (10 μl) was added to the denatured DNA and the mixture 
was briefly mixed. A volume of glutaraldehyde solution, equal to the DNA labelling reagent 
(10 μl), was added and the suspension was mixed thoroughly. The mixture was incubated 
for 10 minutes at 37°C and used immediately or within 10 – 15 min. 
 
 11.1 ECL signal detection (DNA and HRPO-linked antibodies) 
 
An equal volume of Detection Reagent 1 (Amersham) was mixed with Detection Reagent 2 
(Amersham) to a solution volume sufficient to cover the whole blot. The DNA or protein side 
of blots was exposed to the Detection Reagent solution for 1 min at RT. The excess 
detection reagent was drained by gently blotting the “back” or non-DNA/ protein bound side 
with a paper towel. The blot was placed in a plastic sleeve and exposed for 1 – 10 min to a 
sheet of x-ray film (Kodak). The film was developed in an automatic X-ray film developer.   
 
12. IN SITU HYBRIDISATION (ISH) 
 
 12.1 Brief description 
 
The in situ hybridisation method was designed for non-radioactive detection of mRNA and 
DNA in tissue preparations. This method provides a sensitive detection system for 
biotinylated probes that takes advantage of the very high affinity of biotin for strepavidin (a 
non-glycosylated 60 kDa protein with near neutral pI). These complexes are also extremely 
stable over a wide range of temperatures and pH. In brief, a biotin labelled DNA probe is 
hybridised to target mRNA in cells or tissues, which are fixed on a microscope slide (see 
Figure 5). A signalling group (eg. alkaline phosphatase and horseradish peroxidase), 
covalently attached to streptavidin, is then bound to the biotinylated probe. The hybridised 
probe is then detected by incubating the samples with dye substrates for alkaline 
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phosphatase. Formation of a brown signal indicates the location of the hybridised probe, 
which could be visualised under a light microscope.  
 
The variables influencing the sensitivity of ISH are dependant on the effect that tissue 
preparation has on the retention and accessibility of target mRNA or DNA, the type of probe 
construction and labelling, the sensitivity of the method used for signal detection and the 
effect of hybridisation conditions on the efficiency of hybridisation.   
 
 
Figure 5. An 18-mer biotinylated riboprobe complementary to a specific target mRNA 
molecule (fixed on a microscope slide) can be detected through an enzyme reaction 
detecting a substrate such as horseradish peroxidase (HRP) covalently linked to strepavidin  
 
 12.2 Patient selection and tissue specimens 
 
Lung tissue biopsy material was collected from patients who had an episode of tuberculosis 
disease. Biopsy tissue was collected by the Department of Anatomical Pathology 
(Stellenbosch University) and immersed in saline in a clean, sterile container. The biopsy 
tissue was fixed in formalin, processed and embedded in wax as described in Fenhalls et al.  
2002a. Sections of each tissue were prepared and used for histological analysis and ZN-
staining (Section 1.4) to confirm the presence of M. tuberculosis. Informed consent was 
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obtained from all the patients and the study was approved by the Stellenbosch University 
Ethical Review Committee (Amendment of project 94/107).    
 
 12.3 Slide preparation 
 
Glass microscope slides were pre-treated with an adhesive agent so that tissue does not 
detach during the protocol. This was carried out by pre-cleaning the microscope slides with 
O/N immersion in chromic acid (Appendix A.3.6), followed by 5 successive washes and a 
final 30 min incubation in ddH2O. After the washes with ddH2O, the slides were immersed in 
acetone (Merck) for 30 min followed by a 30 min immersion in 2% 3-
aminopropyltriethoxysilane (Sigma) in acetone. The slides were dried by baking at 70°C for 
1 h and then incubated in diethyl-pyrocarbonate (DEPC; Sigma) treated ddH2O (Appendix 
A.3.10) for 2 hours to remove RNases. The slides were dried by baking at 70°C overnight. 
 
 12.4 Pre-treatment of tissue samples for ISH 
 
Paraffin embedded lung biopsy tissue was cut into 5 µm thick sections with a microtome. 
The tissue sections were applied to prepared RNase free glass microscope slides (Section 
12.3).  Paraffin was removed from the tissue sections by 2 times 10 min incubations in 
xylene at room temperature. Thereafter, the xylene-treated sections were re-hydrated by 2 x 
2 min immersions in absolute (95%) ethanol, followed by 90% ethanol and finally 70% 
ethanol. Slides were then immersed in 0.1 M PBS (pH 7.0) for 5 min. The slides were 
incubated in a proteinase / DNase digestion preparation (Appendix A.3.16) for 20 min in a 
370C humidified chamber. The slides were then washed with 0.1 M PBS for 5 min and 
immersed in 0.4% (v/v) paraformaldehyde for a further 5 min to inhibit residual protease 
activity and paraformaldehyde also to re-fix digested tissue. The slides were subsequently 
washed with DEPC-treated ddH2O (Appendix A.3.10) for 2 min and acetylated (to limit non-
specific riboprobe hybridisation) for 10 min in a 1:400 (v/ v) triethanolomine (Merck) DEPC-
treated ddH2O solution. The slides were rinsed with DEPC-treated ddH2O for 5 min and re-
hydrated through 2 times 2 min immersions in absolute (95%) ethanol, followed by 90% 
ethanol and finally 70% ethanol. The sections were air-dried at RT for 40 – 60 min before 
being used for ISH. 
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 12.5 Biotinylated riboprobe preparation 
 
Deoxyribonucleic acid fragments which were complementary to a 120 bp region of M. 
tuberculosis glnA1 and a 120 bp region of Rv2223c was generated through PCR 
amplification (see Table 4 and Section 3.1.2) and cloned into the Promega pGEMt-Easy 
cloning plasmid system (Section 5). Insert orientation relative to the pGEMt-Easy T7 
promoter (Appendix C.8) was determined by PCR screening of the vectors using the T7 and 
SP6 sequence specific PCR oligonucleotides (Table 4). Plasmids were purified (Section 
7.1.1) and sequenced to confirm the insert sequence and orientation. Subsequently the 
vectors were amplified in an E. coli JM109 host-strain (Section 6.1) and purified for use in 
riboprobe synthesis.  
 
Sense (3’ – 5’) probes that were used for the detection of target mRNA were synthesised 
from the T7 promoter of the pGEMt-Easy construct using T7 RNA polymerase (GibcoBRL), 
while anti-sense probes were synthesised from the 5’ – 3’ cloned insert DNA strand using 
SP6 RNA polymerase (GibcoBRL). The anti-sense probes would therefore be 
complementary to and hybridise to its target mRNA, while the sense probe would be unable 
to form a hybrid and would therefore serve as a control. The biotinylated riboprobe synthesis 
was carried out under RNase free conditions which entailed preparation in a sterile 1.5 mL 
DEPC treated Eppendorf microfuge tube using 1 µg DNA, 1x T7 or SP6 transcript buffer, 1 
mM of each dATP, dGTP, UTP and Biotin-14-CTP, 0.5 mM dCTP, 5 mM DTT, 120 U RNase 
inhibitor (GibcoBRL, Switzerland), 100 U T7 polymerase or 52.2 U SP6 polymerase and 
RNase free (Promega) or DEPC treated ddH2O to a final volume of 50 µl. The contents were 
gently mixed and condensate briefly collected by centrifugation and the transcription reaction 
carried out for 90 min at 370C. The riboprobes were precipitated by addition of 150 µl 95% 
ethanol and precipitation at -200C O/N. Biotinylated riboprobes were collected through 30 
minute centrifugation at 15 000 x g (40C). The riboprobe pellet was washed once with 70% 
ethanol (40C) and collected with a 10 min centrifugation as above. The ethanol supernatant 
was aspirated and the precipitate dried in a Speed Vac Concentrator (Savant, USA) for 5 
min. The dried riboprobes were resuspended in 100 µl RNase free ddH2O (Promega) or 
DEPC treated ddH2O and allowed to completely go into suspension by incubation at 370C for 
30 min. If not used immediately, riboprobes were stored at -200C. 
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Biotinylated riboprobes were confirmed by spotting 5 – 10 µL onto Hybond N+ membranes 
(Amersham, UK) followed by detection with Strepavidin-conjugated alkaline phosphatase in 
conjunction with the NBT/BCIP substrate (GibcoBRL, Switzerland), as discussed in Section 
12.6. 
 
 12.6 RNA: RNA in situ hybridisation 
 
In situ hybridisation was carried out using an ISH kit (Gibco) and the procedure was followed 
essentially as described by the manufacturer. Pre-treated slide-mounted tissue samples 
(Section 12.3) were covered with a hybridisation mixture consisting of 20 μl of a 20% dextran 
sulphate solution, 20 μl 2 x hybridisation buffer (supplied) and anti-sense or sense 
biotinylated riboprobes (see Section 12.5) to a final concentration of 5 μg/ ml. These 
hybridisation preparations were then incubated for 16 – 18 h in a 500C humidified chamber. 
After hybridisation, the slides were washed twice for 15 min in 2 x SSC (Appendix A.3.22) to 
remove non-hybridised riboprobe. The slides were then immersed for 20 min (RT) in 100 μl 
Blocking solution (supplied) to inhibit possible endogenous enzyme activity, which may 
influence enzyme-based detection methods. The blocking solution was removed by capillary 
action (touching absorbent paper to the edge of each slide). A working conjugate mixture 
consisting of 10 μl strepavidin-alkaline phosphatase conjugate (ISH Kit) and 90 μl conjugate 
dilution buffer (ISH Kit) was applied to each slide after which the slides were incubated at RT 
in a humidified chamber for 15 min. A control slide was prepared by omitting the strepavidin-
alkaline phosphatase conjugate treatment for both the M. tuberculosis glnA1 and Rv2223c 
riboprobes that would indicate endogenous enzyme activity and therefore give a false 
positive signal. The strepavidin-alkaline phosphatase conjugate-treated slides were washed 
twice for 15 min each in Buffer A (Appendix A.3.4) at RT and then incubated for 5 min in pre-
warmed Buffer B (Appendix A.3.5) at 370C. Levamisole, a potent inhibitor of endogenous 
alkaline-phosphatases, was added to this preparation at a final concentration of 200 mg/ ml. 
Finally, the slides were incubated in a 4-nitro blue tetrazolium/ 5-bromo-4-chloro-
3indolylphosphate (NBT/ BCIP) solution (Gibco ISH Kit) at 370C until the desired level of 
signal was achieved. Rinsing the slide in ddH2O stopped the reaction.  
 
Counterstaining of the probed tissue that allowed visualisation of cells with no hybridised 
probe were carried out by 5 min incubation in methyl green (DAKO, USA), a basic dye that 
reacts with anionic groups, such as the phosphate groups of nucleic acids. After methyl 
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green treatment, slides were briefly rinsed with 95% ethanol and then dehydrated through 30 
sec immersion in graded alcohols (2 x 90% ethanol, 2 x 95% ethanol) and final 2 min 
incubation in 100% xylene (Merck). Slides were then mounted in a permanent mounting 
medium (Entellen, Merck). A positive hybridisation signal was observed as a brown colour, 
while a blue colour indicated negative hybridisation.  
 
Photographic images were captured using a Zeiss microscope (Axioscope 2) fitted with a 
Sony 3CCV video camera. Images were saved using the Axiovision software (Zeiss, 
Germany). It is important to note that ISH is an empirical staining technique and should not 
be taken as a quantitative measure for bacterial load (see Chapter 5 Discussion).  
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APPENDIX A: SOLUTIONS 
 
A.1 Antibiotic stock solutions: 
 
A.1.1) Ampicillin 
50 mg/ ml in ddH2O, filtered sterilised (0.22 um filter, Millipore, USA) and stored at – 200C 
 
A.1.2) Kanamycin 
50 mg/ ml in ddH2O, filtered sterilised (0.22 um filter, Millipore, USA) and stored at – 200C 
 
A.1.3) Hygromycin B 
50 mg/ ml in ddH2O, filtered sterilised (0.22 um filter, Millipore, USA) and stored at – 200C 
 
A.1.4) Tetracyclin 
50 mg/ ml in ethanol, filtered sterilised (0.22 um filter, Millipore, USA) and stored at – 200C 
 
A.2 Culture Media: 
 
A.2.1) ADC mycobacterial liquid culturing media supplement: 
0.5% w/ v Bovine serum albumin (BSA) Fraction V; 0.2% v/ v glucose; 0.015% v/ v catalase 
(Merck). The supplement was prepared in ddH2O and was sterilised through a 0.22 μm 
filtration unit (Sterilin) ADC was stored at 4oC. 
 
A.2.2) Kirchners medium:  
21.13 mM Na2HPO (anhydrous); 29.4 mM KH2PO4  (anhydrous); 4.34 mM MgSO4.7H2O; 8.5 
mM Trisodiumcitrate; 33 mM L-Asparagine monohydrate and 16.66 % v/ v Glycerol.  
  
Dissolve the reagents, except for the glycerol, in half the final volume dH2O using heat. Once 
dissolved, add the glycerol and make up to final volume with dH2O. Autoclave for 15 min. at 
121oC. Nitrogen limiting conditions were created by preparing Kirchners omitting the 
Asparagine. 
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A.2.3) Luria-Bertani (LB) Medium: 
1% w/ v Bacto-tryptone, 0.5% w/ v Yeast Extract, 171 mM NaCl, pH 7.0. Autoclave for 15 
min at 121oC. 
 
A.2.4) Luria-Bertani (LB) agar: 
1.5% w/ v Bacto-agar in LB medium. Autoclave for 15 min at 121oC. 
 
A.2.5) 7H9 Mycobacterial medium: 
Suspend 4.7 g 7H9 medium powder (Difco) in 900 ml dH2O containing 2 ml glycerol or 0.5 g 
Tween 80 (Sigma). Autoclave for 15 min at 121oC 
 
A.2.6) 7H11 Mycobacterial agar: 
Suspend 21 g 7H11 agar (Difco) in 900 ml dH2O containing 5 ml glycerol. Autoclave for 15 
min at 121oC. 
 
A.2.7) OADC mycobacterial solid culturing media supplement: 
0.005% v/ v oleic acid (Merck), 0.5% w/ v BSA Fraction V, 0.2 % v/ v glucose, 0.02% v/ v 
catalase (Merck), w/ v 0.085% NaCl. The supplement was prepared in ddH2O and filter 
sterilised using a 0.22 μ vacuum filtering unit (Sterillin). OADC was stored at 4oC and added 
to 7H11 Mycobacterial agar at 30oC – 45oC. 
 
A.2.8) Sautons Media:  
3.67 mM KH2PO4; 2.0 mM MgSO4.7H2O; 10.41 mM Citric acid; 0.2 mM Ammonium iron (3+) 
citrate; 27 mM L-Asparagine monohydrate and 16.66 % v/ v Glycerol. 
 
Dissolve the reagents, except for the glycerol, in half the final volume dH2O using heat. Once 
dissolved, add the glycerol and make up to final volume with dH2O. Adjust to pH 7.4 with 1 M 
NaOH. Autoclave for 15 min at 121oC.  
 
A.2.9) SOB medium: 
Dissolve 2.0% w/ v Bacto-tryptone , 0.5% w/ v Bacto-yeast extract, 8.5 mM NaCl, add KCl to 
2.5 mM, pH 7.0. Autoclave for 15 min at 121oC 
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A.2.10) SOC medium: 
Add glucose (20 mM final concentration) and MgCl2 (10 mM final concentration) to SOB 
medium prior to use. 
 
A.3 Buffers and Solutions: 
 
A.3.1) 5% Acid alcohol (ZN-staining): 
5% HCL in methanol 
 
A.3.2) Ammonium persulphate (APS) (10% w/ v): 
1g (NH4)2S2O8 and sterile dH2O to 10 ml. Prepare fresh, or store aliquots at – 200C for not 
longer than 1 month.   
 
A.3.3) BSA-Tween 20 Blocking buffer: 
2% w/ v bovine serum albumin (BSA) in PBS-T buffer 
 
A.3.4) Buffer A: 
100 mM Tris-HCl (pH 7.5), 150 mM NaCl 
 
A.3.5) Buffer B: 
100 mM Tris-HCl (pH 9.5), 50 mM MgCl2, 100 mM NaCl  
 
A.3.6) Chromic acid (H2CrO4): 
1.76 M K2Cr2O7, 2.62 M H2SO4 
 
A.3.7) Colony blotting denaturing solution: 
1.5 M NaCl, 0.5 M NaOH 
 
A.3.8) Colony blotting neutralising buffer: 
1.5 M NaCl, 0.5 M Tris-HCl (pH 7.2), 0.001 M Na2EDTA   
 
A.3.9) Coomassie blue staining solution: 
0.25% m/ v Coomassie Blue (Merck), 45% v/ v methanol, 10% acetic acid. Filter before use. 
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A.3.10) DEPC ddH2O: 
10% v/ v DEPC (Merck) in ddH2O. Autoclave for 15 min at 121oC.  
 
A.3.11) Destaining solution: 
0.1% v/ v Glycerol, 7.5% v/ v Glacial acetic acid, 5% v/ v Methanol.  
 
A.3.12) Ethidium bromide stock solution: 
10 mg/ ml in TE buffer (pH 8.0) 
 
A.3.13) Glutamine synthestase Resuspension Buffer A (RBA): 
10 mM Imidazole-HCl, 10 mM MnCl2.4H2O; pH 7.0 
 
A.3.14) γ-glutamyl-transferase activity assay: 
Assay components prepared in 50 mM Imidazole Buffer (pH 7.15): 
 
 A.3.14.1) 112,9 mM Glutamine  
 A.3.14.2) 70.72 mM MnCl2.4H2O  
 A.3.14.3) 913.33 mM MgCl2.6H2O  
 A.3.14.4) 900 mM NH2O  
 A.3.14.5) 180 mM Na2HAsO4 
 A.3.14.6) 4.45 mM Sodium ADP 
 
This mixture should be used fresh, as the Sodium ADP and hydroxylamine are unstable over 
long periods.  
 
 A.3.14.7) Stop mix: 1 M FeCl3, 201 mM CCl3COOH and 5.2 % v/ v absolute HCl in 
  distilled water. Mix before use. 
 
A.3.15) IPTG (Isopropyl --D-thiogalactopyranoside) stock solution: 
100 mM in ddH2O, sterilise by 0.22 m filter filtration 
 
A.3.16) ISH simultaneous proteinase and Dnase digestion preparation:  
10 mM Tris-HCl (pH = 7.5); 5 mM EDTA; 1 µg/ ml Proteinase K (GibcoBRL) and 10 µg/ ml 
DNase I (GibcoBRL). 
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A.3.17) 6x Loading Buffer for agarose gels 
30% Glycerol, 0.25% w/ v bromophenol blue, 0.6% w/v SDS in TE buffer (pH 8.0) 
 
A.3.18) PBS-T Wash Buffer: 
10 mM Phosphate buffered saline (PBS, Sigma), 0.2% v/ v Tween 20 
 
A.3.19) Primary wash buffer:  
6 M urea, 0.4% w/ v SDS, 0.5x SSC 
 
A.3.20) 2 x Reducing sample buffer: 
34% v/ v 1 M Tris-HCl (pH 6.8), 20% Glycerol, 30% v/ v SDS (20% m/ v), 0.5% v/ v 
Bromophenol Blue (0.75%), 0.2% EDTA (0.5 M) and 10% β-mercaptoethanol. Store at 40C 
or – 200C if not to be used for longer periods. 
 
A.3.21) SDS-PAGE Running buffer: 
25 mM Tris, 192 mM Glycine and 0.1% SDS  
 
A.3.22) 20 x SSC: 
0.3 M Tri-sodiumcitrate, 3 M NaCl; pH 7.0. 2x SSC working concentrations are prepared by 
a 10x dilution with dH2O 
 
A.3.23) 10x Tris-Borate-EDTA (TBE) Buffer: 
0.98 M Tris, 0.98 M Boric Acid, 20 mM EDTA, pH 8.3 
 
A.3.24) Tris-EDTA buffer (TE): 
10 mM Tris, 1 mM EDTA, pH 8.0 
 
A.3.25) Western blot transfer buffer: 
25 mM Tris, 192 mM glycine and 20% v/ v methanol  
 
A.3.26) X-gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside) stock solution:  
50 mM in dimethylformamide (DMF) or dimethylsulfoxide (DMSO) 
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Appendix B: Mathematical equations 
 
Equation B.1: Required insert concentration (ng)  = 
)(
))()(50(3
kBVector
kBInsertng
 
 
Equation B.2: Melting point temperature (Tm) Celsius degrees = 2 (A+T) + 4(G+C) 
 
Equation B.3: To covert pmol to μg = N pmol 
 
Equation B.4: 1Unit = 200 x OD420/mg of protein/minute 
 
Equation B.5: Protein Conc (mg/ml) = [(OD280 x 1.55) - (OD260 x 0.76)]x dilution 
 
Equation B. 6: Solution Volume=  Protein Conc (mg/ml) x Current Solution Volume 
     Required Concentration (mg/ml) 
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APPENDIX C: PLASMID/ CLONING VECTOR MAPS 
 
C.1) p19Kpro Mycobacterial expression plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The p19Kpro mycobacterial expression plasmid was used for the constitutive expression of 
recombinant M. tuberculosis proteins under direction of the 19kDa M. tuberculosis antigen 
promoter (19kDa prom.) in other mycobacterial hosts, such as M. smegmatis and M. bovis 
BCG. The origin of replication (ALori) is derived from the M. fortuitum pAL5000 plasmid and 
is recognised by both E. coli and mycobacteria, enabling the amplification of vector 
constructs in fast-growing E. coli. The p19Kpro plasmid carries a hygromycin B resistance 
(HygR) selection marker. Unique RE-recognitions sites located in the multiple cloning site 
together with their plasmid coordinates are shown. 
 
The p19Kpro plasmid was constructed by Dr. Koen de Smet (Imperial College Medical 
School at St Mary’s) and was used with permission from Dr. Douglas Young (Imperial 
College Medical School at St Mary’s) 
 
p19Kpro
5499 bp
BamHI (1481)
PstI (1493)
EcoRV (1505)
HindIII (1511)
ClaI (1517)
ALori
19kDa prom.
HygR
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C.2) pACE acetamidase operon promoter plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pACE acetamidase operon promoter plasmid was used for the concentration dependant 
acetamide-inducible expression of anti-sense mRNA molecules in mycobacterial hosts such 
as M. smegmatis and M. bovis BCG. The origin of replication (ALori) is derived from the M. 
fortuitum pAL5000 plasmid and is recognised by both E. coli and mycobacteria, enabling the 
amplification of vector constructs in fast-growing E. coli. The pACE acetamidase operon 
promoter plasmid carries a hygromycin B resistance (HygR) selection marker. Unique RE-
recognition sites (only BamHI and ClaI) located in the multiple cloning site together with their 
plasmid coordinates are shown. 
 
The pACE acetamidase operon promoter plasmid was constructed by Dr. Koen de Smet 
(Imperial College Medical School at St Mary’s) and was used with permission from Dr. 
Douglas Young (Imperial College Medical School at St Mary’s) 
 
 
 
pACE
8191 bp
BamHI (2125)
ClaI (2161)
ALori
ACE prom.
HygR
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C.3) pJEM 15 promoter probe plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pJEM 15 promoter probe plasmid was used for the relative quantification of promoter 
activity in M. smegmatis as a mycobacterial expression host. The genetic region that was 
investigated for promoter activity was cloned directly upstream of a functional (but promoter 
less) lacZ gene. Existence of promoter activity in the cloned insert resulted in lacZ 
production, of which the relative activity could be determined by β-galactosidase activity 
assay. The pJEM 15 promoter probe plasmid carries a kanamycin resistance (KanR) 
selection marker. Unique RE-recognition sites located in the multiple cloning site together 
with their plasmid coordinates are shown. 
 
The pJEM 15 promoter probe plasmid was obtained from, and used with permission from Dr. 
Brigitte Gicquel (Institute Pasteur, Paris, France) 
 
 
 
pJEM15
9446 bp
ApaI (4579)
SacII (4583)
BamHI (4587)
BspEI (4590)
KpnI (4603)
KanR
LacZ
ScaI (4573)
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C.4) pYUB412.2 M. tuberculosis cosmid library vector construct  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pYUB412.2 PacI-excisable cosmid cloning vector was used for the permanent 
integration of M. tuberculosis genomic DNA into M. smegmatis. The M. tuberculosis genomic 
library was constructed by cloning Sau3A genomic DNA fragments (approximately 40 000 
kb) into the PacI site of the pYUB412.2 vector. This vector construct cannot replicate in 
mycobacteria (i.e. a suicide plasmid), but has the origin of replication for E. coli (oriE, not 
shown). The vector confers resistance to ampicillin (AmpR) in E. coli and hygromycin B 
(HygR) in mycobacteria. The cosmid vector has the mycobacteriophage L5 attachment site 
(attP), the L5 integrase gene (int). This vector efficiently integrates into the 
mycobacteriophage L5 attachment site (attB) of the mycobacterial chromosome and is 
stable (Lee et al., 1991). 
 
The M. tuberculosis H37Rv genomic DNA integrating cosmid library (Bange et al., 1999) was 
a gift from Dr. F.C. Bange (Medizinische Hochschule, Hannover, Germany).   
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C.5) Bacterial-2-hybrid cloning plasmids 
 
The bacterial-2-hybrid system is based on the cAMP signalling cascade and both the 
plasmids described below (C.5.1 and C.5.2) are required in a double electro-transformation 
of an adenylate cyclase deficient E. coli DMH1 strain. Material transfer agreements (MTA) 
were signed between Dr. Ian Wiid (Stellenbosch University) and Dr. Daniel Ladant (Pasteur 
Institute, Paris, France) for the use of this system.   
 
C.5.1) pUT18 C-terminus fusion plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pUT18 cloning plasmid was used to create recombinant M. tuberculosis proteins fused 
at the C-terminal with the T18 sub-unit of adenylate cyclase (amino acids 225 – 399). The 
T18 open reading frame is situated downstream of the multiple cloning site containing 9 
unique RE-recognition sites. To create successful C-terminal fusion proteins, the insert had 
to be cloned without a stop-codon and in-frame with the 5’ – end of the T18 open reading 
frame. Expression of the fusion-T18 construct is driven by the lac promoter (plac). pUT18 is 
a high copy number plasmid (oriColEI) with an ampicillin resistance selection marker 
(AmpR).  
T18
oriColEI
AmpR
pUT18
(3023 bp)
plac
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C.5.2) pKT25 N-terminus fusion plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pKT25 cloning plasmid was used to create recombinant M. tuberculosis proteins fused 
at the N-terminal with the T25 sub-unit of adenylate cyclase (amino acids 1 - 224). The 
multiple-cloning site is situated at the 3’-end of the T25 open reading frame and contains 5 
unique RE-recognition sites (the SalI RE-site is not unique). Expression of the T25-fusion 
construct is driven by the lac promoter (plac). To create successful N-terminal fusion 
proteins, the insert had to be cloned in-frame with the 3’-end of the T25 open reading frame. 
pKT25 is a low copy number plasmid (ori15A) with an kanamycin resistance selection 
marker (KanR).  
 
 
 
T25
ori15A
KanR
pKT25
(3442 bp)
* SalI restriction site is not unique
plac
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C.6) pBAD/gIII C-terminus hexa-histidine fusion vectors (Invitrogen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pBAD/gIII, pBR322-derived cloning vector was used to express recombinant M. 
tuberculosis proteins as a C-terminus hexa-histidine fusion protein in an E. coli expression 
host. Expression of the fusion-protein is under the control of a arabinose-inducible promoter 
(pBAD or araBAD). Also, the vector has an intrinsic transcription initiation codon (ATG), as 
well as a rrnB transcription termination region (term). The vector contains a ampicillin 
resistance selection marker and also the open reading frame of araC, which encodes a 
regulatory protein responsible for the tight regulation of the PBAD promoter (Lee et al., 1980; 
Lee et al., 1992). 
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C.7) pGEMt-Easy (Promega) 
 
 
The high-copy number pGEM-T Easy plasmid was used for the direct cloning of PCR 
products synthesised by DNA-polymerases without proofreading activity. The PCR product 
synthesised by such a DNA polymerase is amplified with 3’ deoxyadenine overhangs (DNA 
template-independent), which could ligate to the 3’ Thymine overhangs (T) of the pGEM-T 
plasmid.  pGEM®-T Easy Vectors contain T7 and SP6 RNA polymerase promoters flanking 
a multiple cloning region within the peptide coding region of the enzyme β-galactosidase. 
Insertional inactivation of the β-galactosidase peptide allows recombinant clones to be 
directly identified by colour screening on X-Gal containing indicator plates (Materials and 
Methods 1.3). The pGEM-T Easy also contains a ampicillin resistance (AmpR) marker. 
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